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Abstract
This thesis describes novel diastereoselective group selective processes for 
the desymmetrisation of cyclohexa-1,4-dienes, and their application to target 
synthesis of the cladiellin diterpenes. In addition, an enantioselective approach 
to batzelladine C methyl ester is described, permitting stereochemical 
assignment of batzelladine C.
Chapter 1 describes the use of diastereoselective iodocyclisation reactions for 
the desymmetrisation of cyclohexa-1,4-dienes, and also details a novel 
epoxidation-cyclisation transformation, enabling the formation of up to six 
contiguous stereogenic centres, selectively, in a single step.
Chapter 2 introduces the cladiellin diterpenes and describes the application of 
novel diastereoselective Prins chemistry for the synthesis of a model of the 
cladiellin core.
Chapter 3 describes our attempts at elaborating the cladiellin model to 
approach the cladiellin framework and discusses an unexpected but interesting 
Prins cyclisation/rearrangement process.
Chapter 4 describes an enantioselective synthesis of batzelladine C methyl 
ester, permitting assignment of the relative and absolute stereochemistry of 
batzelladine C.
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Chapter 1
lodocyclisation and Epoxidation-Cyclisation 
Reactions of Cyclohexa-1,4-dienes
1.1 Introduction
The desymmetrisation of cyclohexa-1,4-dienes provides a very efficient way of 
developing complex compounds from simple precursors in a single 
transformation. The ability to distinguish between the two double bonds permits 
the selective formation of at least two new stereogenic centres.
Enantioselective desymmetrisation of achiral cyclohexa-1,4-dienes can be 
effected by use of a chiral catalyst or reagent (Figure 1).
X = Ch ra Reagent
Figure 1. Enantioselective desymmetrisation of 
cyclohexa-1,4-dienes.
Alternatively, a pre-existing stereogenic centre within the cyclohexadiene 
system can be used to facilitate diastereotopic group selection (Scheme 1).
2 1 3
Scheme 1. Diastereotopic group selection for desymmetrisation.
There is a wealth of methodology in this area and the desymmetrisation of 
cyclohexa-1,4-dienes has been the subject of a number of reviews.1 More 
recent literature includes an intramolecular hydroamination desymmetrisation 
sequence pioneered by Landais and co-workers (Scheme 2).2
2
Ph
11 10 9
Scheme 2. Reagents and Conditions: (a) n-BuLi (20 mol %), THF,
20 °C, 4 h; 95 % yield, >95 % d.e.
Treatment of secondary amine 4 with catalytic /7-butyllithium results in the 
formation of allylic amine 11 with very high levels of regio- and diastereocontrol. 
Formation of the allylic amine indicates that the reaction is not simply a direct 
hydroamination of one of the diastereotopic double bonds. In fact, Landais 
suggests that treatment of the amine 4 with strong base permits removal of 
both the amine and cyclohexadienyl protons, resulting in an equilibrium 
between the cyclohexadienyl anion 6 and the amide anion 5. The 
cyclohexadienyl anion 6 can subsequently undergo diastereoselective 
protonation from the secondary amine and the resulting lithium amide 9 adds 
selectively to the 1,3-diene on the other side of the ring, as summarised in 
Scheme 2.
3
Work within our own group has yielded extensive methodology for the 
desymmetrisation of cyclohexa-1,4-dienes. Examples include chiral sulfoxide 
directed conjugate addition to a cyclohexadienone 12, which proceeds with 
moderate diastereocontrol, as shown in Scheme 3.3
Scheme 3. Reagents and Conditions: (a) f-BuOK, THF, room 
temperature.
A diastereoselective free-radical cyclisation reaction has also been developed,4 
which has recently been employed in the synthesis of the tricyclic core 18 of 
lycoposerramine S (Scheme 4).5
O O o
12 13 35 % 14 - -• %
OH
TBDPSO
OTBDPS OTBDPS
15 16 52 % 17 23 %
ycoposerram ne S OTBDPS
6 steps 
32 % y e c
18
Scheme 4. Reagents and Conditions: (a) Bu3SnH, AIBN, benzene 
reflux, 18 h.
4
More recent examples include group selective iodocyclisation6 and Prins 
chemistry,7a,b which will be discussed later in this chapter and subsequent 
chapters.
1.2 lodocyclisations
1.2.1 Introduction
Iodocyclisation reactions have been shown to allow formation of a variety of 
heterocyclic ring sizes, often with excellent sterocontrol.8 Previous work within 
the Elliott group has shown that chiral cyclohexa-1,4-diene derived substrates 
will undergo desymmetrisation by haloetherification reactions with essentially 
complete diastereocontrol.6 A range of products of varying ring sizes, formed 
via both exo and endo cyclisation modes are permitted with the 
stereochemistry dictated by chirality present within the tethering chain.
For example, chiral diols 19, with a range of substituents in the R1 and R2 
positions, give predominantly 5-exo cyclisation products 20, with some 6-endo 
products 21 , as single diastereoisomers, when submitted to standard reaction 
conditions (Scheme 5).
Scheme 5. Reagents and Conditions: (a) l2, base, CH3CN; 60 -  90 
% yields.
This preference for 5-exo cyclisation is of course expected, owing to Baldwin’s 
rules.9 In this case, the 5-exo cyclisation mode presents a much more
S examp es
19 20 (5-exo) 21 (6 -endo)
5
favourable transition state geometry than the 6-endo mode in which the bond 
angles of the transition state would be severely distorted in order to achieve the 
necessary trajectory of attack (Figure 2).
6-endo
\
\
5-exo
Figure 2. Regioselectivity of iodocyclisation.
The diastereoselectivity of these reactions can be explained by interaction of 
the substituent on the tethering chain with the cyclohexadiene ring. While 
cyclisation can proceed onto either double bond, one results in a large steric 
interaction between the substituent and the ring, drastically destabilising the 
transition state. Hence the favoured geometry of attack is that in which the 
substituent is furthest from the cyclohexadiene ring (Figure 3). As a result, 
cyclisation occurs onto only one of the diastereotopic double bonds, giving 
complete diastereocontrol.
V  Oh
Favoureo D sfavoureo
Figure 3. Diastereoselectivity of iodocyclisation.
The requisite substrates for these cyclisation reactions are yielded via a Birch 
reduction/ alkylation sequence10 of benzoic acid (Scheme 6). As such, all 
contain a carbon quaternary centre, with a hydroxymethyl group in addition to 
the chiral tethering chain.
6
Scheme 6. Birch Reduction/ alkylation sequence of benzoic acid.
With our knowledge of the origin of the stereocontrol of these reactions, it was 
considered that omission of the hydroxymethyl group in the substrates would 
still permit diastereoselective iodocyclisation. My contribution to the project was 
to investigate this with a view to expanding this methodology further.
1.2.2 Results and Discussion
In this case only 5-exo and competing 6-endo cyclisation modes were 
investigated. The expected products are shown in Scheme 7.
and/or
Scheme 7. Anticipated outcome of iodocyclisations.
The substrates for cyclisation 24 were prepared by deprotonation of 
cyclohexa-1,4-diene 27, using conditions devised by Woerpel11 and employed 
by Landais,12 followed by reaction with an epoxide 28 (Scheme 8). The 
reactions all proceeded smoothly and in moderate to good yield, providing a 
range of substrates for investigation, as shown in Table 1.
Scheme 8. Reagents and Conditions: (a) n-BuLi, TMEDA, THF, 
-78 °C to room temperature, 1 h.
Entry Epoxide R1 R2 Yield 24 (%)
1 28a n-Bu H 66
2 28b Ph H 27
3 28c -(CH2)4- 44
Table 1.
Pleasingly all three compounds underwent successful cyclisation when treated 
with iodine and NaHC03 in acetonitrile for only 10 minutes. 1H NMR spectra of 
the crude reaction mixtures showed, in all three cases, formation of a single 
diastereoisomer. Also, in this case, only single regioisomers were observed, 
with no 6-endo cyclisation products formed. Compounds 25 were easily 
isolated by column chromatography in high yield (Table 2) and determined to 
be of the structure shown in Scheme 9 by analogy with the group’s previous 
iodocyclisation work.
24a-c 25a-c
Scheme 9. Reagents and Conditions: \2, NaHC03, CH3CN, 10 
minutes.
Entry Alcohol R1 = r2 = Yield 25 (%)
1 24a n-Bu H 66
2 24b Ph H 63
3 24c -(CH2)4- 60
Table 2.
The stereochemical outcome of these reactions can be explained as before. 
The complete regiocontrol observed in these examples is presumably due to 
the lack of the hydroxymethyl group altering the geometry in such a way that 
the 6-endo transition state is even more strained, to the extent that this 
cyclisation process is not observed at all.
While, only 5-exo and competing 6-endo cyclisation modes were investigated 
in this case, owing to these results and the group’s previous work, there seems 
to be no reason why the methodology cannot be extended to incorporate larger 
ring sizes.
1.3 Tandem Epoxidation-Cyclisation Reactions
1.3.1 Introduction
Selective oxidation of cyclohexa-1,4-dienes systems has been reported 
extensively by Landais.12,13 The Sharpless asymmetric dihydroxylation was 
used to great effect in the desymmetrisation of cyclohexadienylsilanes 29 
(Scheme 10). Landais et al. also employed further selective oxidation of these 
systems, by means of Sharpless asymmetric epoxidation, to achieve total 
syntheses of conduritol E and a number of deoxyinositols.
9
S Me2R s Me2R
OHa:
29a, R = /-Bu 30a, R = HBu cuant 7 -% e e
29b, R = Me 30b, R = Me 85 % 6C % ee
Scheme 10. Reagents and Conditions: (a) K20 s 0 2(0H)4, K2C0 3 , 
K3Fe(CN)6, f-BuOH/H20  (1:1), MeS02NH2, (DHQ)2Pyr, 0 °C, 12 h.
Use of epoxidation for the desymmetrisation of cyclohexa-1,4-dienes has also 
been reported by Shi.14 A chiral dioxirane, generated from a fructose-derived 
ketone, and oxone are used to effect desymmetrisation and subsequent kinetic 
resolution, permitting highly selective mono-epoxidation of these systems 
(Scheme 11).
4 examp es
32
o°> r  °
R a <u   ^ O 0 R
33 32
Scheme 11. Reagents and Conditions: (a) Oxone, K2 C0 3 , 
CH3CN/DMM/0.05 M Na2B4O7.10H2O of aqueous EDTA, 0 °C. 53 -  
87 % yields, 79 -  95 % ee.
Crich has previously reported epoxidation-cyclisation reactions of 
cyclohexadiene systems.15 Treatment of substrates 34 with m-CPBA, followed 
by BF3.OEt2 to effect cyclisation, results in the formation of compounds 36 
(Scheme 12). However, the cyclisation step is in fact non-group selective, 
since careful control of the amounts of m-CPBA used ensure only the 
mono-epoxide is formed.
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34a, R = H 
34b, R = -0C H 20-
35a, R = H 67 % 
35b, R = -0C H 20- 
6C %
36a, R = h 86 % 
36b, R = -0C H 20- 
68 %
Scheme 12. Reagents and Conditions: (a) m-CPBA, CH2CI2, 0 °C;
(b) BF3.OEt2, 0 °C.
The substrates 19 used for our group’s initial iodocyclisation studies, derived 
from the Birch reduction/ alkylation sequence, contain two hydroxyl groups, one 
of which is homoallylic. We speculated that this homoallylic alcohol could be 
used to direct the facial selectivity of epoxidation of the cyclohexadiene ring, 
and that the chirality present in the tether could again be used to facilitate 
diastereotopic group selection (Scheme 13). The conformational bias provided 
by the chiral tether should ensure ring opening of only one epoxide, giving rise 
to highly functionalised tetrahydrofurans 38 as single diastereoisomers.
19 37 38
Scheme 13. Anticipated outcome of epoxidation.
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1.3.2 Results and Discussion
1.3.2.1 Diastereoselective Epoxidation-Cyclisation Reactions
With a range of substrates in hand from the iodocyclisation studies, the f-Bu 
substituted diol 19b was chosen as a starting point for the investigation. The 
first method of epoxidation considered was simple m-CPBA oxidation. Diol 19b 
was treated with 2.2 equivalents m-CPBA in dichloromethane with NaHCC>3 as 
base for 24 h.
Scheme 14. Reagents and Conditions: (a) /tt-CPBA, NaHC03, 
CH2CI2 , 0 °C to room temperature, 24 h.
1H NMR spectroscopic data of the crude reaction mixture was promising. The 
starting material had been completely consumed and the crude material 
appeared to consist of one major compound with a few minor impurities. After 
purification by column chromatography, the major product was determined to 
be of structure 38b, as shown in Scheme 14, from 1H and 13C NMR 
spectroscopic data. The stereochemistry was determined crystallographically 
(Figure 4) and is in line with the results obtained from the corresponding 
iodocyclisation reaction of compound 19b.6
12
Figure 4. ORTEP plot of compound 38b. Thermal ellipsoids are 
shown at the 50 % probability level.
With this result in hand, the next task was to try and optimise the reaction 
conditions in an attempt to improve upon the yield. Payne epoxidation 
conditions (H20 2/ NaHCCV MeCN) were evaluated, but showed very slow 
epoxidation, such that no products were characterised. With vanadyl 
acetylacetonate and f-butyl hydroperoxide a mixture of compounds 39 and 38b 
were obtained (Scheme 15).
19b 3 9 , 1 5 %  38b, 5 %
Scheme 15. Reagents and Conditions: (a) VO(acac)2, f-BuOOH, 
CH2CI2, 0 °C to room temperature, 16 h.
The stereochemistry of compound 39 was determined by NOESY NMR 
spectroscopy (Figure 5) and arises from directed mono-epoxidation of the
13
substrate followed by cyclisation. The isolation of only this compound and small 
amounts of 38b hints that the epoxidation step itself may exhibit some 
diastereotopic group selection, although the isolated yield of 39 is far too low to 
categorically confirm this.
-nOe 
39
Figure 5. Stereochemical determination of 39.
Owing to the limited success of these two different epoxidation methods, it was 
decided best to try and optimise the original m-CPBA epoxidation conditions. 
After testing a range of reaction times and reagent quantities, suitable 
conditions were determined, allowing the yield of 38b isolated to be increased 
to 75 %. This involved adding an initial two equivalents of m-CPBA, again with 
NaHC03 as base and stirring for 24 h, followed by addition of 0.1 equivalents of 
/77-CPBA for every subsequent hour until complete consumption of the starting 
material. Typically a total of 2.4 equivalents of m-CPBA were required. With the 
improved conditions we could now test the diversity of this methodology with a 
range of examples.
The substrates for investigation were prepared in the same manner as for the 
group’s previous iodocyclisation work,6 with the exception of the n-hexyl diol 
19d, which had not previously been prepared. This was synthesised by 
alkylation of ester 23 with n-hexyl oxirane to give lactone 40, which was 
subsequently reduced to the diol 19d by treatment with LiAIH4 (Scheme 16).
14
n-CFh n-Cg h -] 2
56% SC %
(b) 1-0
Oh
23 40 19d
Scheme 16. Reagents and Conditions: (a) LDA, n-hexyl oxirane,
THF, -78 °C to room temperature; (b) LiAIH4, THF.
Pleasingly, all but one of the diols investigated underwent successful reaction, 
with similar results to that obtained with diol 38b as shown in Scheme 17 and 
Table 3. The reaction yields are moderate to good and 1H NMR spectra of 
crude reaction mixtures show the formation of no other diastereoisomers, in all 
cases. There appears to be no logical trend in the yields observed, in terms of 
the variation in substituent size and character. As such, the reason for the 
lower yields observed with entries 1 and 4 is not readily apparent, since no 
other compounds were isolated and the products 38a and 38d are stable to 
chromatography.
19a-f 38a-f
Scheme 17. Reagents and Conditions: (a) m-CPBA, NaHC03 
CH2 CI2 , 0 °C to room temperature.
15
Entry Diol R1 R2 Yield 38 (%)
1 19a n-Bu H 40
2 19b t- Bu H 75
3 19c -(CH2)4- 52
4 19d n-CeHi3 H 36
5 19e Ph H 0
6 19f H Ph 55
Table 3.
Entry 5, with a phenyl group in the R1 position shows a key limitation to the 
methodology. The presence of a benzylic alcohol in the substrate led to no 
identifiable products. This limitation cannot be explained by consideration of 
steric factors, since the same substrate undergoes successful iodocyclisation. 
1H NMR spectroscopic data of the crude reaction mixture showed no starting 
material, just a complex mixture of products, suggesting that the substrate is 
decomposing under these conditions.
The stereochemistry of these compounds was assigned by analogy with 
compound 38b and additionally, the stereochemistry of compound 38f was 
determined by NOESY NMR spectroscopy (Figure 6). It should be noted that 
all reactions were also completely regioselective, with only 5-exo cyclisation 
modes observed.
-nOe 
38f
Figure 6. Stereochemical determination of 38f.
HO.
'OH
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1.3.2.2 Regioselective Epoxide Opening
These compounds are ripe for further elaboration, for example, the other 
epoxide can be regioselectively opened with sodium azide, providing access to 
highly functionalised benzofuran derivatives and sugar analogues. Treatment 
of compounds 38 with sodium azide and NH4CI in MeOH/H20  (8:1) at 80 °C for 
20 h16 afforded azides 41 as single regioisomers in moderate to excellent yield, 
as shown in Scheme 18 and Table 4.
41
Scheme 18. Reagents and Conditions: (a) NaN3, NH4CI, MeOH/H20  
(8:1), 80 °C, 20 h.
Entry Epoxide R1 R2 Yield 41 (%)
1 38a n-Bu H 36
2 38b t- Bu H 67
3 38c -(CH2)4- 46
4 38d A7-C6Hi3 H 96
5 38f H Ph 67
Table 4.
In each case, the regioselective epoxide opening occurs at the least hindered 
end, which actually contradicts the outcome predicted by the Furst-Plattner 
rule.17 The Furst-Plattner rule states that ring-opening of cyclohexene oxide 
derivatives leads directly to frans-diaxial products. This can be used to predict 
the regioselectivity of such reactions. For example, in the case of compound 
38b, the kinetic product of attack at the more hindered C-4 position will be
17
compound 42, as shown in Scheme 19. This is generally the more favoured 
mode of attack since the reaction proceeds via a chair-like transition state. 
Attack at the other end of the epoxide (C-5) will proceed via a diaxial twist-boat 
conformation 41b-fiv, which is approximately 21 kJ mol'1 higher in energy than 
the chair conformation,18 normally making attack at this end much less 
favourable.
bO
Ob
38b
Ob
bO
f-Bu
bO
Ob
f-Bu
bO Ob Ob
38b 41b-fw
Scheme 19. Epoxide opening reaction pathways.
However, in the case of compounds 38, attack at the more hindered C-4 
position would result in significant steric interactions between the incoming 
nucleophile and the tetrahydrofuran ring, which outweighs the conformational 
energy barrier to attack at the other end. As such, the epoxides are opened at 
the least hindered C-5 position.
The regiochemistry of the epoxide-opening reactions was determined by 
analysis of coupling constants in the 1H NMR spectra. Of the two possible 
outcomes of the epoxide-opening, each product can potentially exist in one (or 
both) of two chair conformations (Scheme 20). The two conformations 41b-eg 
and 41 b-ax arising from attack at the least hindered end (C-5) will, most likely, 
be similar in terms of stability, and as such this compound would be expected 
to exist as both conformers. The more favoured conformer arising from
18
ring-opening at the other end (C-4) would presumably be 42-eg. The protons at 
C-6 are clearly visible in the 1H NMR spectra of all of the compounds and in 
each case one shows a single trans-diaxial coupling. From ring-opening at the 
C-4 position, zero (conformer 42-ax) or two (conformer 42-eq) trans-diaxial 
couplings to this proton would be expected. For conformers 41b-egand 41 b-ax, 
arising from attack at C-5, one trans-diaxial coupling would be expected in 
each case, as is observed. Hence it can be concluded that the epoxide opening 
is occurring at the C-5 position.
f-Bu t - B u ,  o
HO
OH
38b
t -Bu
Oh
OH
41b-eq 41 b-ax
■Bu t - B u /  o
HO
OH
38b 42-ax
t- Bu
42-eg
Scheme 20. Regiochemical determination of azides 41.
1.3.2.3 Formation of Six Contiguous Stereogenic Centres
In order to really test the potential of the epoxidation-cyclisation methodology, 
we sought to try and incorporate yet more stereochemistry into these 
compounds. Ester 43 is easily prepared by Birch reduction and esterification of 
p-toluic acid.19 Alkylation of this ester with n-butyl oxirane to give lactone 44 as 
a 1:1 mixture of diastereoisomers, followed by treatment with LiAIH4, afforded a 
mixture of isomers 45 and 46 in overall good yield (Scheme 21). Samples of 
the individual isomers for investigation were obtained by extensive 
chromatography on silica gel, although complete separation was not possible.
19
C 0 2 M 6 OH
O HO
63 % comb nec 
2 steps MeMe
44 45
A7-Bu
OH
HO
Me
46
Scheme 21. Reagents and Conditions: (a) LDA, n-butyl oxirane, 
THF, -78 °C to 5 °C, 3 h; (b) LiAIH4, THF.
Diols 45 and 46 were submitted to our standard epoxidation conditions and 
pleasingly both underwent successful epoxidation-cyclisation to give, in each 
case, a single diastereoisomer of epoxides 47 and 48 (Scheme 22).
(a)
n-Bu
47, 20 %
A7-Bu
48, 38 %
Scheme 22. Reagents and Conditions: (a) /77-CPBA, NaHCC>3 , 
CH2CI2 , 0 °C to room temperature.
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The stereochemistry of compound 48 was assigned by X-ray diffraction (Figure 
7) and the stereochemistry of diols 45 and 46 assigned retrospectively. The 
yields are relatively low, but the complexity of the stereochemistry gained in 
some way justifies this; we are obtaining formation of six contiguous 
stereogenic centres, selectively, in a single step.
Figure 7. ORTEP plot of compound 48. Thermal ellipsoids are 
shown at the 50 % probability level.
The higher yield of compound 48 compared to that of compound 47 is 
unexpected. For diol 46, with the methyl group on the lower face of the 
cyclohexadiene ring, we predicted a significant steric interaction between this 
group and the incoming epoxidising agent (Figure 8), lowering the rate of 
epoxidation and hence the yield of compound 48. This appears not to be the 
case, and in fact there appears to be a greater barrier to reaction of diol 45 
under these conditions. This is presumably due to the presence of the methyl 
group on the top face of the ring hindering attack of the free hydroxyl group on 
the same face, as illustrated in Figure 8.
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Figure 8. Steric barrier to reaction of compounds 45 and 46.
1.4 Conclusion
In conclusion, iodocyclisation and epoxidation-cyclisation reactions of 
cyclohexadienes have been shown to proceed with complete regio- and 
diastereocontrol, providing access to highly functionalised tetrahydrofurans. 
Novel epoxidation methodology has enabled the selective formation of six 
contiguous stereogenic centres in a single step. Furthermore, the epoxides 
yielded can be elaborated further allowing facile access to complex sugar 
analogues. As such this methodology should be of great use in synthesis.
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Chapter 2
The Cladiellin Diterpenes and Prins Cyclisation 
Reactions of Cyclohexa-1,4-dienes
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2.1 Introduction
2.1.1 The Cladiellin Diterpenes
Over the past 40 years, a large number of cyclic diterpenoids containing one of 
the heterocyclic frameworks shown in Figure 9 have been isolated from marine 
invertebrates.20 These secondary marine metabolites, extracted from 
octocorals, have been classified into four categories: the cladiellins (also known 
as the eunicellins), the briarellins, the asbestinins and the sarcodictyins.
16
cladiellins
briarellins
16
sarcodictyins
asbestinins
Figure 9. General framework of the cladiellins, briarellins, 
asbestinins and sarcodictyins.
The cladiellins, briarellins and asbestinins are all structurally similar, being 
comprised primarily of a rare oxatricyclic ring system, made up of 
octahydroisobenzofuran and oxacyclononane moieties. The briarellins and 
asbestinins also feature an additional 7-membered ether bridge between C-3 
and C-16. The sarcodictyins contain a single ether bridge in a different position 
to the others; between C-4 and C-7.
The cladiellins represent the most abundant class of these fascinating natural 
products, and indeed the first of such cyclic diterpenoids isolated was a
24
member of the cladiellin family. Eunicellin (Figure 10) was isolated by Djerassi 
et al in 1968 after extraction of Eunicella stricta, a species of gorgonian coral 
collected off the coast of Banyuls-sur-Mer, France.21 Since then more than 60 
members of the cladiellin family have been isolated.20
The relative and absolute stereochemistries of a number of cladiellins have 
been determined by X-ray crystallographic analysis.20 Additionally, 
stereochemical configurations have been established or confirmed by total 
synthesis. The relative stereochemistry of the core is characterised by an anti 
relationship between the two pairs of ring junction protons, as shown in the 
examples in Figure 10.
HO/.
sc erophyt n A
OAc
OAc
AcO
AcO
c ac e n
Figure 10. Examples of cladiellin diterpenes.
The cladiellin diterpenes exhibit an interesting array of biological activity. These 
secondary metabolites appear to naturally function as a defence mechanism of 
octocorals against predation, possessing, amongst other activities, mollusc and 
brine shrimp lethality.22 This class of compounds also exhibit some interesting 
pharmacological potential, such as anti-inflammatory and anti-tumour activity. 
For example, sclerophytin A (Figure 10) shows very potent cytotoxic activity
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against L1210 leukemia cells23 and cladiellin (Figure 10) has been shown to be 
a cAMP phosphodiesterase inhibitor, providing anti-inflammatory activity.20
Owing to their intriguing structure and interesting pharmacological activity, the 
cladiellins have seen a great deal of interest from a number of synthetic 
research groups, especially the groups of Overman,24 Paquette,25 Molander,26 
Kim 27 Crimmins28 and Hoppe.29 The Overman group was the first to report a 
total synthesis of a member of the cladiellin family in 1995.24a Overman et al. 
employed their key stereoselective Prins-pinacol condensation-rearrangement 
methodology to synthesise the isobenzofuran core 52. The core was then 
further elaborated to achieve an enantioselective total synthesis of 
(-)-7-deacetoxyalcyonin acetate 53 (Scheme 23).
49
4 steps 
£C % y e d
TMS
50
R = CHO
(a) OHC OTIPS
51
AcO/(
"4 steps 
2C % y e c
TMS
TIPSO
53
-7-ceacetoxya cyon n acetate
52 79%
Scheme 23. Reagents and Conditions: (a) BF3.OEt2, CH2Cl2 , -55 °C 
to -20 °C.
In 2001, two independent syntheses of sclerophytin A were reported by the 
groups of Overman and Paquette,24c,25c enabling revision of its structural
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formulation. Previous targeted syntheses by both groups had shown the 
originally proposed structure 54 of sclerophytin A to be incorrect (see Figure 
11).24b>25a Subsequent detailed spectroscopic re-evaluation of sclerophytin B 
(the monoacetate of sclerophytin A) by the Paquette group, suggested the 
absence of the second ether bridge in these natural products.25b As such, 
subsequent syntheses were approached accordingly.
Figure 11. Structural revision of sclerophytin A and B.
The Paquette group devised a synthesis involving a tandem Tebbe-Claisen 
ring expansion strategy for installing the nine-membered ring.250 Beginning with 
a Diels-Alder cycloaddition of diene 55 and furanone 56, compound 58 was 
synthesised in 13 synthetic steps (Scheme 24).
54 sc erophyt n A sc erophyt n B
27
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OMe
55
OMen
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o
56
MenO
(b)
57
" '  steps
27 % y e 0 overa
OH
.OTBDPS
58
Scheme 24. Reagents and Conditions: (a) Toluene, reflux; (b) 
TMSOTf, pyridine, CH2CI2 , -78 °C.
Macrolactonisation of compound 58 gave a separable mixture of 
diastereoisomers 59 and 60, which were then separately submitted to Tebbe 
olefination to give compounds 61 and 62 (Scheme 25). Claisen rearrangement 
of both compounds 61 and 62 gave compound 63.
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59
OTBDPS
60
Cp2TiC^!*AIMe2
Ho
(b)
6 8 %
Cp2TiC ^/A IM e2
h 2
(b)
61 %
.OTBDPS
61
.OTBDPS
62
76%71 %
Me
.OTBDPS
63
Scheme 25. Reagents and Conditions: (a) CI3C6H2 COCI, Et3N, 
4-DMAP, toluene; (b) Pyridine, THF, -50 °C to 20 °C; (c) p-cymene,
140 °C, 3 h; (d) p-cymene, 130 °C, 1.5 h.
Compound 63 was subsequently converted into sclerophytin A (64) in a further 
13 steps (Scheme 26). The spectroscopic data of synthetic 64 was identical to 
that of natural sclerophytin A, confirming the structural revision.
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63
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sc erophyt n A
Scheme 26. Synthesis of sclerophytin A (64).
The Molander group have reported a concise approach to the cladiellin 
skeleton, employing a [4 + 3] annulation strategy to create the 
octahydroisobenzofuran moiety 67, followed by an Sml2-mediated cyclisation 
reaction to install the nine-membered ring.26b The precursor for the 
Sml2-mediated cyclisation 68 was synthesised in 12 steps, including the [4 + 3] 
annulation, from R-(-)-a-phellandrene 65 (Scheme 27).
2 steps 
■ 6 % y e d
65
R = TES
66
OAc
OR OR
OMe
(a)
|4+a; 
annu ai on
(b)
Sml2-mec atec 
eye sat on
MeOoC
67 35 %
S steps 
5 % y e c
OAc
H
69 88 % 68
Scheme 27. Reagents and Conditions: (a) TiCU, CH2CI2; (b) Sml2, 
HMPA, THF.
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Elimination of the cyclisation product 69, followed by oxidative cleavage of the 
resulting double bond enabled formation of the cladiellin skeleton 71 in a total 
of 15 steps (Scheme 28). Further elaboration of the skeleton resulted in the 
synthesis of of the 3,7-diastereoisomer of polyanthellin A (72).
OAc
69
OAc
OAc
8 8 %
H
70
(b) 83%
OAc
3 steps, 
37 % yield
cladiellin skeleton
71
Scheme 28. Reagents and Conditions: (a) Burgess reagent, DMF;
(b) O3 , CH2CI2 then Me2S.
The group of Kim developed a neat strategy for the first synthesis of a 
(6E)-cladiellin, (-)-cladiella-6,11-diene-3-ol, in 2006.27 Using a different 
approach to these compounds, the Kim group began with construction of the 
nine-membered ring sub-unit 77, via a key intramolecular amide enolate 
alkylation reaction (Scheme 29). Treatment of amide 76 with LHMDS in THF 
resulted in the formation of the desired (E)-oxonene 77 as a single 
diastereoisomer, through control of the enolate geometry in the transition state.
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76
Scheme 29. Reagents and Conditions: (a) n-Bu2BOTf, Et3N, CH2 CI2 , 
-78 °C to 0 °C, 2 h; (b) LHMDS, THF, 45 °C, 1 h.
Further elaboration of the (E)-oxonene 77 yielded compound 78, which was 
submitted to an intramolecular Diels-Alder strategy, previously reported by both 
Crimmins28 and Holmes,30 for construction the hydroisobenzofuran core 
(Scheme 30). A further five steps completed the synthesis of 
(-)-cladiella-6,11-diene-3-ol 80.27
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H  OTBDPS
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48 % yield
77
TrO
78
(a) 8 5 %
5 steps, 
45 % yield TrO
7980
(-)-cladiella-6,11-diene-3-ol
Scheme 30. Reagents and Conditions: (a) BHT, xylene, reflux, 1 h.
Kim et al. were then able to further elaborate (-)-cladiella-6,11-diene-3-ol 80 to 
achieve the total synthesis of three additional cladiellins in relatively few 
synthetic steps. (+)-polyanthellin A 81, (-)-cladiell-l 1-ene-3,6,7-triol 82, and 
(-)-7-deacetoxyalcyonin acetate 53 were synthesised using
(-)-cladiella-6,11-diene-3-ol 80 as a common intermediate (Scheme 31).
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HO
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(+)-polyanthellin A
80
(-)-cladiella-6,11-diene-3-ol
53
(-)-7-deacetoxyalcyonin
acetate
Scheme 31. Reagents and Conditions: (a) 0 s 0 4, NMO, THF/H20  
(3:1), 0°C, 1 h.
2.1.2 Diastereoselective Prins-Mediated Desymmetrisation of 
Cyclohexa-1,4-dienes
In recent years our group has established methodology for the 
desymmetrisation of cyclohexa-1,4-dienes via a diastereoselective Prins 
reaction.7a,b Chiral cyclohexa-1,4-diene derived acetals can be treated with a 
Lewis acid catalyst to effect cyclisation reactions with very high levels of 
diastereocontrol. For example, treatment of acetal 83 with TiCU results in the 
formation of three cyclisation products, 84, 85 and 86, as shown in Scheme 
32.7a
34
83 84 (not isolated) 85, 38 %
chromatography 
on silica gel
O LJ
le
O
H Ph
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Scheme 32. Reagents and Conditions: (a) TiCU, CH2 CI2 , -78 °C, 2 h.
This TiCU-mediated reaction is highly diastereoselective, however the low 
selectivity for any one compound posed a problem for any subsequent 
application of the methodology. More recent work within in the group has 
overcome this problem by employing the use of an acid catalyst with a 
non-nucleophilic counter-ion.7b For example, when treated with triflic acid, 
acetal 87 gives predominantly aldehyde 88 along with small amounts of ketone 
89, both as single diastereoisomers (Scheme 33).
Me
O
87 88 66 % 89 6 %
Scheme 33. Reagents and Conditions: (a) TfOH (1.6 equiv.) 
CH2CI2 , room temperature, 15 min.
The formation of these products can be explained by the proposed mechanism 
shown in Scheme 34. Protonation of the least hindered oxygen atom of acetal 
90, followed by acetal opening gives oxocarbenium ion 91. 6-endo cyclisation 
onto one of the diastereotopic double bonds then proceeds, followed by a 
Wagner-Meerwein shift, to give the more stable tertiary allylic cation 93. 
Deprotonation to give the conjugated enol 94, followed by a keto-enol 
tautomerism, gives the aldehyde 95. The ketone product 96 arises from 
protonation of the more hindered oxygen atom of the acetal 90, followed by a 
similar sequence.
OH R1
' 'd1
90
O COH
vd1
© -O.
HCQ O
/ d 1
© ^  6-endo
91 92
Wagner- 
Meerwein shift
HO
©
H
94
HO. M
96
Scheme 34. Proposed mechanism of Prins cyclisation and 
rearrangement.
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Clearly, reduction in the size of the acid cation, when moving from the use of 
TiCU to triflic acid, reduces the regioselectivity of the acetal opening, which is 
why small amounts ketone are observed with the triflic acid-mediated reactions.
The major products 95 of these Prins cyclisation/rearrangement reactions are 
hydroisobenzofurans similar in structure to the core of the cladiellin diterpenes, 
with one major discrepancy- the relative stereochemistry. Instead of the anti 
relationship observed between the ring junction protons in the cladiellins, we 
are obtaining the opposite syn stereochemistry.
The stereochemistry of the formation of compounds 95 is determined by 
minimisation of A1,3 strain in the transition state (Scheme 35). The transition 
state will preferentially adopt a conformation in which the R1 and R2 groups are 
furthest away from each other, as in conformer 97, minimising steric 
interactions. This gives rise to the high levels of diastereocontrol observed.
H R1
 ► H O ^ 'X ^O
H fl © l l
l\ X > R2
90 97 92
I
H
98
Scheme 35. Origin of the stereochemistry of the Prins 
cyclisation/rearrangement.
Owing to this rationale, we proposed that the stereochemical outcome of the 
reaction could be reversed by tethering the R1 and R2 groups, as shown in
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Scheme 36. The generated oxocarbenium ion would preferentially adopt the 
near-attack conformation 99 rather than the alternative eclipsed conformation, 
generating the desired cladiellin stereochemistry. The presence of the tethering 
chain would also have the additional benefit of introducing an extra ring into the 
product 100.
Scheme 36.
2.2 Results and Discussion
In order to test the theory, we first needed to devise a suitable substrate. We 
considered that a compound of structure 101, which would presumably exist 
predominantly as the lactol 102, should give the desired oxocarbenium ion 99, 
when treated with an acid catalyst (Scheme 37).
HO H . ChO
H
99 100
OH
HO
OH
CHO
HO H©
HO
101 102 99
Scheme 37. Proposed Prins substrate.
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2.2.1 First Generation Approach to the Cladiellin Core
To construct the substrate 101, we envisaged installing the aldehyde 
functionality by hydroboration and subsequent oxidation of the corresponding 
terminal alkene 103. Synthesis of the alkene 103 would be approached via 
alkylation of ester 23 (Scheme 38).
C 0 2Me
6  
23
(PG = protect no croup)
Scheme 38. Retrosynthesis of compound 101.
From previous work in the group, we knew that ester 23 could be acylated 
efficiently with acyl chlorides.73 As such we sought to install the alkenyl 
side-chain with 4-pentenoyl chloride, which was made by a known literature 
procedure from 4-pentenoic acid.31 Ester 23 was deprotonated by treatment 
with LDA and, following reaction of the resulting enolate with 4-pentenoyl 
chloride, gave compound 104 in good yield (Scheme 39).
C 02Me
6 
23
Scheme 39. Reagents and Conditions: (a) LDA, THF, -78 °C then 
4-pentenoyl chloride.
The p-keto-ester 104 was then globally reduced with LiAIH4 and the resulting 
diol 105 was treated with TBSOTf to protect the free hydroxyl groups as silyl 
ethers (Scheme 40).
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Scheme 40. Reagents and Conditions: (a) LiAIH4, THF; (b) TBSOTf, 
2,6-lutidine, CH2 CI2 , 0 °C to room temperature, 18 h.
Hydroboration of compound 106 required the use of a significantly hindered 
organoborane, which would selectively attack the terminal alkene rather than 
the cyclohexadiene double bonds. For this purpose, 9-BBN was chosen. 
Treatment of compound 106 with 9-BBN in THF, followed by a hydrogen 
peroxide work-up gave the bis-protected triol 107 in excellent yield (Scheme 
41).
OTBS
106
OTBS
84 %
TBSO OH
107
Scheme 41. Reagents and Conditions: (a) 9-BBN, THF, 18 h then 
H20 2, NaOH.
Compound 107 was subsequently oxidised to the aldehyde 108, using PDC as 
the oxidising agent (Scheme 42).
OTBS OTBS
TBSO Oh
107
5S %
CHO
TBSO
108
Scheme 42. Reagents and Conditions: (a) PDC, CH2CI2, 18 h.
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With the aldehyde 108 in hand, we initially decided to treat this compound 
directly with triflic acid in an attempt to effect deprotection and subsequent 
Prins cyclisation/rearrangement in a one-pot reaction. Compound 108 was 
treated with 1 equivalent of triflic acid in dichloromethane for 20 minutes at 
room temperature. We were very pleased to find that this gave compound 109 
as a single diastereoisomer, albeit in moderate yield (Scheme 43).
OTBS
TBSO^XS^^^o 
108
Scheme 43. Reagents and Conditions: (a) TfOH (1 equiv.), CH2CI2 ,
0 °C to room temperature, 20 minutes.
The mass balance for the reaction was low, such that the crude reaction 
mixture consisted almost entirely of compound 109. The relatively low yield 
observed can be attributed to the complexity of the chemistry involved in the 
sequence; deprotection of the primary and secondary alcohols followed by 
lactol formation, oxocarbenium ion generation and the Prins 
cyclisation/rearrangement. Attempts were made to improve the overall 
efficiency of the process by initial deprotection of compound 97, but to no avail. 
Treatment of the aldehyde 108 with TBAF in THF resulted in a complex mixture 
of products.
Confirming the stereochemistry of compound 109 was not straightforward as 
there were no diagnostic cross-peaks in the NOESY NMR spectrum. However, 
based on molecular modelling of the two possible diastereoisomers, the 
observed 1H NMR coupling constants are far more compatible with compound 
109. For example the signal for H-7 in the 1H NMR spectrum appears as a 
doublet of J 8.6 Hz and H-1 shows an 8.6 Hz coupling, which is presumably to 
H-7. We would expect H-7 to show coupling to both H-1 and H-6. However 
molecular modelling of diastereoisomer 109 shows that the dihedral angle
CHO
32%
109
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between H-6 and H-7 is approaching 90°, as illustrated in Figure 12. As such, 
a coupling constant of close to 0 Hz would be expected between these two 
protons, so it is very feasible that the signal of H-7 would appear as a doublet 
of J 8.6 Hz in the 1H NMR spectrum of this diastereoisomer.
Figure 12. Chem3D representation of diastereoisomer 109.
For the alternative diastereoisomer 110, molecular modelling shows that the 
dihedral angle between H-6 and H-7 is approaching 0°, as illustrated in Figure 
13. Hence for this diastereoisomer, a relatively large coupling constant would 
be expected between these two protons, so we would expect a more complex 
coupling pattern for H-7 than is observed.
OHC , , H
H 1 3 
H
110
Figure 13. Chem3D representation of diastereoisomer 110.
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Owing to this evidence and our previous mechanistic reasoning, we are 
confident in the stereochemical assignment of compound 109.
We were very pleased with this result; we had obtained the cladiellin core as a 
single diastereoisomer in relatively few synthetic steps. However, the low yield 
of our key step posed a significant problem. In an attempt to overcome this 
problem we endeavoured to synthesise a substrate for our key step, similar to 
compound 108, but without the use of extensive silyl protecting groups. This 
would reduce the complexity of the reaction pathway and hopefully improve 
upon the yield of the reaction.
2.2.2 Improved Approach to the Cladiellin Core
Previous work in the group had identified (3-keto-ester 111 as an intermediate 
in the synthesis of a number of the chiral acetals 112 used in the initial Prins 
cyclisation/rearrangement studies (Scheme 44).7a
C 0 2Me
R
0 ^ 0
65 %
23 111
(b) (c)
112
Scheme 44. Reagents and Conditions: (a) LDA, THF, -78 °C then 
AcCI; (b) LiAIH4, THF; (c) RCHO, PPTS, CH2CI2 or H2S04, DMF.
We originally envisaged alkylation of compound 111 with commercially 
available 2-(2-bromoethyl)-1,3-dioxolane 113 leading to compound 114. This 
could then be globally reduced with LiAIH4 giving substrate 115 for the Prins 
reaction in very few steps (Scheme 45).
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Scheme 45. Proposed synthesis of substrate 115.
Unfortunately, treatment of compound 111 with LDA as base resulted in 
deacylation of the (3-keto-ester 111 and the resulting anion went on to react 
with the 2-(2-bromoethyl)-1,3-dioxolane 113 to give compound 116, as shown 
in Scheme 46.
o
M e02C
Me
111
6C %
116
Scheme 46. Reagents and Conditions: (a) LDA, THF, -78 °C then 2- 
(2-bromoethyl)-1,3-dioxolane 113.
Owing to this result, we attempted a different approach (Scheme 47). Again, 
with the knowledge that ester 23 could be readily alkylated with acyl chlorides, 
we endeavoured to synthesise compound 117. This would hopefully then allow 
access to compound 114 and subsequently substrate 115.
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117
Scheme 47. Retrosynthesis of compound 103.
Starting with 2-(2-bromoethyl)-1,3-dioxolane 113, a two carbon homologation 
was performed with acetonitrile, to give nitrile 118 in good yield. Hydrolysis of 
compound 118 with KOH in Et0H/H20  (2:1) gave acid 119, as shown in 
Scheme 48.
- 51*  8 V
8S %  h 0
119
Scheme 48. Reagents and Conditions: (a) LDA, MeCN, THF, -78 °C 
to room temperature, 18 h; (b) KOH, Et0H/H20  (2:1), reflux, 16 h.
The group of Wissner reported a strategy for forming acyl chlorides from 
carboxylic acids containing additional acid-sensitive functionality. 32 The 
methodology involved converting the acid to the corresponding 
te/t-butyldimethylsilyl ester, which was then treated with oxalyl chloride and 
catalytic DMF at room temperature to give the acyl chloride. This enabled the 
formation of acyl chlorides under much milder conditions than would usually be 
required. Applying these conditions to acid 119, silyl ester 120 was obtained in 
excellent yield and was converted successfully into compound 117 (Scheme 
49).
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Scheme 49. Reagents and Conditions: (a) TBS-CI, imidazole, 
4-DMAP, CH2CI2, 30 minutes; (b) (COCI)2, DMF (cat.), CH2CI2, 0 °C 
to room temperature, 2  h.
The acyl chloride 117 was relatively unstable, such that any attempts at 
purification resulted in its decomposition. As a result, it was used directly in 
subsequent reactions and an isolated yield was never recorded. Alkylation of 
ester 23 proceeded smoothly and the resulting keto-ester 114 was immediately 
reduced with LiAIH4  to give compound 115 (Scheme 50).
115
Scheme 50. Reagents and Conditions: (a) LDA, THF, -78 °C then 
117; (b) LiAIH4, THF.
The stated yield of compound 115 is low, although it actually represents the 
yield over 3 steps from the silyl ester 120. In any case, the sequence yielded 
enough of substrate 115 to test our key Prins cyclisation/rearrangement 
reaction. Gratifyingly, treatment of compound 115 with triflic acid under the
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same conditions as before gave compound 109 as a single diastereoisomer in 
88 % yield (Scheme 51).
OH
HO'
115
8 8 %
OH
H
O' vWOH
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d u CHO H
109
Scheme 51. Reagents and Conditions: (a) TfOH ( 1  equiv.), CH2 CI2, 
0 °C to room temperature, 20 minutes.
2.3 Conclusion
A model for the hydroisobenzofuran core (109) of the cladiellin diterpenes has 
been synthesised, as a single diastereoisomer, using Prins 
cyclisation/rearrangement methodology developed within the group. A revised 
approach enabled our key step to be optimised to an excellent 8 8  % yield. The 
results obtained now provided scope for access to the cladiellin diterpenes.
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Chapter 3
Studies Towards the Synthesis of the Cladiellin
Framework
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3.1 Introduction
With our model of the cladiellin core in hand, we could now think about 
expanding the model to approach the cladiellin framework. In order to achieve 
this, we first needed to find a way of incorporating a larger ring size into the 
system. As previously stated, the cladiellins contain a nine-membered 
oxacyclic component in addition to the octahydroisobenzofuran moiety, 
whereas our model compound (109) only contains an additional six-membered 
ring (Figure 14).
Figure 14.
We considered that attempting to install the nine-membered ring directly by 
formation of a nine-membered lactol 1 2 2  and generation of the corresponding 
oxocarbenium ion 123 (Scheme 52) would be a near-impossible task.
Scheme 52.
Consequently, we proposed that a compound of structure 125 with an 
additional five-membered ring fused onto the six-membered lactol might be 
more easily obtained (Scheme 53). Subsequent generation of the
c ac e n 
framework
109
CHO OH
1 2 1 1 2 2 123
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corresponding oxocarbenium ion 126 is also more plausible as we have 
already demonstrated the formation and successful Prins cyclisation of a 
six-membered cyclic oxocarbenium ion in the model studies.
OH
CHO
HO
124 125
©
126
Scheme 53. Proposed Prins substrate.
Successful Prins cyclisation/rearrangement of oxocarbenium ion 126 would 
theoretically give compound 127 (Scheme 54). From this point, we could 
consider converging with Molander’s approach to the cladiellin skeleton. 2 6 We 
could envisage selective oxidative cleavage of the tetra-substituted double 
bond, to give the nine-membered ring directly, 3 3  as shown in Scheme 54.
126
H . V H0
128
Scheme 54. Proposed selective oxidative cleavage of compound 
127.
However, the Molander group were unable to achieve selective oxidative 
cleavage of the tetra-substituted double bond in a similar compound, during 
their synthesis of (-)-7-deacetoxyalcyonin acetate 53.26a To overcome this 
problem, Molander et al. chemoselectively protected the tri-substituted double 
bond as the epoxide 130 before the oxidative cleavage step (Scheme 55). The 
epoxide 130 was subsequently reduced using Sharpless’ reagent and a further 
three synthetic steps led to (-)-7-deacetoxyalcyonin acetate 53.
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Scheme 55. Reagents and Conditions: (a) m-CPBA, 0 °C, 1 h; (b) 
0 3, -78 °C, then DMS, room temperature, 3 h; (c) WCI6, n-BuLi ( 2  
equiv.).
Molander’s work would suggest that selective oxidative cleavage of compound 
127 could be difficult, although the presence of the more electron-deficient enal 
in compound 127 might facilitate more selective cleavage of the 
tetra-substituted double bond. If selective cleavage is not possible, the enal 
could potentially be protected as the epoxide first, to allow cleavage of the 
desired double bond.
There are a number of possible retrosynthetic approaches to substrate 124, a 
few of which are illustrated in Scheme 56. We chose the third approach as our 
starting point. We proposed that if we could synthesise compound 137, where 
X is a halogen, we could generate the corresponding organolithium reagent via 
a lithium-halogen exchange. This could then be reacted with the epoxide 136 to 
give our desired substrate 124.
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Scheme 56. Retrosyntheses of substrate 124.
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3.2 Results and Discussion
2-Bromocyclopent-1-enecarbaldehyde 139 was easily prepared from 
cyclopentanone 138 by a known literature procedure (Scheme 57).3 4  Before 
any subsequent organolithium reactions however, the aldehyde 139 needed to 
be protected. We originally envisaged protecting the aldehyde functionality as 
an acetal 140. Unfortunately any attempts at forming an acetal, under a variety 
of standard conditions, resulted in decomposition of the aldehyde 139.
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(a)
Br
CHO
Br
ORRO
138 139 140
Scheme 57. Reagents and Conditions: (a) PBr3, DMF, CH2CI2 , 0  °C 
to room temperature, 18 h; (b) Attempted Conditions: (i) MeOH, 
NH4 CI, reflux, 1 h; (ii) MeOH, NH4 CI, room temperature, 18 h; (iii) 
MeOH, TMSCI, room temperature, 16 h.
As a result, we decided to reduce the aldehyde 139 and protect the resulting 
alcohol 141, in the hope that deprotection and subsequent oxidation could be 
achieved at a later stage. Treatment of aldehyde 139 with sodium borohydride, 
according to a known literature procedure, 3 5 gave compound 141, which was 
subsequently protected as the silyl ether 142 (Scheme 58).
Scheme 58. Reagents and Conditions: (a) NaBH4, MeOH, 0  °C to 
room temperature, 1 h; (b) TBSCI, imidazole, 4-DMAP, CH2CI2 , 18 h.
In order to test whether compound 142 could be effectively lithiated and 
reacted with an epoxide, a model study was conducted. Compound 142 was 
treated with f-butyllithium and the resulting organolithium reagent was reacted 
with n-butyloxirane. Pleasingly, this gave compound 143 in good yield 
(Scheme 59).
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Scheme 59. Reagents and Conditions: (a) f-BuLi, THF, -78 °C, then 
n-butyloxirane, BF3 .OEt2.
With this result in hand, we were confident in our approach and could now 
devise a synthesis of the desired epoxide 136. Ester 144 was prepared by 
Birch reduction and subsequent esterification of benzoic acid 22. Alkylation of 
ester 144 with methyl chloroformate afforded the diester 145 in excellent yield 
(Scheme 60).
c o 2h C 0 2Et
(a) (b)
74%
(c) E t02C ^ / C 0 2Me
84 %
22 144 145
Scheme 60. Reagents and Conditions: (a) Na, NH3-EtOH (4:1), -78 
°C; (b) EtOH, H2S04, 16 h; (c) LDA, THF, -78 °C, then methyl 
chloroformate.
Compound 145 was then globally reduced by treatment with LiAIH4 and the 
resulting diol 146 was mono-protected as the silyl ether 147 (Scheme 61).
Et02C;>< C 0 2Me (a) h O ^ > O o H  (b) T B S O ^ X ^ O h
O “  O x r O
145 146 147
Scheme 61. Reagents and Conditions: (a) LiAIH4, THF, 2  h; (b) 
n-BuLi, -78 °C to room temperature, then TBSCI, imidazole, 16 h.
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Oxidation of compound 147 under Swern conditions proceeded smoothly, 
giving aldehyde 148 in excellent yield. To make the epoxide 149, aldehyde 148 
was treated with dibromomethane and />butyl lithium. An incomplete reaction 
gave a 1 : 2  mixture of starting material and product, which were inseparable by 
column chromatography (Scheme 62).
TBSO TBSO
(b) 148:149 = 1 24C % overa
TBSO TBSO
Scheme 62. Reagents and Conditions: (a) (COCI)2, DMSO, NEt3, 
CH2CI2, -78 °C to room temperature, 2  h; (b) n-BuLi, CH2 Br2,
THF, -78 °C to room temperature, 18 h.
From this point, we decided to react the inseparable mixture of compounds 148 
and 149 with the organolithium reagent derived from compound 142, in the 
hope that we might be able to separate the two possible coupling products. 
Compound 142 was treated sequentially with Fbutyllithium and the mixture of 
compounds 148 and 149. Unfortunately, the only species isolated from the 
reaction was compound 150, arising from coupling of the bromide 142 and the 
aldehyde 148 (Scheme 63).
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OHO O
TBSO + TBSO (a) TBSO
148 149 150 65 %
* Yield based on the calculated amount of aldehyde 148 present in the 1:2 mixture 
of compounds 148 and 149.
Scheme 63. Reagents and Conditions: (a) f-BuLi, 142, BF3 .OEt2,
THF, -78 °C.
Compound 150 could theoretically be elaborated to give a substrate for our 
Prins cyclisation reaction, but it would give the wrong ring size for the cladiellin 
framework. Consequently, we decided it was necessary to find a way of either 
driving the epoxide formation to completion, or separating the aldehyde 148 
and epoxide 149 after the reaction. In an effort to achieve this, the reaction time 
of the epoxide formation was increased from 18 h to 24 h. While this still gave 
incomplete conversion of the starting material, we did see an increase in the 
amount of epoxide 149 formed relative to recovered aldehyde 148 (Scheme 
64). We were then able to treat the mixture of compounds 148 and 149 with 
sodium borohydride to reduce the remaining aldehyde 148 to the alcohol 147, 
allowing facile isolation of the epoxide 149.
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CHO
TBSO
CHO + TBSO(a)
148:149 = 27
148 148 149
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TBSO'
149
Scheme 64. Reagents and Conditions: (a) n-BuLi, CH2 Br2, THF, -78 
°C to room temperature, 24 h; (b) NaBH4, MeOH, 0 °C to room 
temperature, 1 h.
With the epoxide 149 in hand, we were now in a position to attempt coupling 
the two fragments. Compound 149 was treated with the organolithium reagent 
derived from compound 142 and gratifyingly this gave compound 151, albeit in 
a relatively low yield (Scheme 65).
Scheme 65. Reagents and Conditions: (a) HBuLi, 142, BF3 .OEt2,
THF, -78 °C.
From this point, we envisaged global deprotection of compound 151 followed 
by selective oxidation of the allylic alcohol, to give the substrate 124 for our key 
Prins cyclisation/rearrangement step. Unfortunately, whilst effective 
deprotection of both primary alcohols was possible, attempted selective
OTBS
149 151
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oxidation of the allylic alcohol with manganese dioxide resulted in a complex 
mixture of products (Scheme 66).
TBSO
78 %
(a) HO
OH
151 152
CHO
124
Scheme 66. Reagents and Conditions: (a) TBAF, THF, 18 h; (b) 
Mn0 2 , CH2 CI2 , room temperature, 1 h.
Owing to the limited amount of compound 151 we were able to synthesise, 
rather than testing a range of different oxidising agents at this point, we devised 
a new plan. We decided it was necessary to develop a more orthogonal 
protecting group strategy, preferably working with the cyclopentene fragment at 
the desired aldehyde oxidation level. Pleasingly, searching the literature 
identified a procedure for protecting aldehyde 139 as the dimethyl acetal 153 
(Scheme 67).36
139 153
Scheme 67. Reagents and Conditions: (a) CH(OMe)3, MeOH 
camphorsulfonic acid, 18 h.
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However, compound 153 proved to be relatively unstable and unfortunately any 
attempts at effecting lithiation and subsequent reaction with the epoxide 149 
were unsuccessful (Scheme 68).
Scheme 6 8 . Reagents and Conditions: (a) f-BuLi, 153, BF3 .OEt2,
THF, -78 °C.
Owing to this result, we decided to carry out another model study. We 
considered that acetal 155, with a benzene ring in place of the cyclopentene 
ring, might be more stable and more easily reacted with the epoxide 149 
(Scheme 69). The presence of the benzene ring in substrate 156 should still 
allow it to undergo successful Prins cyclisation reaction, although obviously the 
product 157 could not be further elaborated to achieve the cladiellin framework. 
However, this study would provide proof of concept.
TBSO TBSO
149 154
149 155 156
H CHO 
¥ H |
H
157
Scheme 69. Proposed model study.
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Acetal 155 was prepared according to a known literature procedure.37 In order 
to assess the ability to lithiate compound 155 and react it with an epoxide, a 
test reaction was conducted. Compound 155 was treated with f-butyllithium, 
followed by n-butyloxirane and gratifyingly this gave compound 158, albeit in 
moderate yield (Scheme 70).
Scheme 70. Reagents and Conditions: (a) f-BuLi, THF, -78 °C, then 
/7-butyloxirane, BF3 .OEt2.
With this result in hand, the reaction was repeated, this time with epoxide 149 
instead of n-butyloxirane. After chromatography on silica gel, the reaction 
initially appeared to have given compound 156, by analysis of 1H and 13C NMR 
spectroscopic data. However, submitting this reaction product to our Prins 
cyclisation conditions did not give the desired compound 157. Instead, the 
major product of the reaction was compound 159, as shown in Scheme 71.
Scheme 71. Apparent outcome of reaction. Reagents and 
Conditions: (a) f-BuLi, 155, BF3 .OEt2, THF, -78 °C; (b) TfOH ( 2  
equiv.), CH2 CI2, 0 °C to room temperature, 25 minutes.
Br
MeU OMe
3S %
(a)
C4Hg u  OMe
155 158
Br
TBSO
Br
159
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The structural assignment of compound 159 was by no means straightforward. 
Extensive analysis of 1H and 13C NMR spectroscopic data, and 1H -  1H and 1H 
-  13C correlation data (COSY, HMBC and HSQC) enabled determination of the 
carbon-hydrogen framework connectivity. Mass spectrometric studies identified 
the presence of the two bromine atoms in the compound 159.
The unexpected formation of compound 159 clearly showed that the isolated 
species from the coupling reaction was not compound 156. Ketone products, 
similar to compound 159, were observed in our group’s original Prins 
cyclisation studies.715 As previously stated (see Chapter 2), these products arise 
from protonation of the more hindered oxygen atom of the cyclic acetal 90, and 
the reaction proceeds via an oxocarbenium ion 160, as illustrated in Scheme 
72.
/ d 1
90
©
O COh
' 'dI
R1
HO
160
Scheme 72. Origin of ketone 96.
Owing to this, we can deduce that we must be generating a similar 
oxocarbenium ion (161) in the formation of compound 159, as shown in 
Scheme 73.
Br
n .Br^
161
159
Scheme 73. Formation of compound 159.38
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The coupling reaction between epoxide 149 and compound 155 was 
subsequently repeated under similar conditions (Scheme 74). This time, after 
extensive chromatography of the crude reaction mixture on silica gel, one of 
two possible regioisomers 162 and 163 was isolated. The regiochemistry, with 
regards to the position of the silyl group, could not be ascertained 
spectroscopically.
OTBS
TBSOTBSO
Scheme 74. Reagents and Conditions: (a) f-BuLi, 155, BF3 .THF,
THF, -78 °C.
Subsequent re-evaluation of the 1H and 13C NMR spectroscopic data of the 
initial coupling reaction identified the presence of either compound 162 or 
compound 163, along with one other major compound. This other compound 
was identified as acetal 155 by comparison of 1H and 13C NMR spectroscopic 
data, the recovery of which would suggest incomplete lithiation during the 
reaction.
Owing to the fact that we must have generated oxocarbenium ion 161 to give 
the ketone product 159, it seems far more likely that the silyl protecting group is 
on the secondary alcohol, as in compound 163. For the alternative regioisomer 
162, silyl deprotection would need to occur before the Prins 
cyclisation/rearrangement sequence in order to generate the ketone product 
159. If this was the case, we might expect the reaction to proceed via a cyclic 
acetal intermediate 164 (Scheme 75). Formation of the necessary 
oxocarbenium ion 165 from this acetal 164 requires protonation of the more 
hindered oxygen atom, which would imply a directing effect from the bromine 
atom. Since this is highly unlikely, we can conclude with some confidence that 
the silyl group is on the secondary alcohol, as in compound 163.
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Scheme 75.
Explaining this apparent silyl migration is not straightforward. Firstly, we might 
propose that the lithium bromide, generated from the lithium-halogen exchange 
of compound 155, provides a source of bromide, which preferentially opens the 
epoxide 149, instead of the organolithium reagent doing so (Scheme 76). From 
this point, a direct silyl migration from the primary to the secondary alcohol 
would give compound 163.
©
TBSO
O OTBS
149 166 163
Scheme 76. Direct silyl migration.
However, while there are many examples of silyl groups migrating from 
secondary to primary alcohols in the literature, 3 9  we could find no evidence of
primary to secondary migration, and we assume that such a process would be 
kinetically disfavoured.
Alternatively, we might consider that boron trifluoride present in the reaction 
mixture, instead of activating the epoxide 149, provides a source of fluoride for 
removal of the TBS group from the primary alcohol. The lithium bromide 
generated then provides a source of bromide, which exchanges with the 
fluoride to give the silyl bromide 168. The group of Detty have reported the 
reaction of silyl halides with oxiranes giving silylated halohydrins. 40 The 
reaction is initiated by electrophilic attack of silicon onto the oxygen atom of the 
epoxide to give an oxonium ion 169. Ring-opening by the halide then proceeds 
to give the silylated halohydrin 163 (Scheme 77).
L Br L F
149 167 168
TBS
0O'
169
HO
163
Scheme 77. Reaction of silyl bromide 168 with epoxide 149.
However, this pathway also seems unlikely. The displacement of fluoride with 
bromide would require breaking the comparatively strong silicon-fluorine bond, 
which would be energetically disfavoured under these reaction conditions.
Perhaps in fact, there is a combination of these two proposed pathways 
occurring, whereby the silyl group is removed and it coordinates directly to the
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oxygen atom of the epoxide, giving oxonium ion 169. Ring-opening by the 
bromide, derived from lithium bromide, then proceeds to give compound 163 
(Scheme 78).
TBS OTBSO
Br
TBSO O HO
Br
149 169 163
Scheme 78. Proposed formation of compound 163.
We subsequently reviewed 1H NMR spectroscopic data of crude reaction 
mixtures from all of the previous attempts at coupling the various alkyl and aryl 
bromides with the epoxide 149. In each case we were able to identify 
compound 163 as one of the major reaction products, showing that formation of 
this silylated bromohydrin is highly favoured under these conditions.
Having established the formation of regioisomer 163, we could now propose a 
plausible mechanism for its subsequent reaction with compound 155 to give 
compound 159 (Scheme 79). Treatment of the mixture of compounds 155 and 
163 with triflic acid results in them condensing to give oxocarbenium ion 170. 
6 -endo cyclisation then proceeds onto one of the diastereotopic double bonds, 
followed by a Wagner-Meerwein shift to give cation 172. Deprotonation gives 
the silyl enol ether 173, and finally removal of the silyl protecting group and a 
keto-enol tautomerism gives compound 159.
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HO
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MeO OMe
155
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TBSO
172
Br>
TBSO
171
Br Br
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173
Scheme 79. Proposed pathway to compound 159. Reagents and 
Conditions: (a) f-BuLi, 155, BF3 .OEt2, THF, -78 °C; (b) TfOH ( 2  
equiv.), CH2 CI2 , 0  °C to room temperature, 25 minutes.
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Owing to the outcome of this sequence and the apparent role of the bromide in 
the attempted coupling reactions, in a final attempt to synthesise a substrate for 
our Prins cyclisation reaction, we considered that omission of the source of 
bromide in the reaction would remove the undesired reaction pathway. To 
achieve this we opted for a directed lithiation reaction, instead of the 
lithium-halogen exchange approach. Comins et ai. have reported an effective 
strategy for directing ortho lithiation of benzaldehyde 174.41 This involves 
forming an a-amino alkoxide 175 with A/,A/,A/-trimethylethylenediamine, which 
has the effect of protecting the aldehyde functionality as well as directing 
lithiation (Scheme 80). Reaction of the lithiated species 176 with epoxide 149 
was attempted, but unfortunately this gave a complex mixture of products.
ChO
(a)
174 175 176
(c) X
V
TBSO
CHO
177
Scheme 80. Reagents and Conditions: (a)
A/,A/,A/-trimethylethylenediamine, n-BuLi (1 equiv.), THF, -20 °C, 15 
minutes; (b) n-BuLi (3 equiv.), 24 h; (c) 149, BF3 .THF, -42 °C, 40
minutes.
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3.3 Conclusion
From these studies it can be concluded that the described synthetic strategy is 
not ideal for approaching the cladiellin framework. The main weakness in the 
sequence appears to be the use of epoxide 149 as a synthetic intermediate. 
Formation of the silylated bromohydrin 163 appears to be the dominant 
process in each of the lithium-halogen exchange experiments with epoxide 149. 
This process appears to be triggered by the removal of the silyl protecting 
group from the primary alcohol with boron trifluoride. Unfortunately, the use of 
boron trifluoride is necessary for activation of the epoxide, as no reaction is 
observed when this reagent is omitted. Whilst simply changing from a silyl 
protecting group might inhibit the undesired reaction process, the unreliable 
formation of the epoxide 149 from the aldehyde 148 still poses a significant 
problem.
However, the aldehyde 148 has been shown to react very effectively with the 
organolithium reagent derived from compound 142. Owing to this, the next 
logical step would be to devise a strategy for using aldehyde 148 directly. 
Comins has also described a method for directed lateral lithiation of 
o-tolualdehyde 178, again by forming an a-amino alkoxide with 
A/,A/,A/-trimethylethylenediamine. 41 Using these conditions, we could envisage 
coupling o-tolualdehyde 178 with aldehyde 148 directly, to give a model 
substrate 177 for the Prins cyclisation (Scheme 81).
Scheme 81. Proposed route to compound 177.
If this approach proves successful, directed lateral lithiation of 
2 -methylcyclopent-1 -enecarbaldehyde 180 and subsequent reaction with
TBSO
178 179 177
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aldehyde 148 is also plausible (Scheme 82). Successful Prins cyclisation of 
compound 181 would provide the desired ring system for installing the 
oxacyclononane moiety observed in the cladiellin diterpenes.
TBSO TBSO
Scheme 82.
Unfortunately, due to time constraints I was not able to pursue this proposed 
work, but hopefully it will provide a good starting point for future investigation.
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Chapter 4
An Enantioselective Approach to Batzelladine C
Methyl Ester
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4.1 Introduction
4.1.1 The Batzelladine Alkaloids
The batzelladine alkaloids are a family of biologically and structurally intriguing 
natural products isolated from marine sources. Containing acyclic, bicyclic and 
tricyclic guanidine moieties, in some cases all within the same compound 
(Figure 15), the batzelladines present a significant synthetic challenge.
A total of 15 of these fascinating compounds have been isolated to date. The 
first, batzelladines A -  E, were isolated from the Caribbean marine sponge 
Batzella sp. in 1995 by a group from SmithKline Beecham . 4 2  A further four 
compounds, batzelladines F -  I, were isolated two years later. 43 Batzelladine J 
was isolated from the Caribbean marine sponge Monanchora unguifera in 
200544 and finally batzelladines K -  N and dehydrobatzelladine C were 
isolated from the same sponge in 2007.45
The batzelladine alkaloids exhibit an interesting array of biological activity. Most 
significantly, a number of these natural products have been shown to exhibit 
anti-HIV functionality. 4 2 ,4 4 ,4 5  The HIV virus affects the human immune system 
by targeting vital cells, particularly CD4+ T-cells. When the number of CD4+ 
cells falls below a certain critical level, the immune system loses its ability to 
regenerate and combat other infections. 4 6  HIV binds to the CD4 receptor 
through the gp120 protein on the surface of the virus . 4 7  A number of the 
batzelladine alkaloids and batzelladine analogues have been shown to inhibit 
gp120-CD4 binding. 4 1 ,4 8
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H
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Figure 15. Representative examples of the batzelladine alkaloids.
Owing to their challenging structures and biological potential, the batzelladines 
have seen a great deal of interest from a number of research groups in recent 
years, particularly the groups of Overman, 4 9 Gin, 5 0  Nagasawa, 51 Snider, 52  
Murphy5 3 and Evans. 5 4  The Overman group reported the first enantioselective 
total synthesis of a batzelladine alkaloid, batzelladine D, in 1999. 49a Overman
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et al. employed their key tethered Biginelli condensation of a guanidine 
aldehyde 183 and an acetoacetic ester 184 to generate the bicyclic guanidine 
moiety 185 (Scheme 83). Further elaboration of compound 185 gave 
batzelladine D as the bistrifluoroacetate salt (186) in a total of 12 steps from 
compound 182.
O
h 2n ^ n h  o h  ¥
NH.HCI
O OH 7 steps
182
183
O O
(a) 0 (C H 2)4NHCbz
184
HO
CbzHN(H2C)40 '
Me N NH.HOAc 
H
185
4 steps,
6 % yield overall
©
c f 3c o 2 ©
OF 3 C 0 2
186
batzelladine D bistrifluoroacetate
Scheme 83. Reagents and Conditions: (a) morpholinium acetate 
Na2 S04, CF3 CH2OH, 70 °C.
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The Overman group also employed this Biginelli chemistry to achieve total 
syntheses of batzelladine F49d and dehydrobatzelladine C.49g
The group of Nagasawa reported an enantioselective approach to batzelladine 
A in 2004.51d Starting with an enantiopure nitrone 187, a key 1,3-dipolar 
cycloaddition with an a,p-unsaturated ester 188 gave compound 189, which 
was further elaborated to give the left-hand side of batzelladine A (190) 
(Scheme 84).
TIPSO,
C ^© © yN"0
187
TIPSO
OMPM
E t02C OMPM
189
188
14 steps,
1 % yield overall
NBoc
N
H
OH
NBoc
NBoc
190
Scheme 84. Reagents and Conditions: (a) toluene, 90 °C.
The Nagasawa group synthesised the right-hand side of batzelladine A, again 
employing a key 1 ,3 -dipolar cycloaddition, in a similar sequence to their 
synthesis of batzelladine D (the right-hand side of batzelladine A is identical to 
that of batzelladine D).51c Coupling of the two fragments and some further 
manipulation gave batzelladine A.
More recently, the Evans group have reported an enantioselective approach to 
batzelladine D. 5 4  Throughout the majority of the sequence, Evans employs the 
clever use of azides as latent amines, avoiding the use of extensive protecting
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group chemistry. The key step was a stereoselective radical cyclisation of 
compound 192, which was synthesised in 8  steps from compound 191 
(Scheme 85).
o
'OMe  
M eC f 'O M e
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8 steps 
23 % y e d
Me'
R
192
(a)
(R = (iS)-(+)-camphorsu fony
SC %
Me'
R
193
Scheme 85. Reagents and Conditions: (a) Bu3 SnH, Et3 B, PhH, 0 2, 
room temperature.
From compound 193, a further two synthetic steps generated compound 194. 
Hydrogenation of the diazide 194, to promote reductive cyclisation, followed by 
installation of the acyclic guanidine, gave batzelladine D as the bisformate salt 
(195) (Scheme 8 6 ).
75
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81 % yield
Me'' N UMe
O
193 194
(
steps, 
% yield
© M r .
HCOo ©
H C 0 2
195
batzelladine D bisformate
Scheme 86. Reagents and Conditions: (a) 10 % Pd/C, H2, MeOH, 
room temperature; (b) 1 H-pyrazole-1 -carboxamidine hydrochloride, 
/Pr2 NEt, DMF, room temperature.
4.1.2 Batzelladine C
Batzelladine C is a tricyclic guanidine, which has not yet been synthesised. The 
stereochemistry at the C-4 position5 5  is unknown, as is the absolute 
stereochemistry (Figure 16), an ambiguity which is shared by batzelladines J, 
M and N.
batze ad ne C
Figure 16. Batzelladine C.
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Recent work within our group has been focussed on an approach to 
batzelladine C and assignment of its relative and absolute stereochemistry. My 
predecessor developed a strategy for synthesising the tricyclic guanidine 
moiety, 5 6 beginning with commercially available succinic anhydride 196. 
Condensation of succinic anhydride 196 with (S)-(-)-a-methylbenzylamine 197, 
followed by chemoselective reduction of the resulting imide 198, gave 
compound 199 (Scheme 87).
(a) 0 ^ \ ^ 0  (b)
NH2 Me' Ph 8 7 %  Me' Ph
. X  198 (2 steps) 199
Me' Ph
197
Scheme 87. Reagents and Conditions: (a) (i) toluene, reflux, (ii) CDI,
THF, reflux; (b) LiEt3 BH, THF.
Introduction of an allyl side-chain, followed by an oxidative cleavage of the 
double bond, gave compound 201. The aldehyde 201 was subsequently 
submitted to a Z-selective Wittig reaction, affording compound 202 (Scheme 
88).
196
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O ^ ^ O H
Me'' ^ P h  
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(a)
95 %, 
5.5:1 d.r.
O HN H
Ph,^/x
Me H
O
Ph Me
Me Ph
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(b) 9 0 %
O
Me'' ^ P h  
201
CHO
(c) 5 6 %
Me' Ph
202
Scheme 8 8 . Reagents and Conditions: (a) BF3 .OEt2,
allyltrimethylsilane, CH2 CI2 , -78 °C; (b) K2 0 s0 4 .2 H2 0 , Nal04, 
2,6-lutidine, dioxane-H2 0; (c) C7 Hi5 PPh3 l, n-BuLi, THF.
From this point, removal of the chiral auxiliary, followed by thionation with 
Lawesson’s reagent gave compound 203, which was submitted to an 
Eschenmoser sulfide contraction, giving compound 204 (Scheme 89).
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( 2  steps)
(a) (b)
H
203
H13E t02C H
204
Scheme 89. Reagents and Conditions: (a) Na, NH3 -EtOH-THF; (b) 
Lawesson’s reagent, THF; (c) (i) BrCH2 C 0 2 Et, CH2CI2, (ii) PPh3, 
/BuOK, xylene, reflux.
The alkylidenepyrrolidine 204 was submitted to a three-component coupling 
reaction, originally developed by Kishi, 5 7  to give a separable mixture of 
diastereoisomers 205 and 206 (Scheme 90).
Scheme 90. Reagents and Conditions: (a) TMS-NCS, hexanal, 
CH2 CI2, room temperature, 45 minutes.
The stereochemical outcome of the three-component coupling was determined 
with a model study. Compound 208 was synthesised in three steps from the
H
205 £8 %
+
204
206 28 %
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allyl lactam 200, using methodology developed within the group.5 8 Submitting 
the alkylidenepyrrolidine 208 to the three-component coupling reaction, gave a 
1 .8:1 mixture of separable diastereoisomers 209 and 210 (Scheme 91 ).56
200
(a)
MeOoC
207
(b) (c)
6 6 %
(3 steps)
M e02C
208
SC %  y e d 
209 210 = 1 8 1
+
210
Scheme 91. Reagents and Conditions: (a) Na, NH3 -EtOH-THF; (b) 
Boc20 ,  NEts, 4-DMAP, CH2 CI2; (c) (i) MeOAc, LDA, THF, (ii) TFA; (d) 
TMS-NCS, hexanal, CH2 CI2, room temperature, 1 h.
The major diastereoisomer 209 provided suitable crystals for X-ray analysis, 
which confirmed the trans relationship between protons Ha and Hb. (Figure 16).
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n -C5 H1 1
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Figure 16. Structure of compound 209 from X-ray data. 59
With the stereochemistry confirmed, compound 205 was subsequently 
converted into the guanidine 211. Intramolecular iodoamination of compound 
2 1 1 , followed by immediate hydrogenolysis to remove the iodine, afforded the 
tricyclic guanidine 2 1 2  (Scheme 92).
2 0 5
(a) Et02C
8C %
n-CeH1 3
A7-C5 H11v N "N H 2 HC0 2
211
(b) (c) 8C %
( 2  steps)
212
Scheme 92. Reagents and Conditions: (a) (i) Mel, MeOH, reflux, (ii) 
NH3, NH4 OAc, MeOH, sealed tube, 80 °C, 60 h; (b) l2, K2C03, 
MeCN, room temperature; (c) H2, Pd/C, NEt3, EtOAc, room 
temperature.
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When the 1H and 13C NMR spectroscopic data of compound 212 and natural 
batzelladine C were compared, some small but significant differences were 
observed between the two. In particular, the observed 1H chemical shift for 
H-8 a, and the 13C chemical shift for C-7 were considerably different for the two 
compounds. As a result, it was considered that the stereochemistry at the C-4 
position in compound 2 1 2  may not be that of the natural product.
I took up the project with the aim of determining if this was indeed the case. We 
hoped to achieve this by converting the minor diastereoisomer 206, from the 
three-component coupling reaction, to the corresponding tricyclic guanidine 
213 (Scheme 93).
Scheme 93. Proposed route to compound 213.
Comparison of 1H and 13C NMR spectroscopic data for both epimers 212 and 
213 with that of natural batzelladine C should enable determination of the 
stereochemistry at C-4 in the natural product. We then hoped to complete the 
synthesis of batzelladine C by installing the acyclic guanidine side-chain.
The synthetic approach to the alkylidenepyrrolidine 204, for the 
three-component coupling reaction, would be similar to that described above. 
However, there were some problems with the strategy, particularly the 
Eschenmoser sulfide contraction. This reaction had proved to be very 
unreliable, especially on scales above 500 milligrams, which limited the amount 
of synthetic material that could be quickly brought through the sequence. As 
such we hoped to improve upon this reaction and rectify the problem.
206 213
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There had also been similar problems with subsequent formation of guanidine 
211 from the thiourea 205. As well as proving unreliable, the 60 h reaction time 
made the reaction highly impractical. Again, we hoped to resolve this issue.
4.2 Results and Discussion
4.2.1 A Synthetic Approach to Batzelladine C Methyl Ester
At this point, the absolute stereochemistry of batzelladine C was unknown, and 
since we had proposed that the relative stereochemistry of compound 2 1 2  was 
not that of the natural product, it was not clear which enantiomeric series would 
give the natural product stereochemistry. As a result, and due to the ready 
availability of (R)-(+)-a-methylbenzylamine 214 in our lab, we initiated the 
sequence with the opposite enantiomer to before. Condensation of succinic 
anhydride 196 and (R)-(+)-a-methylbenzylamine 214 proceeded smoothly, and 
following chemoselective reduction of the imide 215 with Super-Hydride®, gave 
compound 216 (Scheme 94).
Scheme 94. Reagents and Conditions: (a) (i) toluene, reflux, 18 h, (ii) 
acetic anhydride, reflux, 2 h; (b) (i) LiEt3 BH, THF, -78 °C, 40 minutes,
(ii) 30 % H2 0 2.
From this point, the allyl side-chain was introduced by formation of an A/-acyl 
iminium ion from compound 216 with boron trifluoride, followed by subsequent 
reaction with allyltrimethylsilane, according to conditions described by 
Polniaszek and co-workers. 6 0  The terminal alkene was then oxidatively cleaved
214
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with potassium osmate dihydrate and sodium periodate, to give compound 218 
as a 6.4:1 mixture of diastereoisomers (Scheme 95).
Scheme 95. Reagents and Conditions: (a) BF3.OEt2 ,
allyltrimethylsilane, CH2CI2 , -78 °C to room temperature, 16 h; (b) 
K2 0 s0 4 .2 H2 0 , Nal04> 2 ,6 -lutidine, dioxane-H20, 18 h.
Aldehyde 218 was subsequently submitted to a c/s-selective Wittig reaction to 
give compound 219, by which time the diastereomeric ratio had been increased 
to 6.6:1. The chiral auxiliary was removed by treatment with sodium metal in 
liquid ammonia, giving compound 2 2 0 , which was then converted to the 
thiolactam 221 with Lawesson’s reagent (Scheme 96).
(b) 89 %
v
H 8 4 % H
221 220
Scheme 96. Reagents and Conditions: (a) C7 H1 5PPh3 l, n-BuLi, THF, 
-78 °C to room temperature, 16 h; (b) Na, NH3 -EtOH-THF 
(8:1:1), -78 °C; (c) Lawesson’s reagent, THF, 2 h.
The c/s-geometry of compound 219 could not be confirmed spectroscopically, 
however the selectivity of the Wittig reaction was proved later in the sequence 
by analysis of coupling constants in the 1H NMR spectrum of compound 221.
At this point, instead of employing the unreliable single-step sulfide contraction 
used initially, we opted for a different two-step sequence, which had previously 
been used within the group on a similar compound. 61 Compound 221 was 
treated with methyl 2 -bromoacetoacetate and pleasingly this gave compound 
222 in excellent yield (Scheme 97). A simple deacetylation of compound 222 
with sodium methoxide, gave alkylidenepyrrolidine 223, again in excellent yield.
Scheme 97. Reagents and Conditions: (a) methyl
2 -bromoacetoacetate, NaHC0 3 , CH2 CI2 , reflux, 16 h; (b) NaOMe, 
MeOH, reflux, 2 h.
This two-step sequence proved to be much more reliable and scaleable, 
allowing fast access to multi-gram quantities of the alkylidenepyrrolidine 223. 
The decision was made to install the methyl rather than the ethyl ester at this 
point, as this would eventually allow direct comparison with batzelladine C 
methyl ester, which the original isolation team prepared by methanolysis of 
natural batzelladine C . 4 2
With compound 223 in hand, the three-component coupling reaction was 
carried out, giving a 2:1 mixture of separable diastereoisomers 224 and 225
MeOC H
221 222
(b) 84 %
223
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(Scheme 98). Stereochemical assignments were made by analogy with 
compounds 205 and 206.56
M e02C H
223
Scheme 98. Reagents and Conditions: (a) TMS-NCS, hexanal, 
CH2CI2 , room temperature, 75 minutes.
At this point, in an attempt to improve upon the current unreliable guanidine 
formation, a model study was carried out. Compound 228 was prepared in two 
steps from 2 -pyrrolidinone 226, using methodology developed within the 
group. 5 8  This alkylidenepyrrolidine 228 was then submitted to the 
three-component coupling reaction, to give compound 229 (Scheme 99).
M e02C
±  L  n’CeHl3
n -C .jH u^N 'S
H
224 46 %
A7-Cp H 13
224 225 = 2 1
225 23 %
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(b)
96%
IN
Boc 42%
227
IN
E t02C H 
228
(c) 3C %
229
Scheme 99. Reagents and Conditions: (a) Boc20, NEt3 , 4-DMAP, 
CH2CI2 , 18 h; (b) (i) EtOAc, LDA, THF, -78 °C to room temperature, 
18 h, (ii) TFA, 3 h; (c) TMS-NCS, hexanal, CH2 CI2 , room 
temperature, 75 minutes.
Peters et al. have reported a strategy for forming guanidines from thioureas, 
which involves fully S-methylating the thiourea before heating in a microwave 
with ammonium hydroxide. 6 2  Using similar conditions, compound 229 was 
treated with methyl iodide to give the isothiourea 230, which was subsequently 
heated in a microwave with ammonium hydroxide. Pleasingly this gave 
compound 231 in excellent yield (Scheme 100).
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229
(a) EtC^ C
(b) 8S %
231
Scheme 100. Reagents and Conditions: (a) Mel, Me2CO, 18 h; (b) 
NH4 OH, H2 0-MeCN (1:1), microwave, 130 °C, 15 minutes, then 165 
°C, 30 minutes.
This methodology dramatically reduced the reaction time of the guanidine 
formation and the result was reproducible with the model system. Unfortunately 
however, when the same conditions were applied to compounds 224 and 225, 
we simply observed regeneration of starting material (Scheme 101). Clearly, 
the added steric bulk of the alkenyl side-chain, in both cases, causes the 
ammonia nucleophile to attack at the wrong position, resulting in reformation of 
the thiourea.
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MeO'
224
(a)
(b)
V 9  n-CeH13
n -C s H ^ ^N ^ S  H
224
225
(a)
M e 0 2C
" - C 6 H 1 3
M e 0 2C
6 3
N
M e ^ M e 'N
n h 3
#
NH3
(b)
225
Scheme 101. Reagents and Conditions: (a) Mel, Me2CO, 18 h; (b) 
NH4OH, H20-MeCN (1:1), microwave, 130 °C, 15 minutes, then 165 
°C, 30 minutes.
Owing to this, we decided to proceed with our original conditions for guanidine 
formation. While we were able to successfully synthesise both guanidines 232 
and 233 (Scheme 102), the reactions did not work well on scales above 200 
milligrams and were not always reproducible, which limited the amount of 
synthetic material obtained.
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224
S6 %
M6 O2C
n - CsHu’A  A ®^ N ^ N H 2HC02 
H ©
232
225
(a) 8 6 %
Me02C
n - CgHn' N ^ N H 2 HC0 2  
H ©
CpHeni3
233
Scheme 102. Reagents and Conditions: (a) (i) Mel, MeOH, reflux,
1 h, (ii) NH4OAc, NH3, MeOH, 80 °C, sealed tube, 48 h.
From this point, iodoamination of compound 232 proceeded smoothly under 
standard conditions, and following removal of the iodine by hydrogenolysis, 
gave compound 234 (Scheme 103).
MeO
x  A ®A7-C5H11^ N ^ N H 2HC02 
H ©
CPH (a) (b)e n i3
58 % 
( 2  steps)
232 234
Scheme 103. Reagents and Conditions: (a) b, K2 CO3 , MeCN, room 
temperature, 3 h; (b) H2, Pd/C, NEt3, EtOAc, room temperature, 16 h.
The relative stereochemistry of protons H-7 and H-8a was determined by 
NOESY NMR spectroscopy (Figure 17).
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234
1O 1 -nOe
Figure 17. Determination of the relative stereochemistry of 
compound 234.
lodoamination of compound 233 proved slightly more troublesome, but was 
eventually effected using iodine monochloride and potassium carbonate in 
dichloromethane. Again, immediate hydrogenolysis to remove the iodine gave 
compound 235 (Scheme 104). The relative stereochemistry of protons H-7 and 
H-8a was assigned by analogy with compound 234.
\  (a) (b)
I IO ----------------------
n - CgHn'' N ^ N H 2 HC0 2  4 5  %
H ©  (2 steps)
233
Scheme 104. Reagents and Conditions: (a) ICI, K2C 0 3, CH2CI2, 0 
°C to room temperature, 3 h; (b) H2, Pd/C, NEt3, EtOAc, room 
temperature, 16 h.
The reason for the more difficult iodoamination of compound 233 is not readily 
apparent. Calculations show that there is a significant conformational difference 
between the bicyclic portions of compounds 232 and 233.63 However, this does 
not seem to result in the side-chain double bond being further from the 
guanidine nitrogen in compound 233.
4.2.2 Stereochemical Assignment of Batzelladine C
With both epimers 234 and 235 in hand, we could now compare NMR 
spectroscopic data of the two, with that of natural batzelladine C. When
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comparing 1H NMR spectra of compound 234 and batzelladine C,64 we could 
immediately identify some significant differences (Figure 18).
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Figure 18. 1H NMR spectra of compound 234 and batzelladine C 
(400 MHz; MeOD).
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The major difference is the chemical shift for H-8a in the two compounds. The 
1H chemical shift of H-8a for compound 234 is 4.11 ppm compared with 3.86 
ppm for batzelladine C.42 There are also some small, but significant differences 
in some of the peak shapes for the two compounds, particularly the signals for 
H-1p and H-8p.
When 1H NMR spectra of compound 235 and batzelladine C were 
subsequently compared, it was immediately apparent that the data for these 
two compounds showed much more similarity (Figure 19). The 1H chemical 
shift for H-8a in compound 235 is 3.93 ppm, which is much closer to that of 
batzelladine C (3.86 ppm).42 The general peak shapes are also a lot more 
similar in these two spectra, particularly for H-1 p and H-8p.
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Figure 19. 1H NMR spectra of compound 235 and batzelladine C 
(400 MHz; MeOD).
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The 1H and 13C NMR chemical shifts of selected peaks for compounds 234 and 
235, batzelladine C and batzelladine C methyl ester are shown in Table 5, with 
key points highlighted. It should be noted that the 13C NMR spectroscopic data 
for naturally derived batzelladine C methyl ester was not reported in the original 
isolation paper.42
Batzelladine
C
Batzelladine 
C methyl 
ester
Compound
234
Compound
235
H-2cx 2.84 2.82 2.89 2.79
H-2p 3.35 3.37 3.41 3.32
H-4 4.45 4.48 4.40 4 .4 6 -4 .4 4
H-7 3.61 3.62 3 .6 7 -3 .6 0 3.60
H-8a 3.86 3.86 4.11 3.93
C-4 49.8 — 50.9 52.5
C-7 53.2 - 51.3 53.8
C-8a 57.3 - 57.4 58.9
Table 5.
The 13C chemical shifts for C-4 are highlighted because, in this case, the 
chemical shift for compound 234 is closer to that of the natural product. 
However, the 13C chemical shift of C-7 for compound 235 is much closer to that 
of batzelladine C compared with compound 234. Indeed, when all the 13C NMR 
spectroscopic data is compared, the data for compound 235 is much more 
comparable with that of the natural product.
Owing to this comparison of spectroscopic data, we can assign the relative 
stereochemistry of batzelladine C methyl ester as that of compound 235. The 
specific rotation of compound 235 was -  2.4 (c. 0.5, MeOH) compared to -  4.2 
(c. 0.93, MeOH) for the same compound formed by methanolysis of natural 
batzelladine C. As a result, we can also assign the absolute stereochemistry of
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batzelladine C methyl ester as that of compound 235. Hence, the relative and 
absolute stereochemistry of batzelladine C is readily deduced as shown in 
Figure 20.
batze ad ne C
Figure 20. Stereochemistry of batzelladine C.
4.2.3 Further Manipulation of Batzelladine C Methyl Ester
Having determined the stereochemistry of batzelladine C, we now aimed to 
complete the synthesis of the natural product. We envisaged using Evans’ 
method for installing the acyclic guanidine side-chain by transesterification with 
4-azidobutanol.54 The azide could then be reduced and converted to the 
guanidine. Before attempting this with compound 235, a model study was 
conducted. Compound 236 was refluxed with 4-azidobutanol and Otera’s 
catalyst65 in toluene, and pleasingly this gave compound 237, albeit in 
moderate yield (Scheme 105).
Scheme 105. Reagents and Conditions: (a) (CIBu2Sn)20, 
N3(CH2)4OH, toluene, reflux, 24 h.
Unfortunately, applying the same conditions to compound 235 resulted in a 
complex mixture of products (Scheme 106).
0
236 237
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Scheme 106. Reagents and Conditions: (a) (CIBu2Sn)20, 
N3(CH2)4OH, toluene, reflux, 24 h.
My predecessor had previously attempted a number of different methods for 
introducing the acyclic guanidine side-chain, but to no avail.56 Owing to this and 
the failed transesterification of compound 235, combined with the small 
amounts of synthetic material available, we decided not to pursue the synthesis 
further.
4.3 Conclusion
The two possible diastereoisomers of batzelladine C methyl ester 234 and 235 
have been synthesised, each in 13 steps from commercially available succinic 
anhydride 196, with 4.3 % and 1.6 % overall yields respectively. Comparison of 
spectroscopic data of the two compounds with that of the natural product has 
enabled assignment of the relative and absolute stereochemistry of 
batzelladine C.
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Chapter 5 
Experimental Details
5.1 General Experimental Points
Melting points were determined on a Gallenkamp melting point apparatus and 
are uncorrected. Infrared spectra were recorded on a Perkin Elmer 1600 FTIR 
spectrophotometer. Mass spectra were recorded on a Fisons VG Platform II 
spectrometer and on a Micromass Q-TOF Micro spectrometer. NMR spectra 
were recorded on a Bruker DPX 400 spectrometer operating at 400 MHz for 1H 
and at 100 MHz for 13C at 25 °C, or on a Bruker Avance 500 spectrometer 
operating at 500 MHz for 1H and 125 MHz for 13C at 25 °C. All chemical shifts 
are reported in ppm downfield from TMS. Coupling constants (J) are reported 
in Hz. Multiplicity in 1H NMR spectroscopy is reported as singlet (s), doublet 
(d), double doublet (dd), double triplet (dt), double quartet (dq), triplet (t), and 
multiplet (m). Multiplicity in 13C NMR spectroscopy was obtained using the 
DEPT pulse sequence. Optical rotations were recorded on an Optical Activity 
AA 100 polarimeter. Specific rotations are reported in units of deg dm'1 cm3 g'1. 
Flash chromatography was performed using Matrex silica 60 35-70 micron.
Solvents for moisture-sensitive reactions were dried by distillation; THF over 
sodium benzophenone ketal, CH2 CI2 and toluene over CaH2, and MeOH over 
Mg(OMe)2. Such reactions were carried out under an atmosphere of nitrogen.
Where mixtures of diastereoisomers were not separated, NMR data reported 
are for the major diastereoisomer.
Supporting mass spectrometric data for compounds 41c, 115, 145, 146, 148 
and 158 could not be obtained.
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5.2 Experimental Data for Chapter 1
1-(1-(Hydroxymethyl)cyclohexa-2,5-dienyl)octan-2-ol (19d)
n-CeH^
23 19d
n-Butyllithium (8.79 ml of a 1.6 M solution in hexanes, 14.1 mmol) was added 
to a solution of diisopropylamine (1.97 ml, 14.1 mmol) in dry THF (20 ml) at 0 
°C, and the resulting solution was allowed to stir at 0  °C for 15 minutes. The 
reaction mixture was then cooled to -78 °C and the ester 23 (1.74 g, 1 2 . 6  
mmol) added dropwise. After stirring at -78 °C for 30 minutes, n-hexyloxirane 
(1.8 g, 14.1 mmol) was added dropwise and the reaction mixture allowed to 
warm to room temperature. The reaction was quenched with saturated 
aqueous ammonium chloride solution and extracted with diethyl ether, the 
combined extracts being dried over Na2 S0 4  before the solvent was removed in 
vacuo. Chromatography on silica gel (Et2 0 /petroleum ether 1:19) afforded the 
intermediate lactone 40 (1.64 g, 56%) as a colourless oil. This lactone 40 (1.64 
g, 7.01 mmol) was immediately re-dissolved in dry THF (10 ml) and added 
dropwise to a suspension of LiAIH4  (266 mg, 7.01 mmol) in dry THF ( 2 0  ml). 
The resulting suspension was allowed to stir for 15 minutes before the reaction 
was quenched with 2 M NaOH. The solution was filtered and dried over 
Na2 S0 4  before the solvent was removed in vacuo. Chromatography on silica 
gel (eluent 2:1 hexane:ethyl acetate) afforded the title compound (1.33 g, 80%) 
as a colourless oil.
Vmax (Neat): 3354, 3017, 2930, 2882, 2856, 1615, 1516, 1458, 1377, 1244, 
1040, 947, 877, 823 and 711 cm'1.
8 h (400 MHz; CDCI3): 6.00-5.93 ( 2  H, m, alkene CH), 5.63 ( 1  H, app. dq, J
10.2, 2.0, alkene CH), 5.37 (1 H, app. dq, J10.9, 2.1, alkene CH), 3.77-3.71 (1 
H, m, CHOH), 3.30 (2 H, app. s, CH2 OH), 2.68-2.66 (2 H, m, ring CH2), 1.67 (2
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H, broad s, 2  x OH), 1.43 (1 H, dd, J  14.2, 9.0, one of CH2 CHOH), 1.36 (1 H, 
dd, J  14.2, 2.3, one of CH2 CHOH), 1.33-1.27 (2 H, m, CH2), 1.26-1.16 ( 8  H, m, 
(CH2)4) and 0.81 (3 H, t, J 6 .8 , CH3).
5c (100 MHz; CDCI3): 130.6 (CH), 129.7 (CH), 128.0 (CH), 127.4 (CH), 70.4 
(CH2), 69.4 (CH), 44.9 (CH2), 42.3 (C), 38.0 (CH2), 31.9 (CH2), 29.3 (CH2), 26.6 
CH2), 25.6 (CH2), 22.6 (CH2) and 14.1 (CH3).
MS-EI: m/z (%) = 220 (M+ -  H2 0, 13), 2 0 2  (98), 190 (90), 131 (93), 117 (97) 
and 104(100).
HRMS-EI: m/z[M -  H2O f  calcd for C 1 5H2 4 0: 220.1827; found: 220.1837.
1 -(Cyclohexa-2,5-dienyl)hexan-2-ol (24a)
n-Bu
0
27 24a
To a solution of 1,4-cyclohexadiene 27 (323 mg, 4.03 mmol) in dry THF (10 ml) 
at -78 °C were added n-butyllithium (2.5 M solution in hexanes, 1 .77 ml, 4.43 
mmol) and TMEDA (0.67 ml, 4.43 mmol). The yellow solution was warmed 
to -41 °C and after 2.5 h was treated with n-butyloxirane 28a (0.58 ml, 4.84 
mmol). After 10 minutes at -41 °C the solution was warmed to room 
temperature and left to stir for 1 h before being quenched with saturated 
ammonium chloride solution. The product was then extracted with ether, the 
ether extracts being washed with brine and dried over sodium sulfate. The 
solvent was removed in vacuo and the product purified by chromatography on 
silica gel (1:5 EtOAc:hexane), yielding the title compound (422 mg, 6 6 %) as a 
colourless oil.
Vmax (Neat): 3354, 3022, 2930, 2857, 1466, 1033 and 699 cm'1.
8 h (400 MHz; CDCI3): 5.72 -  5.60 (3 H, m, alkene CH), 5.51 -  5.45 ( 1  H, m, 
alkene CH), 3.73 -  3.66 (1 H, m, CHOH), 2.89 -  2.81 (1 H, m, CH), 2.58 -  2.51
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( 2  H, m, CH2), 1.51 -  1.38 (5 H, m, 2 x CH2 and OH), 1.34 -  1.26 ( 2  H, m, CH2),
1.25 -  1.15 (2 H, m, CH2) and 0.77 (3 H, t, J 7.0, CH3).
5c (100 MHz; CDCI3): 129.3 (CH), 129.1 (CH), 124.9 (CH), 124.5 (CH), 69.5 
(CH), 43.7 (CH2), 37.7 (CH2), 35.6 (CH), 27.8 (CH2), 26.2 (CH2), 22.8 (CH2) 
and 14.1 (CH3).
MS-EI: m/z (%) = 180 (M+, 3), 162 (9), 131 (1 2 ), 117 (25), 92 (92) and 91 (100). 
HRMS-EI: m /z[M]+ calcd for C i2 H2 0 O: 180.1514; found; 180.1514.
2-(Cyclohexa-2,5-dienyl)-1 -phenylethanol (24b)
o
27
To a solution of 1,4-cyclohexadiene 27 (397 mg, 4.95 mmol) in dry THF (10 ml) 
at -78 °C were added n-butyllithium (2.5 M solution in hexanes, 2.18 ml, 5.45 
mmol) and TMEDA (0.82 ml, 5.45 mmol). The yellow solution was warmed 
to -41 °C and after 2.5 h was treated with styrene oxide 28b (0 . 6 8  ml, 5.95 
mmol). After 10 minutes at -41 °C the solution was warmed to room 
temperature and left to stir for 1 h before being quenched with saturated 
ammonium chloride solution. The product was then extracted with ether, the 
ether extracts being washed with brine and dried over sodium sulfate. The 
solvent was removed in vacuo and the product purified by chromatography on 
silica gel (9:1 Et2 0:petroleum ether), yielding the title compound {268 mg, 27%) 
as a colourless oil.
Vmax (Neat): 3384, 3026, 2926, 2818, 1603, 1493, 1453, 1054 and 700 cm'1.
8 h (400 MHz; CDCI3): 7.24 -  7.12 (5 H, m, aromatic CH), 5.71 -  5.62 (3 H, m, 
alkene CH), 5.54 (1 H, app. ddt, J 12.2, 3.5, 1.6, alkene CH), 4.78 (1 H, ddd, J
9.1, 4.0, 2.8), 2.87 -  2.78 (1 H, m, CH), 2.58 -  2.52 ( 2  H, m, CH2), 1.93 (1 H,
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broad d, J 2.8, OH), 1.82 ( 1  H, ddd, J 14.2, 9.1, 5.4, one of CH2) and 1.64 ( 1  H, 
ddd, J 14.2, 7.2, 4.0, one of CH2).
5c (100 MHz; CDCI3): 144.8 (C), 129.0 (CH), 128.8 (CH), 128.5 (CH), 127.5 
(CH), 125.8 (CH), 125.0 (CH), 124.7 (CH), 72.2 (CH), 45.9 (CH2), 32.7 (CH) 
and 26.2 (CH2).
MS-ES: m/z (%) = 200 (M+, 37), 182 (79) and 1 2 1  (1 0 0 ).
HRMS-ES: m /z[M]+ calcd fo rC i4 Hi60: 200.1201; found 200.1199.
(1 SR,2RS)-2-(Cyclohexa-2,5-dienyl)cyclohexanol (24c)
27 24c
To a solution of 1,4-cyclohexadiene 27 (314 mg, 3.92 mmol) in dry THF (10 ml) 
at -78 °C were added n-butyllithium (2.5 M solution in hexanes, 1.72 ml, 4.31 
mmol) and TMEDA (0.65 ml, 4.31 mmol). The yellow solution was warmed 
to -41 °C and after 2.5 h was treated with cyclohexene oxide 28c (0.48 ml, 4.70 
mmol). After 10 minutes at -41 °C the solution was warmed to room 
temperature and left to stir for 1 h before being quenched with saturated 
ammonium chloride solution. The product was then extracted with ether, the 
ether extracts being washed with brine and dried over sodium sulfate. The 
solvent was removed in vacuo and the product purified by chromatography on 
silica gel (1:6 EtOAc:hexane), yielding the title compound (309 mg, 44%) as a 
colourless oil.
Vmax (Neat): 3385, 3023, 2927, 2855, 1448, 1261 and 698 cm'1.
5h (400 MHz; CDCI3): 5.77 -  5.65 (3 H, m, alkene CH), 5.52 -  5.46 (1 H, m, 
alkene CH), 3.44 ( 1  H, app. dt, J 4.3, 10.1, CHO), 3.15 -  3.07 ( 1  H, m, CH),
2.62 -  2.56 ( 2  H, m, CH2), 2.06 (1 H, broad s, OH), 1.94 -  1.88 (1 H, m, CH),
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1.66-1 .51 (3 H, m), 1 .3 5 - 1.28 (1 H, app. ddt, J12.0, 10.2, 3.1) and 1 .2 3 - 
0.96 (4 H, m).
5C (100 MHz; CDCI3): 128.1 (CH), 127.4 (CH), 125.4 (CH), 125.4 (CH), 71.7 
(CH), 49.8 (CH), 35.9 (CH), 35.8 (CH), 27.1 (CH2), 26.5 (CH2), 25.8 (CH2) and
25.0 (CH2).
MS-ES: m/z (%) = 178 (M+, 3), 160 (1 0 0 ), 117 (76), 104 (40) and 92 (78). 
HRMS-ES: /r?/z[M]+ calcd fo rC i2 Hi80: 178.1358; found 178.1361.
(2SR,3aRS,7RS,7aRS)-2-Butyl’2,3,3a,6,7,7a-hexahydro-7-iodobenzofuran
(25a)
n-Bu 
OH
n - B u
H/./ o
II p H
24a 25a
To a solution of alcohol 24a (224 mg, 1.24 mmol) in MeCN (20 ml) were added 
iodine (948 mg, 3.73 mmol) and sodium hydrogen carbonate (314 mg, 3.73 
mmol). The reaction was monitored by TLC and on complete consumption of 
the starting material ( 1 0  min) the reaction was quenched with saturated sodium 
thiosulfate solution. The product was then extracted with ether, the ether 
extracts being washed with brine and dried over sodium sulfate. The solvent 
was removed in vacuo and the product purified by chromatography on silica gel 
(1:50 Et20  petroleum ether), yielding the title compound (252 mg, 6 6 %) as a 
pale oil.
Vmax (Neat): 3026, 2927, 2858, 1653, 1456, 1085 and 6 8 6  cm'1.
5h (400 MHz; CDCI3): 5.36 -  5.54 ( 2  H, m, alkene CH), 4.40 -  4.33 ( 2  H, m, 
CHO and CHI), 3.90 (1 H, app. dq, J 9.4, 6 .2 , CHO), 3.00 -  2.93 (1 H, m, CH), 
2.80 -  2.71 (1 H, m, one of CH2), 2.43 -  2.35 (1 H, m, one of CH2), 1.79 (1 H,
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ddd, J 12.2, 5.4, 2.5, one of CH2), 1.69 (1 H, ddd, J 1 2 .2 , 9.4, 7.5, one of CH2), 
1 .57 -  1.48 (1 H, m), 1.38 -  1 . 1 2  (5 H, m) and 0.82 (3 H, t, J7 .0, CH3).
6 c (100 MHz; CDCI3): 128.1 (CH), 124.8 (CH), 80.5 (CH), 80.3 (CH), 38.0 
(CH2), 37.9 (CH), 35.8 (CH2), 30.3 (CH2), 28.2 (CH2), 27.5 (CH), 22.8 (CH2) 
and 14.1 (CH3).
MS-ES: rn/z (%) = 348 (MH+.CH3 CN, 100) and 224 (19).
HRMS-ES: m/z [M + H + CH3 CN]+ calcd for C i4 H2 3 INO: 348.0824; found 
348.0838.
(2RS,3aRS,7RS,7aRS)-2,3,3a,6,7,7a-Hexahydro-7-iodo-2- 
phenylbenzofuran (25b)
Ph
f  I'H
24b 25b
To a solution of alcohol 24b (178 mg, 0.89 mmol) in MeCN (20 ml) were added 
iodine (680 mg, 2.67 mmol) and sodium hydrogen carbonate (220 mg, 2.67 
mmol). The reaction was monitored by TLC and on complete consumption of 
the starting material ( 1 0  min) the reaction was quenched with saturated sodium 
thiosulfate solution. The product was then extracted with ether, the ether 
extracts being washed with brine and dried over sodium sulfate. The solvent 
was removed in vacuo and the product purified by chromatography on silica gel 
(1:20 EtOAc:hexane), yielding the title compound (182 mg, 63%) as a pale oil.
Vmax (Neat): 3026, 2930, 2870, 1493, 1450, 1082, 950 and 698 cm'1.
§H (400 MHz; CDCI3): 7.29 -  7.16 (5 H, m, aromatic CH), 5.73 -  5.68 (1 H, m, 
alkene CH), 5.64(1 H, app. dt, J 10.2, 2.6, alkene CH), 4.94 (1 H, dd, J 9.5, 5.7, 
CH-Ph), 4.66 (1 H, app. t, J 5.0, CHO), 4.44 ( 1  H, app. q, J 4.2, CHI), 3.15 -
3.07 ( 1  H, m, CH), 2.86 (1 H, app. ddq, J 18.7, 4.9, 2.5, one of CH2), 2.48 -
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2.40 ( 1  H, m, one of CH2), 2 . 1 2  ( 1  H, ddd, J 12.4, 5.7, 2.6, one of CH2) and 
2.03 (1 H, ddd, J 12.4, 9.5, 7.0, one of CH2).
5c (100 MHz; CDCI3): 142.8 (C), 128.5 (CH), 127.5 (CH), 127.4 (CH), 125.6 
(CH), 125.4 (CH), 81.9 (CH), 81.6 (CH), 41.4 (CH2), 38.3 (CH), 30.3 (CH2) and
26.8 (CH).
MS-ES: m /z (%) = 326 (M+, 2 ), 199 (100), 105 (81) and 91 (6 8 ).
HRMS-ES: m/z [M]+ calcd for C i4 H1 5 IO: 326.0168; found 326.0163.
(4aSR,5aRS,6RS,9aSR,9bRS)-6-lodo 
1,2,3,4,4a,5a,6,7,9a,9bdecahydrodibenzo[b,d]furan (25c)
To a solution of alcohol 24c (290 mg, 1.63 mmol) in MeCN (20 ml) were added 
iodine (1.24 g, 4.89 mmol) and sodium hydrogen carbonate (410 mg, 4.89 
mmol). The reaction was monitored by TLC and on complete consumption of 
the starting material ( 1 0  min) the reaction was quenched with saturated sodium 
thiosulfate solution. The product was then extracted with ether, the ether 
extracts being washed with brine and dried over sodium sulfate. The solvent 
was removed in vacuo and the product purified by chromatography on silica gel 
(1:9 EtOAc:hexane), yielding the title compound (299 mg, 60%) as an 
orange/brown solid, m.p. 61 -  62 °C.
vmax (Nujol): 2960, 1612, 1413, 1260, 1020, 797 and 6 8 8  cm'1.
8 h (400 MHz; CDCI3): 5.74 (1 H, broad app. ddd, J 1 0 .2 , 6.0, 1.3, alkene CH),
5.62 (1 H, app. dt, J 10.2, 3.2, alkene CH), 4.49 -  4.42 ( 2  H, m, CHO and CHI), 
3.22 (1 H, app. dt, J4.0, 10.7, CHO), 2.95 -  2.89 (1 H, m, CH), 2.72 -  2.64 (1 
H, m, one of CH2), 2.36 (1 H, broad app. ddd, J 18.6, 6.0, 1.3, one of CH2),
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2.02 -  1.96 (1 H, m), 1.85 -  1.80 (1 H, m), 1.74 -  1.56 (3 H, m) and 1.26 -  1.05 
(4 H, m).
6 c (100 MHz; CDCI3): 126.3 (CH), 125.3 (CH), 82.7 (CH), 80.6 (CH), 49.4 (CH),
39.4 (CH), 32.1 (CH2), 29.4 (CH2), 27.8 (CH), 26.1 (CH2), 25.6 (CH2) and 24.0 
(CH2).
MS-ES: m/z (%) = 346 (MH+.CH3CN, 60), 279 (74) and 177 (100).
HRMS-ES: m/z [M + H + CH3 CN]+ calcd for C i4 H2 iINO: 346.0668; found 
346.0667.
G ene ra l P ro c e d u re  1- Epoxidation Reactions
50% m-CPBA (1.04 g, 3.01 mmol) and solid NaHC03 (379 mg, 4.51 mmol) 
were added to a solution of diol 19a-f, 45, 46 (1.50 mmol) in CH2 CI2 (20 ml) at 
0 °C. The solution was stirred for 24 hours, after which an additional 0 . 1  
equivalents of rn-CPBA was added every hour until complete consumption of 
the starting material (TLC; typically 2.4 equivalents of m-CPBA was required). 
The reaction was quenched with saturated aqueous sodium thiosulfate solution 
and extracted with CH2 CI2 (3 x 25 ml). The combined organic extracts were 
washed with saturated aqueous NaHC03 solution (50 ml) and dried over 
Na2 S 04. The solvent was removed in vacuo and the residue purified by flash 
column chromatography on silica gel to give the pure epoxide 38.
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(1aS/?,3flS53af?S,5S/?,6a/?S,6b/?S)-5-Butyl-octahydro-6a-(hydroxymethyl)-
7-oxa-bicyclo[4.1.0]hept-1 (6)-eno[3,2-b]furan-3-ol (38a)
HO
S'! ,
19a
n - B u
HO
OH
38a
Epoxide 38a was prepared from diol 19a (316 mg, 1.50 mmol) according to 
general procedure 1. Purification by flash column chromatography (eluent 1:1 
ethyl acetate:hexane) afforded the title compound (144 mg, 40%) as a 
colourless oil.
V m a x  (Neat): 3415, 2922, 2862, 1466, 1426, 1381, 1259, 1127, 1058 and 838 
cm'1.
5h (400 MHz; CDCI3): 3.88-3.81 ( 1  H, m, H-5), 3.82 ( 1  H, d, J 10.9, one of H-7), 
3.79-3.74 (1 H, m, H-3), 3.74-3.72 (1 H, d, J 5.3, H-3a), 3.67 (1 H, d, J 10.9, 
one of H-7), 3.39-3.38 (1 H, m, H-1a), 3.30 (1 H, broad s, OH), 3.16 (1 H, app. 
dd, J 4.1, 1.2, H-6 b), 2.60 (1 H, broad s, OH), 2.24-2.17 (1 H, m, one of H-2), 
2.13 (1 H, ddd, J 15.8, 3.8, 1.3, one of H-2), 2.02 (1 H, dd, J 12.8, 5.3, one of 
H-6 ), 1.76 (1 H, dd, J 12.8, 9.9, one of H-6 ), 1.60-1.51 (1 H, m, one of 
CH2 (CH2 )2 CH3), 1.43-1.35 (1 H, m, one of CH2 (CH2 )2 CH3), 1.32-1.19 (4 H, m, 
(CH2)2) and 0.83 (3 H, t, J7.0, CH3).
5C (100 MHz; CDCI3): 78.6 (CH), 78.1 (CH), 67.6 (CH2), 67.0 (CH), 56.6 (CH),
53.5 (CH), 46.5 (C), 41.8 (CH2), 35.3 (CH2), 28.2 (CH2), 25.7 (CH2), 22.7 (CH2) 
and 14.1 (CH3).
MS-EI: m/z(%) = 242 (M+, 1), 211 (100), 149 (80) and 95 (94).
HRMS-EI: m/z [M]+ calcd fo rC i3 H2 2 0 4: 242.1518; found: 242.1519.
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(1aS/?,3/?S,3af?S,5RS,6a/?S,6bflS)-5-ferf-Butyl-octahydro-6a-
(hydroxymethyl)-7-oxa-bicyclo[4.1.0]hept-1 (6)-eno[3,2-b]furan-3-ol (38b)
Epoxide 38b was prepared from diol 19b (161 mg, 0.77 mmol) according to 
general procedure 1. Purification by flash column chromatography (eluent 3:1 
ethyl acetate:hexane) gave the title compound (139 mg, 75%) as a colourless 
solid, m.p. 86-87 °C.
vmax (Nujol): 3388, 2923, 2853, 1259 and 1059 cm'1.
8 h (400 MHz; CDCI3): 3.89 ( 1  H, d, J 10.9, one of H-7), 3.87-3.85 ( 1  H, m, H-3), 
3.74-3.72 ( 1  H, m, H-3a), 3.72 ( 1  H, d, J 10.9, one of H-7), 3.60 (1 H, dd, J 
10.8, 5.8, H-5), 3.46-3.43 (1 H, m, H-1a), 3.17 (1 H, app. dd, J4.0, 1.2, H-6 b), 
2.75 (2 H, broad s, 2 x OH), 2.25 (1 H, app. dt, J 15.8, 2.4, one of H-2), 2.18 (1
H, ddd, J 15.8, 3.8, 1.3, one of H-2), 1.93 (1 H, dd, J 12.8, 10.8, one of H-6 ),
I . 8 8  (1 H, dd, J 12.8, 5.8, one of H-6 ) and 0.86 (9 H, s, f-Bu).
8 C (100 MHz; CDCI3): 85.8 (CH), 79.3 (CH), 67.9 (CH2), 67.0 (CH), 56.7 (CH),
53.7 (CH), 46.4 (C), 37.2 (CH2), 33.6 (C), 25.7 (CH2) and 25.6 (3 x CH3).
MS-EI: m/z (%) = 224 (M+ -  H2 0, 3), 185 (100), 149 (33), 121 (44) and 95 (39). 
HRMS-EI: /7?/z[M]+ calcd for C i3 H2 0O3: 224.1412; found: 224.1413.
Crystallographic data for compound 38b. C i3 H2 20 4, FW = 242.31, T = 150(2) 
K, >.= 0.71073 A, monoclinic, P2 ,/a, a = 11.8532(3) A, b = 7.1565(2) A, c = 
16.0428(4), P= 102.4210(10), V = 1329.02(6) A3, Z = 4, l’ (calc) = 1 . 2 1 1  Mg/m3, 
crystal size = 0.38 x 0.25 x 0.10 mm3, reflections collected = 20521, 
independent reflections = 3023, R(int)= 0.109, parameters = 160, R1 [l>2a(l)]= 
0.075, wR2 [l>2a(l)] = 0.19, R1 (all data) = 0.10, wR2 (all data) = 0.21, Flack 
parameter = 0.056(10).
t - B u
19b 38b
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(1 RS,2SR,4RS,4aRS,5aSR,SaRS,9bSR)-9b-( Hydroxymethyl)-1,2-
epoxydodecahydrodibenzo[b,d]furan-4-ol 38c
Epoxide 38c was prepared from diol 19c (85 mg, 0.41 mmol) according to 
general procedure 1. Purification by flash column chromatography (eluent 1:1 
ethyl acetate:hexane) afforded the title compound (51 mg, 52%) as a 
colourless solid, m.p. 153-154 °C.
V m a x  (Nujol): 3417, 2927, 2854, 1064, 1046 and 722 cm'1.
8 h (400 MHz; CDCfe): 3.92-3.86 ( 2  H, m, H-4 and H-4a), 3.91 (1 H, d, J 11.0, 
one of H-10), 3.87 (1 H, d, J 11.0, one of H-10), 3.47-3.44 (1 H, m, H-2), 3.36- 
3.29 (2 H, m, H-1 and H-5a), 2.35 (1 H, app. broad d, J 16.0, one of H-3), 2.20-
2.01 (4 H, m, one of H-3, H-9a and 2 x OH), 1.85-1.77 (2 H, m, cyclohexyl 
CH2), 1.74-1.66 ( 2  H, m, cyclohexyl CH2) and 1.39-1.13 (4 H, m, 2  x 
cyclohexyl CH2).
6 C (100 MHz; CDCI3): 81.1 (CH), 79.2 (CH), 67.7 (CH), 67.1 (CH2), 53.8 (CH),
53.5 (CH), 52.3 (CH), 45.8 (C), 32.2 (CH2), 25.7 (CH2), 25.6 (CH2), 25.2 (CH2) 
and 23.9 (CH2).
MS-ES: m/z (%) = 2 2 2  (M+ -  H2 0, 1 ), 192 (8 6 ) and 79 (100).
HRMS-ES: m/z[U  -  H2 0 ]+ calcd for C i3 H1 80 3: 222.1256; found: 222.1253.
19c 38c
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(1aSfl,3flS,3af?S,5S/?,6af?S,6bf?S)-5-Hexyl-octahydro-6a-(hydroxymethyl)-
7-oxa-bicyclo[4.1.0]hept-1 (6)-eno[3,2-b]furan-3-ol (38d)
HO
0‘Ce^i3
19d
HO
OH
38d
n -  Cg H 3
Epoxide 38d was prepared from diol 19d (509 mg, 2.14 mmol) according to 
general procedure 1. Purification by flash column chromatography (eluent 2:1 
hexane:ethyl acetate) afforded the title compound (209 mg, 36%) as a 
colourless solid, m.p. 72-73 °C.
Vmax (Nujol): 3406, 2922, 2854, 1249, 1130, 1075, 1057, 1021, 932, 840, 721 
and 668 cm'1.
5h (400 MHz; CDCI3): 3.89-3.84 (1 H, m, H-5), 3.85 (1 H, d, J 10.8, one of H-7), 
3.82-3.77 (1 H, m, H-3), 3.75 (1 H, d, J 3.9, H-3a), 3.69 (1 H, d, J10.8, one of 
H-7), 3.40-3.37 (1 H, m, H-1a), 3.26 (1 H, app. dd, J4.0, 1.2, H-6b), 2.22 (1 H, 
app. dt, J 15.8, 2.5, one of H-2), 2.13 (1 H, ddd, J 15.8, 3.8, 1.4, one of H-2),
2.03 (1 H, dd, J 12.8, 5.3, one of H-6), 1.75 (1 H, dd, J 12.8, 9.9, one of H-6), 
1.58-1.50 (2 H, m, CH2(CH2)4CH3), 1.43-1.14 (10 H, m, (CH2)4 and 2 x OH) 
and 0.81 (3 H, t, J6.8, CH3).
5C (100 MHz; CDCI3): 78.8 (CH), 78.1 (CH), 68.0 (CH2), 67.0 (CH), 56.6 (CH),
53.5 (CH), 46.5 (C), 41.9 (CH2), 35.7 (CH2), 31.8 (CH2), 29.3 (CH2), 26.0 (CH2),
25.8 (CH2) 22.6 (CH2) and 14.1 (CH3).
MS-ES: m/z (%) = 252 (M+ -  H20, 40), 185 (100), 123 (98) and 95 (88). 
HRMS-ES: m/z[U  -  H20 ]+ calcd for C i5H240 3: 252.1725; found: 252.1725.
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(1aS/?,3/?S,3aflS,6f?S,6aA?S,6bf?S)-Octahydro-6a-(hydroxymethyl)-6-
phenyl-7-oxa-bicyclo[4.1.0]hept-1 (6)-eno[3,2-b]furan-3-ol (38f)
Epoxide 38f was prepared from diol 19f (136 mg, 0.59 mmol) according to 
general procedure 1. Purification by flash column chromatography (eluent 3:2 
hexane:ethyl acetate) afforded the title compound (85 mg, 55%) as a 
colourless solid, m.p. 89-90 °C.
Vmax (Nujol): 3488, 3335, 2923, 2851, 1076, 1059 and 1040 cm'1.
8h (400 MHz; CDCI3): 7.39-7.25 (5 H, m, Ph), 4.20 (1 H, dd, J9.1, 5.0, one of 
H-5), 4.10 (1 H, dd, J9.1, 6.8, one of H-5), 4.03-3.98 (1 H, m, H-3), 3.92 (1 H, 
d, J  11.0, one of H-7), 3.90 (1 H, d, J 11.0, one of H-7), 3.86-3.83 (1 H, m, 
H-3a), 3.71 (1 H, dd, J  6.8, 5.0, H-6), 3.50 (1 H, broad s, OH), 3.15-3.11 (1 H, 
m, H-1a), 111  (1 H, app. dd, J  4.2, 1.5, H-6b), 2.34-2.23 (2 H, m, H-2) and 
1.65 (1 H, broad s, OH).
5c (100 MHz; CDCI3): 139.1 (C), 128.6 (2 x CH), 128.5 (2 x CH), 127.2 (CH), 
80.6 (CH), 72.5 (CH2), 66.7 (CH2), 66.3 (CH), 55.4 (CH), 53.6 (CH), 51.5 (CH),
48.5 (C) and 25.7 (CH2).
MS-ES: m/z (%) = 244 (M+ -  HsO, 9), 214 (100), 171 (21) and 104 (85). 
HRMS-ES: m/z[M -  H20 ]+ calcd for C16H160 3: 244.1099; found: 244.1091.
19f 38f
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(2A7S,3af?S,7f?S,7a/7S)-2-fe/t-Butyl-3a-(hydroxymethyl)-2,3J3aJ6,7,7a-
hexahydro-benzo[b]furan-7-ol (39)
HO
OH
^  HO
7 O H
19b 39
Vanadyl acetylacetonate (73 mg, 0.28 mmol) and terf-butyl hydroperoxide (1.22 
ml of 5.0-6.0 M solution in decane, 6.08 mmol) were added to a solution of diol 
19b (580 mg, 2.76 mmol) in CH2CI2 (10 ml) at 0 °C. The reaction mixture was 
allowed to warm slowly to room temperature and stirred for 16 h. The reaction 
was quenched with saturated aqueous Na2 S0 3  solution and extracted with 
CH2CI2 ( 3 x 1 0  ml). The combined organic extracts were dried over Na2S 04 
before the solvent was removed in vacuo. Chromatography on silica gel (eluent 
hexane:ethyl acetate 2:1) afforded the title compound (93 mg, 15%) as a 
colourless solid, m.p. 83-85 °C.
Vmax (Nujol): 3186, 2922, 2856, 1205, 1171, 1131, 1043, 964, 910, 836, 776 
and 746 cm'1.
5h (400 MHz; CDCI3): 5.83-5.79 (1 H, m, H-5), 5.43 (1 H, d, J 10.2, H-4), 4.22 
(2 H, broad s, 2 x OH), 4.05-4.01 (1 H, m, H-7), 3.88 (1 H, d, J3.9, H-7a), 3.62 
(1 H, d, J 10.4, one of H-8), 3.55 (1 H, dd, J 10.5, 5.6, H-2), 3.46 (1 H, d, J 10.4, 
one of H-8), 2.36-2.31 (1 H, m, one of H-6), 2.04 (1 H, app. dd, J 17.9, 4.7, one 
of H-6), 1.52(1 H, dd, J12.1, 10.5, one of H-3), 1.48(1 H, dd, J 12.1, 5.6, one 
of H-3) and 0.82 (9 H, d, C(CH3)3).
5C (100 MHz; CDCI3): 129.7 (CH), 126.5 (CH), 85.2 (CH), 83.5 (CH), 68.0 
(CH2), 64.7 (CH), 48.8 (C), 36.6 (CH2), 33.5 (C), 28.2 (CH2) and 25.7 (3 x CH3). 
MS-AP: m/z (%) = 209 (MH+ -  H20, 100).
HRMS-AP: m/z[MH -  H20 ]+ calcd for C i3H2i0 2: 209.1542; found: 209.1532.
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In addition, compound 38b (34 mg, 5%) was obtained.
G e n e ra l P ro c e d u re  2 Azide Ring-Openings
Sodium azide (285 mg, 4.38 mmol) and ammonium chloride (117 mg, 2.19 
mmol) were added portionwise to a solution of the epoxide 38a-d, 38f (0.44 
mmol) in an 8:1 mixture of methanol/water (9 ml). The solution was stirred at 80 
°C for 24 hours before being cooled to room temperature and quenched with 
water. The crude product was extracted into CH2CI2 ( 3 x 1 0  ml). The combined 
organic extracts were dried over Na2S04 and the solvent removed in vacuo. 
The residue was purified by flash column chromatography on silica gel to give 
the pure azide 41.
(2Sf?,3aS/?,4/?S,5flS,7flS,7a/?S)-5-Azido-2-butyl-octahydro-3a- 
(hydroxymethyl)benzofuran-4,7-diol (41 a)
A7-BU
38a
n -  BuOh
HO,
41a
Azide 41a was prepared from epoxide 38a (106 mg, 0.44 mmol) according to 
general procedure 2. Purification by flash column chromatography (eluent 2:1 
hexane:ethyl acetate) afforded the title compound (45 mg, 36%) as a 
colourless solid, m.p. 107-108 °C.
Vmax (Nujol): 3185, 2923, 2853, 2111, 1082, 721 and 668 cm'1.
8h (400 MHz; CD3OD): 4.02 (1 H, app. tt, J 12.9, 6.5, H-2), 3.91 (1 H, ddd, J
12.3, 10.3, 4.3, H-5 or H-7), 3.89-3.85 (2 H, m, one of H-8 and H-5 or H-7), 
3.69 (1 H, app. broad s, H-4 or H-7a), 3.48 (1 H, d, J 11.0, one of H-8), 3.40 (1
115
H, d, J 10.2, H-4 or H-7a), 2.18 (1 H, dd, J 12.7, 6.5, one of H-3), 1.88 (1 H, 
app. dt, J 13.8, 3.1, one of H-6 ), 1.65-1.49 ( 2  H, m, one of H- 6  and butyl H),
I.44-1.18 ( 6  H, m, one of H-3 and butyl H) and 0.86 (3 H, t, J 6 .8 , CH3).
5c (100 MHz; CD3OD): 85.1 (CH), 78.3 (CH), 76.5 (CH), 66.9 (CH), 65.0 (CH2),
60.9 (CH), 53.9 (C), 41.3 (CH2), 37.5 (CH2), 34.6 (CH2), 29.3 (CH2), 23.8 (CH2) 
and 14.5 (CH3).
MS-ES: m/z (%) = 267 (M* -  H2 0, 26), 208 (100), 181 (58), 155 (64) and 72 
(81).
HRMS-ES: m/z[M -  H2 0 ]+ calcd for C1 3H2 1 N3 O3 : 267.1583; found: 267.1588.
(2 A7S,3aS/?,4/?S,5 R S J  R S ,7aR S )-2-te rt-B  uty l-5-azido-octahyd ro-3 a- 
(hydroxymethyl)benzofuran-4,7-diol (41 b)
■ B u
38b
/-Bu
Oh
HO,
7 'O h
41b
Azide 41b was prepared from epoxide 38b (101 mg, 0.42 mmol) according to 
general procedure 2. Purification by flash column chromatography (eluent 2:1 
hexane:ethyl acetate) afforded the title compound (80 mg, 67%) as a 
colourless solid, m.p. 155-156 °C.
Vmax (Nujol): 3192, 2920, 2853, 2113, 1258 and 1070 cm'1.
8 h (400 MHz; CD3OD): 4.03-3.92 (3 H, m, one of H-8 , H-5 and H-7), 3.78 (1 H, 
dd, J 9.9, 6 .6 , H-2), 3.69 (1 H, app. broad s, H-4 or H-7a), 3.54 (1 H, d, J 11.0, 
one of H-8 ), 3.48 (1 H, d, J 10.3, H-4 or H-7a), 2.02 (1 H, app. dd, J  12.9, 6 .6 , 
one of H-3), 1.93 (1 H, app. broad d, J 13.4, one of H-6 ), 1.67 (1 H, ddd, J 13.4, 
12.7, 3.0, one of H-6 ), 1.57 ( 1  H, app. dd, J 12.9, 9.9, one of H-3) and 0.88 (9 H, 
s, f-Bu).
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8c (100 MHz; CD3OD): 86.5 (CH), 86.1 (CH), 76.5 (CH), 67.0 (CH), 65.0 (CH2),
60.8 (CH), 53.9 (C), 35.9 (CH2), 35.6 (C), 34.5 (CH2) and 25.9 (3 x CH3).
MS-EI: m/z (%) = 267 (M+ -  H20, 34), 240 (17), 182 (100), 137 (38), 111 (33) 
and 81 (28).
HRMS-EI: m/z[U  -  H20 ]+ calcd for Ci3H2iN30 3: 267.1583; found: 267.1581.
(1RS,2flS,4/?S,4a/?S,5aS/?,9aflS,9bSfi)-2-Azido-9b- 
(hydroxymethyl)dodecahydrodibenzo[b,c/]furan-1,4-diol (41 c)
HO,
41c38c
Azide 41c was prepared from epoxide 38c (78 mg, 0.33 mmol) according to 
general procedure 2. Purification by flash column chromatography (eluent 1:1 
hexane:ethyl acetate) afforded the title compound (42 mg, 46%) as a 
colourless solid, m.p. 156-157 °C.
Vmax (Nujol): 3418, 2922, 2103, 1303, 1064, 1036, 979, 826 and 722 cm'1.
5h (400 MHz; CD3OD): 3.75 (1 H, d, J 11.1, one of H-10), 3.72 (1 H, app. broad 
d, J 3.6, H-1 or H-4a), 3.70-3.65 (1 H, broad m, H-2 or H-4), 3.60 (1 H, d, J
11.1, one of H-10), 3.33-3.26 (2 H, m, H-5a and H-2 or H-4), 3.18 (1 H, app. d, 
J3 .1 , H-1 or H-4a), 2.15 (1 H, app. broad d, J 16.0, one of H-3), 2.04 (1 H, app. 
ddd, J 16.0, 3.7, 1.0, one of H-3), 2.00-1.91 (2 H, broad m, H-9a and one of 
CH2), 1.70-1.62 (3 H, broad m, one of CH2 and CH2) and 1.33-1.10 (4 H, m, 2 
x CH2).
5c (100 MHz; CD3OD): 80.9 (CH), 78.9 (CH), 67.5 (CH), 65.0 (CH2), 53.0 (CH),
52.8 (CH), 51.8 (CH), 45.5 (C), 32.1 (CH2), 25.5 (CH2), 25.4 (CH2), 24.7 (CH2) 
and 23.6 (CH2).
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(2S/?,3aS/?,4/?S,5/?S,7/?S,7af?S)-5-Azido-2-hexyl-octahydro-3a-
(hydroxymethyl)benzofuran-4,7-diol (41 d)
n - Cgh -13
38d
OH
HO,
7 'OH
41d
Azide 41 d was prepared from epoxide 38d (67 mg, 0.25 mmol) according to 
general procedure 2. Purification by flash column chromatography (eluent 2:1 
hexane:ethyl acetate) afforded the title compound (75 mg, 96%) as a 
colourless solid, m.p. 97-98 °C.
Vmax (Nujol): 3199, 2927, 2853, 2114, 1256, 1183, 1068, 1037, 1009, 961, 921 
and 802 cm'1.
§ h (400 MHz; CD3OD): 4.13-4.03 (1 H, m, H-2), 3.97 (1 H, ddd, J 12.2, 10.2,
4.3, H-5 or H-7), 3.95-3.91 (2 H, m, one of H-8 and H-5 or H-7), 3.76-3.74 (1 H, 
m, H-4 or H-7a), 3.55 (1 H, d, J 11.0, one of H-8), 3.46 (1 H, d, J 10.2, H-4 or 
H-7a), 2.24 (1 H, dd, J 12.7, 6.5, one of H-3), 1.94 (1 H, app. broad d, J 13.7, 
one of H-6), 1.67 (1 H, ddd, J 13.7, 12.4, 3.0, one of H-6), 1.62-1.48 (1 H, m, 
hexyl H), 1.49-1.24 (9 H, m, hexyl H), 1.37 (1 H, dd, J 12.7, 9.0, one of H-3) 
and 0.91 (3 H, t, J6.8, CH3).
6c (100 MHz; CD3OD): 85.1 (CH), 78.3 (CH), 76.5 (CH), 66.9 (CH), 65.0 (CH2),
60.9 (CH), 53.9 (C), 41.3 (CH2), 37.8 (CH2), 34.6 (CH2), 33.1 (CH2), 30.5 (CH2),
27.1 (CH2), 23.7 (CH2) and 14.5 (CH3).
MS-ES: m/z (%) = 331 (M + NH4+, 67), 287 (22), 286 (100), 268 (7), 252 (2) 
and 222(1).
HRMS-ES: m /z [M + NH4]+ calcd for C i5H3iN40 4: 331.2345; found: 331.2359.
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(3/?S,3aSfl,4flS,5/?S,7flS57aftS)-5-Azido-octahydro-3a-(hydroxymethyl)-3-
phenylbenzofuran-4,7-diol (41 f)
Azide 41 f was prepared from epoxide 38f (45 mg, 0.17 mmol) according to 
general procedure 2. Purification by flash column chromatography (eluent 1:1 
hexane:ethyl acetate) afforded the title compound (35 mg, 67%) as a 
colourless solid, m.p. 140-141 °C.
Vmax (Nujol): 3260, 2924, 2854, 2100, 1246, 1158, 1061 and 722 cm'1.
SH (400 MHz; CD3OD): 7.24-7.12 (5 H, m, Ph), 4.21 (1 H, dd, J 9.9, 8.9, one of 
H-2), 4.03 (1 H, app. t, J 8.7, one of H-2), 3.99 (1 H, d, J  10.9, one of H-8), 3.90 
(1 H, app. q, J 3.1, H-5 or H-7), 3.86 (1 H, app. d, J 2.8, H-4 or H-7a), 3.84- 
3.78 (1 H, m, H-5 or H-7), 3.68 (1 H, d, J9.9, H-4 or H-7a), 3.53 (1 H, d, J10.9, 
one of H-8), 3.40 (1 H, app. t, J 9.5, H-3), 1.87 (1 H, app. dt, J 13.5, 3.9, one of 
H-6) and 1.71-1.64 (1 H, m, one of H-6).
6C (100 MHz; CD3OD): 136.7 (C), 128.4 (CH), 128.3 (CH), 128.2 (CH), 126.8 
(CH), 126.6 (CH), 85.9 (CH), 71.1 (CH), 69.1 (CH2), 65.8 (CH), 62.7 (CH2),
60.8 (CH), 53.9 (C), 51.0 (CH) and 32.5 (CH2).
MS-ES: m/z (%) = 323 (M + NH4+, 100), 278 (97), 260 (14) and 242 (1). 
HRMS-ES: m /z [M + NH4]+ calcd for C i5H23N40 4: 323.1719; found: 323.1734.
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(±)-1 -((1,4-frans)-1 -(Hydroxymethyl)-4-methylcyclohexa-2,5-dienyl)hexan- 
2-ol (45) and (±)-1-((1,4-c#s)-1-(hydroxymethyl)-4-methylcyclohexa-2,5- 
dienyl)hexan-2-ol (46)
n-Butyllithium (10.1 ml of a 2.5 M solution in hexanes, 25.3 mmol) was added 
to a solution of diisopropylamine (3.55 ml, 25.3 mmol) in dry THF (30 ml) at 
-78 °C and the resulting solution was allowed to warm to room temperature. 
After re-cooling to -78 °C, the ester 23 (3.50 g, 23.0 mmol) was added 
dropwise. After stirring for 30 minutes at -78 °C, n-butyloxirane 28a (3.61 ml,
29.9 mmol) was added and the reaction mixture allowed to warm to 5 °C over 3 
h. The reaction was quenched with saturated aqueous ammonium chloride 
solution (50 ml) and extracted with diethyl ether (3 x 30 ml). The combined 
organic extracts were dried over Na2S04 before the solvent was removed in 
vacuo affording the crude intermediate lactones 44 (5.44 g) as a yellow oil. 
These lactones (3.99 g, 18.1 mmol) were redissolved in dry THF (20 ml) and 
added dropwise to a suspension of LiAIH4 (688 mg, 18.1 mmol) in dry THF (30 
ml). The resulting suspension was allowed to stir for 15 minutes before the 
reaction was quenched slowly with 2 M NaOH. The solution was filtered and 
dried over Na2S04 before the solvent was removed in vacuo. Chromatography 
on silica gel (eluent hexane:diethyl ether 2:1) afforded a 1:1 mixture of diols 45 
and 46 (2.56 g, 63%) as a colourless oil. Further chromatography (eluent 
hexane:diethyl ether 4:1) provided pure samples of the individual 
diastereoisomers.
Data for compound 45
Vmax (Neat): 3384, 3011, 2957, 2928, 2871, 1636, 1456, 1378, 1278, 1122, 
1037, 918, 804 and 746 cm'1.
c4hc
Me
23
Me
45
Me
46
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5h (400 MHz; CDCI3): 5.97-5.88 (2 H, m, alkene CH), 5.65 (1 H, app. dt, J10.3,
2.3, alkene CH), 5.38 (1 H, app. dt, J 10.8, 2.1, alkene CH), 3.82-3.74 (1 H, 
broad m, CHOH), 3.35 (2 H, s, CH2OH), 2.85-2.77 (1 H, broad m, CHCH3), 
1.99 (2 H, broad s, 2 x OH), 1.50 (1 H, dd, J 14.2, 9.1, one of CCH2), 1.42 (1 H, 
dd, J 14.2, 2.1, one of CCH2), 1.38-1.22 (6 H, broad m, (CH2)3), 1.06 (3 H, d, J
7.3, CH3) and 0.88 (3 H, t, J6.8, CH3).
6c (100 MHz; CDCI3): 134.4 (CH), 133.7 (CH), 129.5 (CH), 128.4 (CH), 70.4 
(CH2), 69.2 (CH), 44.6 (CH2), 42.7 (C), 37.6 (CH2), 30.9 (CH), 27.8 (CH2), 22.8 
(CH2), 22.1 (CH3) and 14.1 (CH3).
MS-EI: m/z (%) = 206 (M+ -  H20, 32), 188 (100), 176 (62), 159 (50), 145 (97) 
and 131 (99).
HRMS-EI: m/z [M -  H20 ]+ calcd fo rC i4H220: 206.1671; found: 206.1668.
Data for compound 46
vmax (Neat): 3355, 3012, 2957, 2928, 2871, 1457, 1124, 1038, 945, 899, 802 
and 746 cm'1.
5h (400 MHz; CDCI3): 5.96-5.89 (2 H, m, alkene CH), 5.64 (1 H, app. dt, J10.1,
2.0, alkene CH), 5.38 (1 H, app. dt, J 10.6, 2.0, alkene CH), 3.82-3.75 (1 H, 
broad m, CHOH), 3.34 (2 H, s, CH2OH), 2.86-2.77 (1 H, broad m, CHCH3), 
1.82 (2 H, broad s, 2 x OH), 1.51 (1 H, dd, J14.2, 9.0, one of CCH2), 1.44(1 H, 
dd, J 14.2, 2.3, one of CCH2), 1.41-1.22 (6 H, broad m, (CH2)3), 1.11 (3 H, d, J
7.3, CH3) and 0.89 (3 H, t, J 6.7, CH3).
6c (100 MHz; CDCI3): 134.2 (CH), 133.7 (CH), 129.5 (CH), 128.5 (CH), 70.0 
(CH2), 69.3 (CH), 44.9 (CH2), 42.7 (C), 37.7 (CH2), 30.9 (CH), 27.8 (CH2), 22.7 
(CH2), 22.4 (CH3) and 14.1 (CH3).
MS-AP: m/z (%) = 207 (MH+ -  H20, 30), 189(100), 146 (3), 118 (3) and 91 (1). 
HRMS-AP: m/z[MH -  H20 ]+ calcd for C i4H230: 207.1749; found: 207.1757.
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(1aSfl,2/?S,3flS,3aflS,5S/?,6a/?S,6bflS)-5-Butyl-octahydro-6a- 
(hydroxymethyl)-2-methyl-7-oxa-bicyclo[4.1.0]hept-1(6)-eno[3,2-b]furan-3- 
ol (47)
HO
'  6b 3a /
3 O H
47
Epoxide 47 was prepared from diol 45 (105 mg, 0.47 mmol) according to 
general procedure 1. Purification by flash column chromatography (eluent 2:1 
diethyl ether:hexane) afforded the title compound (24 mg, 20%) as a colourless 
oil.
vmax (Solution in CH2CI2): 3410, 2931, 1645, 1456, 1379, 1034, 899 and 837 
cm'1.
5h (400 MHz; CDCI3): 3.95 (1 H, app. quintet, J6.9, H-5), 3.76 (1 H, d, J 10.8, 
one of H-7), 3.69 (1 H, d, J10.8, one of H-7), 3.65 (1 H, d, J 6.9, H-3a), 3.42 (1 
H, app. dt, J 6.9, 4.8, H-3), 3.16 (1 H, d, J3.8, H-1a), 3.00 (1 H, dd, J3.8, 1.0, 
H-6b), 2.56 (2 H, broad s, 2 x OH), 2.09-2.02 (1 H, m, H-2), 1.97 (1 H, dd, J
13.1, 7.6, one of H-6), 1.71 (1 H, dd, J 13.1, 7.1, one of H-6), 1.61-1.52 (1 H, m, 
one of CH2(CH2)2CH3), 1.45-1.36 (1 H, m, one of CH2(CH2)2CH3), 1.30-1.22 (4 
H, m, (CH2)2), 1.18 (3 H, d, J 7.5, CH3) and 0.83 (3 H, t, J 7.0, CH3).
5C (100 MHz; CDCI3): 81.5 (CH), 77.0 (CH), 70.7 (CH), 67.9 (CH2), 57.5 (CH),
56.9 (CH), 47.2 (C), 38.6 (CH2), 36.2 (CH2), 34.6 (CH), 28.4 (CH2), 22.7 (CH2),
15.9 (CH3) and 14.1 (CH3).
MS-EI: m /z (%) = 238 (M+ -  H20, 9), 190 (75), 147 (100), 121 (82) and 91 (71). 
HRMS-EI: m/z[U  -  H20 ]+ calcd for C i4H220 3: 238.1569; found: 238.1573.
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(1 aS R ,2S R ,3R S ,3aR S ,5S R ,6aR S ,6bR S )-5 -B u \y \-oc \ahydro -6a -  
(hydroxymethyl)-2-methyl-7-oxa-bicyclo[4.1.0]hept-1(6)-eno[3,2-b]furan-3- 
ol (48)
Me
OH
Me
46 48
Epoxide 48 was prepared from diol 46 (278 mg, 1.24 mmol) according to 
general procedure 1. Purification by flash column chromatography (eluent 2:1 
diethyl ether:hexane) afforded the title compound (120 mg, 38%) as a 
colourless solid, m.p. 66-68 °C.
V m a x  (Nujol): 3394, 2926, 2853, 1644, 1152, 1053 and 834 cm'1.
8h (400 MHz; CDCI3): 3.86-3.77 (3 H, m, one of H-7, H-3a and H-5), 3.66 (1 H, 
d, J 10.9, one of H-7), 3.59 (1 H, app. broad s, H-3), 3.21 (1 H, d, J 4.2, H-1 a), 
3.17 (1 H, dd, J4.2 1.5, H-6b), 2.94 (2 H, broad s, 2 x OH), 2.23 (1 H, app. qd, 
J 7.3, 3.3, H-2), 2.02 (1 H, dd, J 12.8, 5.1, one of H-6), 1.77 (1 H, dd, J 12.8,
10.2, one of H-6), 1.59-1.51 (1 H, m, one of CH2 (CH2)2 CH3), 1.42-1.34 (1 H, m, 
one of CH2 (CH2)2 CH3), 1.25 (3 H, d, J 7.3, CH3) 1.25-1.20 (4 H, m, (CH2)2) and 
0.83 (3 H, t, J7.0, CH3).
5C (100 MHz; CDCI3): 79.9 (CH), 78.3 (CH), 71.4 (CH), 67.9 (CH2), 58.9 (CH),
58.0 (CH), 46.7 (C), 42.1 (CH2), 35.3 (CH2), 28.2 (CH2), 27.9 (CH), 22.8 (CH2),
14.4 (CH3) and 14.1 (CH3).
MS-EI: m/z(%) = 238 (M+ -  H20, 12), 190 (69), 147 (100) and 121 (86). 
HRMS-EI: m/z[M -  H20 ]+ calcd for C14H220 3: 238.1569; found: 238.1574.
Crystallographic data for compound 48. CmH^O^ FW = 256.33, T = 150(2) 
K, /.= 0.71073 A, triclinic, P-1, a = 6.3080(2) A, b = 13.5420(5) A, c = 
17.5900(7) A, « =  73.293(2)°, P= 81.756(2)°, 7 =  79.108(2)°, V =  1406.88(9) A3, 
Z = 4, P(calc) = 1.210 Mg/m3, crystal size = 0.50 x 0.18 x 0.08 mm3, reflections
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collected = 7267, independent reflections = 4761, R(int) = 0.079, parameters = 
333, R1 [l>2<r(l)]= 0.14, wR2 [l>2a(l)] = 0.34, R1 (all data) = 0.19, wR2 (all data) 
= 0.37. The asymmetric unit of compound 48 consists of two independent 
molecules. The higher R indices for 48 are due to the poor quality of the 
available sample and thus data were recorded using a twinned crystal.
5.3 Experimental Data for Chapter 2
Methyl 1-pent-4-enoylcyclohexa-2,5-dienecarboxylate (104)
n-Butyllthium (15.8 ml of a 2.5 M solution in hexanes, 39.6 mmol) was added to 
a solution of diisopropylamine (5.55 ml, 39.6 mmol) in THF (50 ml) at 0 °C. 
After stirring for 30 mins at 0°C, the reaction mixture was cooled to -78 °C 
before the ester 23 (4.97 g, 36.0 mmol) was added dropwise. The resulting red 
suspension was allowed to stir for 30 mins at -78 °C before 4-pentenoyl 
chloride (4.37 ml, 39.6 mmol) was added drop-wise. The yellow solution was 
allowed to stir for 20 minutes before being quenched at -78 °C with sat. 
aqueous NH4CI solution. The aqueous layer was extracted with diethyl ether, 
the combined organic extracts being dried over Na2 S0 4 , before the solvent was 
removed in vacuo. Chromatography on silica gel (1:49 Et20:petroleum ether) 
afforded the title compound (4.67 g, 59 %) as a colourless oil.
Vmax (Neat): 3042, 2969, 2830, 1719, 1640, 1435, 1351, 1237, 1098, 1057, 991, 
915, 795, 711 and 647 cm'1.
5h (400 MHz; CDCI3): 6.08 -  6.04 (2 H, m, ring alkene CH), 5.99 -  5.96 (2 H, m, 
ring alkene CH), 5.76 (1 H, ddt, J 17.1, 10.2, 6.5, alkene CH), 5.01 (1 H, app. 
ddd, J 17.1, 3.3, 1.5, one of terminal alkene CH2), 4.96 (1 H, app. ddd, J 10.2,
O
23 104
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3.0, 1.5, one of terminal alkene CH2), 3.75 (3 H, s, OCH3), 2.79 -  2.76 (2 H, m, 
ring CH2), 2.62 (2 H, t, J 7.3, CH2C=0) and 2.31 -2 .2 5  (2 H, m, CH2).
5C (100 MHz; CDCI3): 205.2 (C), 170.9 (C), 136.9 (CH), 128.1 (2 x CH), 122.8 
(2 x CH), 115.3 (CH2), 62.7 (C), 52.7 (CH3), 37.6 (CH2), 27.6 (CH2) and 26.1 
(CH2).
MS-ES: m/z (%) = 221 (MH+, 32), 203 (5), 173 (11), 161 (14), 143 (12) and 116 
(5).
HRMS-ES: m/z[U  + H]+ calcd for C i3Hi70 3: 221.1178; found: 221.1171.
1 -(1 -(Hydroxymethyl)cyclohexa-2,5-dienyl)pent-4-en-1 -ol (105)
O OH
104
HO
105
A solution of the keto-ester 104 (1.64 g, 7.01 mmol) in THF (5 ml) was added 
dropwise to a suspension of lithium aluminium hydride (266 mg, 7.01 mmol) in 
THF (15 ml). The suspension was allowed to stir for 20 mins before being 
quenched slowly with 2 M aqueous NaOH solution. The solution was filtered 
and dried over Na2S04 before the solvent was removed in vacuo. 
Chromatography on silica gel (1:4 EtOAc:hexane) afforded the title compound 
(1.02 g, 75 %) as a colourless solid, m.p. 61 -  62 °C.
Vmax (Nujol): 3306, 1404, 1338, 1312, 1260, 1136, 1097, 720 and 650 cm'1.
5h (400 MHz; CDCI3): 5.96 -  5.92 (1 H, m, ring alkene CH), 5.88 (1 H, app. dtd, 
J 10.2, 3.4, 1.6, ring alkene CH), 5.77 (1 H, app. ddt, J 17.1, 10.2, 6.9, alkene 
CH), 5.70 (1 H, app. ddd, J 10.3, 3.9, 1.8, ring alkene CH), 5.37 (1 H, app. dq, 
J 10.2, 1.9, ring alkene CH), 5.00 (1 H, ddd, J 17.1, 3.3, 1.6, one of terminal 
alkene CH2), 4.94 -  4.91 (1 H, m, one of terminal alkene CH2), 3.59 -  3.53 (3 H, 
m, CH2OH and CHOH), 3.18 (2 H, broad s, 2 x OH), 2.70 -  2.57 (2 H, m, ring 
CH2), 2.28 -  2.19 (1 H, m, one of CH2C=C), 2.09 -  1.99 (1 H, m, one of
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CH2C=C), 1.51 (1 H, dddd, J 14.2, 9.2, 7.1, 2.0, one of CH2) and 1.36 (1 H, 
dddd, J 14.2, 10.5, 8.9, 5.3, one of CH2).
5C (100 MHz; CDCI3): 138.7 (CH), 127.6 (CH), 127.5 (2 x CH), 125.6 (CH),
114.8 (CH2), 76.0 (CH), 69.5 (CH2), 46.4 (C), 32.3 (CH2), 30.6 (CH2) and 27.2 
(CH2).
MS-EI: m/z (%) = 176 (M+ -  H20, 10), 158 (50), 143 (67), 128 (85), 117 (91), 
105 (63), 91 (100), 77 (87) and 65 (37).
HRMS-EI: m/z [M -  H20 ]+ calcd fo rC i2Hi60: 176.1201; found: 176.1202.
fe#?-Butyl(1-(1-((ferf-butyldimethylsilyloxy)methyl)cyclohexa-2,5- 
dienyl)pent-4-enyloxy)dimethylsilane (106)
Oh OTBS
HO
105
TBSO
106
2,6-Lutidine (6.20 ml, 53.2 mmol) and tert-butyldimethylsilyl 
trifluoromethanesulfonate (9.16 ml, 39.9 mmol) were added to a solution of diol 
105 (2.58 g, 13.3 mmol) in CH2CI2 (30 ml) at 0 °C. The reaction mixture was 
allowed to warm to room temperature and stirred for 18 h, before being 
quenched with water. The crude product was extracted with CH2CI2, the 
combined extracts being dried over Na2S04. Chromatography on silica gel 
(hexane) afforded the title compound (5.01 g, 89 %) as a colourless oil.
Vmax (Neat): 3027, 2954, 2857, 2360, 1640, 1471, 1255, 1086, 835, 775, 720 
and 667 cm'1.
5h (400 MHz; CDCI3): 5.85 -  5.80 (1 H, m, ring alkene CH), 5.79 -  5.71, (2 H, 
m, one of ring alkene CH and alkene CH) 5.63 (1 H, app. dq, J 10.3, 2.0, ring 
alkene CH), 5.52 (1 H, app. dq, J 10.3, 2.0, ring alkene CH), 4.96 (1 H, app. 
ddd, J 17.1, 3.6, 1.6, one of terminal alkene CH2), 4.90 (1 H, ddt, J 10.2, 2.2,
1.2, one of terminal alkene CH2), 3.83 (1 H, dd, J6.6, 3.8, CHOTBS), 3.62 (1 H,
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d, J 9.3, one of CH2OTBS), 3.27 (1 H, d, J9.3, one of CH2OTBS), 2.65 -  2.62 
(2 H, m, ring CH2), 2.23 -  2.13 (1 H, m, one of CH2C=C), 2.04 -  1.94 (1 H, m, 
one of CH2C=C), 1.61 (1 H, dddd, J 14.6, 10.9, 5.6, 3.8, one of CH2), 1.44 -  
1.35 (1 H, m, one of CH2), 0.91 (9 H, s, f-Bu), 0.89 (9 H, s, t-Bu), 0.09 (3 H, s, 
Me), 0.07 (3 H, s, Me) and 0.00 (6 H, s, 2 x Me).
6C (100 MHz; CDCI3): 139.4 (CH), 129.9 (CH), 127.2 (CH), 126.1 (CH), 124.7 
(CH), 113.9 (CH2), 73.0 (CH), 67.9 (CH2), 47.5 (C), 34.0 (CH2), 31.0 (CH2),
27.4 (CH2), 26.1 (3 x CH3), 26.0 (3 x CH3), 18.4 (2 x C), -3.9 (CH3), -4.2 (CH3), 
-5.1 (CH3) and -5.4 (CH3).
MS-EI: m/z (%) = 422 (M+, 12), 365 (49), 199 (100) and 147 (70).
HRMS-EI: m/z[M]+ calcd for C24H460 2Si2: 422.3036; found: 422.3035.
5-(ferf-Butyldimethylsilyloxy)-5-(1-((fe/T- 
butyldimethylsilyloxy)methyl)cyclohexa-2,5-dienyl)pentan-1 -ol (107)
OTBS OTBS
TBSO
106
TBSO Oh
107
0.5 M 9-BBN (4.00 ml, 2.00 ml) was added to a solution of the bis-protected 
diol 106 (767 mg, 1.82 mmol) in THF (15 ml) and the resulting solution was 
allowed to stir for 18 h. Aqueous 0.5 M NaOH solution (7 ml, 3.5 mmol) and 
aqueous hydrogen peroxide solution (30 %, 8 ml) were then added slowly at 0 
°C. The solution was allowed to warm to room temperature and stirred for 3 h, 
before being diluted with ethyl acetate, washed with brine and extracted with 
CH2CI2. The combined organic extracts were dried over Na2S04 and the 
solvent removed in vacuo. Chromatography on silica gel (1:9 Et20:petroleum 
ether) afforded the title compound (673 mg, 84 %) as a colourless oil.
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Vmax (Neat): 3331, 3027, 2928, 2859, 2364, 1472, 1361, 1255, 1085, 939, 838, 
775, 719 and 666 cm'1.
8h (400 MHz; CDCI3): 5.82 (1 H, app. dtd, J 10.2, 3.2, 1.6, alkene CH), 5.75 (1 
H, app. dtd, J 10.3, 3.3, 1.6, alkene CH), 5.63 (1 H, app. dq, J 10.3, 1.9, alkene 
CH), 5.51 (1 H, app. dq, J 10.3, 1.9, alkene CH), 3.79 (1 H, dd, J 5.8, 3.3, 
CHOTBS), 3.63 -  3.58 (3 H, m, CH2OH and one of CH2OTBS), 3.26 (1 H, d, J
9.3, one of CH2OTBS), 2.65 -  2.62 (2 H, m, ring CH2), 1.57 -  1.44 (4 H, broad 
m, alkyl), 1.38 -  1.27 (2 H, broad m, alkyl), 0.90 (9 H, s, t-Bu), 0.88 (9 H, s, 
t-Bu), 0.09 (3 H, s, CH3), 0.06 (3 H, s, CH3) and 0.00 (6 H, s, 2 x CH3).
6C (100 MHz; CDCI3): 130.0 (CH), 127.3 (CH), 126.1 (CH), 124.6 (CH), 73.5 
(CH), 67.9 (CH2), 63.0 (CH2), 47.5 (C), 34.5 (CH2), 33.3 (CH2), 27.4 (CH2), 26.1 
(3 x CH3), 26.0 (3 x CH3), 22.9 (CH2), 18.4 (2 x C), -3.9 (CH3), -4.3 (CH3), -5.1 
(CH3) and -5.4 (CH3).
MS-ES: m/z (%) = 441 (MH+, 24), 315 (53), 309 (100), 259 (65), 177 (79) and 
159 (28).
HRMS-ES: m/z[U + H]+ calcd for C24H490 3Si2: 441.3220; found: 441.3226. 
5-(ferf-Butyldimethylsilyloxy)-5-(1-((ferf-
butyldimethylsilyloxy)methyl)cyclohexa-2,5-dienyl)pentanal (108)
OTBS OTBS
107 108
A solution of the bis-protected triol 107 (866 mg, 1.97 mmol) in DCM (10 ml) 
was added to a suspension of PDC (1.11 g, 2.95 mmol) in DCM (10 ml). The 
reaction mixture was allowed to stir for 18 h, before being filtered through silica 
and the solvent removed in vacuo. Chromatography on silica gel (1:99 
Et20:petroleum ether) afforded the title compound (505 mg, 59 %) as a 
colourless oil.
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vmax (Neat): 3027, 2955, 2857, 2361, 1729, 1471, 1361, 1255, 1085, 1006, 
938, 837, 775, 720 and 666 cm'1.
8h (400 MHz; CDCfe): 9.71 (1 H, t, J 2.0, aldehyde CH), 5.83 (1 H, app. dtd, J
10.3, 3.1, 1.5, alkene CH), 5.76 (1 H, app. dtd, J 10.3, 3.3, 1.6, alkene CH),
5.62 (1 H, app. ddd, J 10.2, 4.0, 2.2, alkene CH), 5.53 -  5.49 (1 H, m, alkene 
CH), 3.84 -  3.80 (1 H, m, CHOTBS), 3.62 (1 H, d, J 9.3, one of CH2OTBS),
3.25 (1 H, d, J 9.3, one of CH2OTBS), 2.66 -  2.59 (2 H, broad m, ring CH2), 
2.33 (2 H, app. tt, J7.4, 2.0, CH2 next to aldehyde), 1.84 -  1.66 (1 H, broad m, 
alkyl), 1.64 -  1.48 (2 H, broad m, alkyl), 1.41 -  1.30 (1 H, broad m, alkyl), 0.90 
(9 H, s, f-Bu), 0.88 (9 H, s, f-Bu), 0.10 (3 H, s, CH3), 0.07 (3 H, s, CH3) and 
0.00 (6 H, s, 2 x CH3).
5C (100 MHz; CDCI3): 202.9 (aldehyde CH), 129.7 (CH), 127.1 (CH), 126.2 
(CH), 124.8 (CH), 73.1 (CH), 67.8 (CH2), 47.4 (C), 44.4 (CH2), 34.4 (CH2), 27.3 
(CH2), 26.1 (3 x CH3), 26.0 (3 x CH3), 19.5 (CH2), 18.4 (2 x C), -3.9 (CH3), -4.3 
(CH3), -5.1 (CH3) and -5.4 (CH3).
MS-ES: m/z (%) = 439 (MH+, 8), 308 (26), 307 (100) and 175 (9).
HRMS-ES: m/z[M + H]+ calcd for C24H470 3Si2: 439.3064; found: 439.3083.
Compound 109
OTBS
108 H 109
Trifluoromethanesulfonic acid (0.02 ml, 0.18 mmol) was added dropwise to a 
solution of aldehyde 108 (78 mg, 0.18 mmol) in CH2CI2 (2 ml) at 0 °C. The 
resulting brown solution was warmed to room temperature and stirred for 20 
min before being quenched with saturated aqueous sodium hydrogen 
carbonate solution. The crude product was extracted with CH2CI2. The 
combined extracts were dried over Na2S 04 before the solvent was removed in
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vacuo. Chromatography on silica gel (1:6 EtOAc/ petroleum ether) afforded 
compound 109 (11 mg, 32%) as a colourless oil.
Vmax (Neat): 2933, 2850, 1682, 1643, 1464, 1430, 1177, 1010, 872, 739 and 
668 cm'1.
5h (400 MHz; CDCI3): 9.37 (1 H, s, aldehyde), 6.97 (1 H, dd, J5.1, 4.1, alkene 
CH), 3.96 (1 H, app. s, CH-O), 3.89 (1 H, app. br s, CH-O), 2.95 (1 H, d, J 8.6, 
ring junction CH), 2.41 (1 H, app. dt, J8.6, 5.5, ring junction CH), 2.33 -  2.24 (1 
H, m, one of CH2C=C), 2.21 -  2.11 (1 H, m, one of CH2C=C), 1.72 -  1.53 (7 H, 
m) and 1.44 -  1.38 (1 H, m)
5C (100 MHz; CDCI3): 194.5 (CH), 153.3 (CH), 143.8 (C), 82.5 (CH), 82.3 (CH),
39.4 (CH), 38.9 (CH), 30.7 (CH2), 30.6 (CH2), 26.5 (CH2), 23.0 (CH2) and 16.5 
(CH2).
MS-EI: m/z (%) = 192 (M+, 76), 145 (44) and 91 (100).
HRMS-EI: m/z [M]+ calcd for C i2Hi60 2: 192.1150; found: 192.1141.
Methyl 1 -(2-(1,3-dioxolan-2-yl)ethyl)cyclohexa-2,5-dienecarboxylate (116)
116111
n-Butyllithium (9.20 ml of a 1.6 M solution in hexanes, 14.7 mmol) was added 
to a solution of diisopropylamine (2.06 ml, 14.7 mmol) in THF (30 ml) at 0 °C. 
After stirring for 30 minutes, the solution was cooled to -78 °C and the 
(3-keto-ester 111 (2.41 g, 13.4 mmol) was added. The resulting solution was 
stirred at -78 °C for a further 40 minutes before 2-(2-bromoethyl)-1,3-dioxolane 
(113) (1.89 ml, 16.1 mmol) was added. The solution was warmed to room 
temperature and stirred for 2.5 h before being quenched with water. The 
reaction mixture was extracted with Et20, the combined extracts being dried 
(Na2S0 4 ) before the solvent was removed in vacuo. Chromatography on silica
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gel (Et20: hexane 1:9) afforded the title compound (1.90 g, 60 %) as a 
colourless oil.
8h (400 MHz; CDCI3): 5.93 -  5.88 (2 H, m, alkene CH), 5.73 -  5.71 (1 H, m, 
alkene CH), 5.70 -  5.69 (1 H, m, alkene CH), 4.84 (1 H, t, J4.6, OCHO), 3.96 -  
3.93 (2 H, m, OCHHCHHO), 3.85 -  3.81 (2 H, m, OCHHCHHO), 3.68 (3 H, s, 
OCH3), 2.65 -  2.61 (2 H, m, ring CH2), 1.82 -  1.78 (2 H, m, CH2) and 1.61 -  
1.55 (2 H, m, CH2).
8c (100 MHz; CDCI3): 175.1 (C), 126.7 (2 x CH), 126.2 (2 x CH), 104.3 (CH),
64.9 (2 x CH2), 52.1 (CH3), 47.3 (C), 33.2 (CH2), 28.8 (CH2) and 26.1 (CH2).
4-(1,3-Dioxolan-2-yl)butanenitrile (118)
Br^ "O 
113
n-Butyllithium (22.1 ml of a 2.5 M solution in hexanes, 55.2 mmol) was added 
to a solution of diisopropylamine (7.74 ml, 55.2 mmol) in THF (50 ml) at 0°C. 
The resulting solution was stirred for 30 minutes before being cooled to -78°C. 
Acetonitrile (5.77 ml, 110 mmol) was added and the mixture allowed to stir 
at -78°C for 1 hour before 2-(2-bromoethyl)-1,3-dioxolane (113) (5.03 g, 27.8 
mmol) was added. The reaction mixture was allowed to warm to room 
temperature and stirred for 18 hours. The reaction was quenched with water 
and the aqueous layer extracted with ether. The combined extracts were dried 
over Na2 S0 4  before the solvent was removed in vacuo. Chromatography on 
silica gel (EtOAc: hexane 1:3) afforded the title compound (2.84 g, 72 %) as a 
colourless oil.
Vmax (Neat): 2952, 2885, 2246, 1475, 1457, 1412, 1364, 1219, 1182, 1142, 
1048, 942, 839, 814 and 710 cm'1.
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8h (400 MHz; CDCI3): 4.90 -  4.88 (1 H, m, OCHO), 4.01 -  3.93 (2 H, m, 
OCHHCHHO), 3.90 -  3.82 (2 H, m, OCHHCHHO), 2.44 -  2.41 (2 H, m, CH2CN) 
and 1.84 -  1.78 (4 H, m, 2 x CH2).
5c (100 MHz; CDCI3): 119.6 (C), 103.5 (CH), 65.0 (2 x CH2), 32.3 (CH2), 19.9 
(CH2) and 17.2 (CH2).
MS-EI: m/z (%) = 140 (M -  H+, 56), 110 (15), 96 (23), 74 (100) and 71 (10). 
HRMS-EI: m /z [M -  H]+ calcd for C7Hi0NO2: 140.0712; found: 140.0707.
4-(1,3-Dioxolan-2-yl)butanoic acid (119)
o 0 ^
119
Potassium hydroxide (13.6 g, 242 mmol) was added to a solution of nitrile 118 
(2.84 g, 20.1 mmol) in a 2:1 mixture of ethanol and water (60 ml). The resulting 
solution was heated under reflux for 16 hours before being cooled to room 
temperature and acidified to -pH 2 with 2 M HCI. The aqueous layer was 
extracted with ether and the combined extracts dried over Na2 S0 4 . The solvent 
was removed in vacuo affording the title compound (2.86 g, 89 %) as a pure 
colourless oil.
Vmax (Neat): 3172, 2962, 2889, 1716, 1412, 1228, 1142, 1029, 943, 827 and 
710 cm'1.
8h (400 MHz; CDCI3 ): 4.88 (1 H, t, J 4.3, OCHO), 4.01 -  3.93 (2 H, m, 
OCHHCHHO), 3 .90-3.81 (2 H, m, OCHHCHHO), 2.43 (2 H, t, J 7.2, CH2C=0) 
and 1.83 -  1.71 (4 H, broad m, 2 x CH2).
8c (100 MHz; CDCI3): 179.4 (C), 104.1 (CH), 64.9 (2 x CH2), 33.7 (CH2), 32.9 
(CH2) and 19.0 (CH2).
MS-AP: m/z (%) = 161 (MH+, 100), 143 (65), 99 (6) and 83 (3).
HRMS-AP: m/z[M + H]+ calcd for C 7 H 13O 4 : 161.0814; found: 161.0817.
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terf-Butyldimethylsilyl 4-(1,3-dioxolan-2-yl)butanoate (120)
O 0 " \  O O
HO ^  O TBSO O
119 120
terf-Butyldimethylsilyl chloride (1.33 g, 8.8 mmol), imidazole (1.20 g, 17.6 mmol) 
and 4-DMAP (cat.) were added to a solution of acid 119 (1.28 g, 8 mmol) in 
CH2 CI2 (10 ml). The resulting solution was allowed to stir for 30 minutes at 
room temperature before being quenched with water. The aqueous layer was 
extracted with CH2 CI2 and the combined extracts were washed with saturated 
aqueous NaHC0 3  and dried over Na2S 04 before the solvent was removed in 
vacuo. Dry flash chromatography (EtOAc: petroleum ether 1:1) afforded the 
title compound (1.93 g, 88 %) as a colourless oil.
Vmax (Neat): 2931, 2859, 1724, 1473, 1412, 1364, 1336, 1253, 1174, 1142, 
1050, 940, 876, 781, 742 and 669 cm '.
§ h  (400 MHz; CDCI3): 4.87 (1 H, t, J 4.4, OCHO), 4.00 -  3.91 (2 H, m, 
OCHHCHHO), 3.89 -  3.80 (2 H, m, OCHMCHHO), 2.37 (2 H, t, J 7.2, CH2C=0), 
1.78 -  1.66 (4 H, broad m, 2 x CH2), 0.92 (9 H, s, f-Bu) and 0.26 (6 H, s, 2 x 
CH3).
8c (100 MHz; CDCI3): 173.8 (C), 104.2 (CH), 64.9 (2 x CH2), 35.7 (CH2), 33.1 
(CH2), 25.6 (3 x CH3), 19.6 (CH2), 17.6 (C) and -4.8 (2 x CH3).
MS-AP: m/z (%) = 275 (MH\ 100), 273 (4), 231 (4) and 143 (5).
HRMS-AP: m /z [M + H]+ calcd for C13H270 4Si: 275.1679; found: 275.1672.
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4-(1,3-Dioxolan-2-yl)-1 -(1 -(hydroxymethyl)cyclohexa-2,5-dienyl)butan-1 -ol 
(115)
OH
HO
115
O O-'N
120
Oxalyl chloride (0.43 ml, 4.98 mmol) and a few drops of DMF were added to a 
solution of silyl ester 120 (1.24 g, 4.53 mmol) in CH2CI2 (20 ml) at 0°C. The 
resulting solution was allowed to stir for 1.5 hours at 0°C and 0.5 hours at room 
temperature before the solvent was removed in vacuo. The acyl chloride 117 
was immediately re-dissolved in THF (5 ml) and added to a solution of lithium 
cyclohexa-2,5-dienylidene(methoxy)methanolate (3.78 mmol) in THF (10 ml) at 
-78°C. The resulting solution was allowed to stir for 20 minutes at -78°C and 10 
minutes at 0°C before being quenched with water. The aqueous layer was 
extracted with ether, the combined extracts being dried over Na2S04 before the 
solvent was removed in vacuo.
The crude p-keto-ester 114 was then immediately re-dissolved in THF (10 ml) 
and added to a suspension of LiAIH4 (143 mg, 3.78 mmol) in THF (20 ml). The 
reaction mixture was allowed to stir for 30 minutes at room temperature before 
being quenched slowly with 2 M NaOH. The mixture was diluted with ether, 
dried over Na2S04 and filtered before the solvent was removed in vacuo. 
Chromatography on silica gel (EtOAc: petroleum ether 1:1) afforded the title 
compound (163 mg, 14 %) as a colourless oil.
Vmax (Neat): 3410, 2938, 2874, 1616, 1456, 1411, 1371, 1315, 1212, 1139, 
1027, 980, 946, 913 and 732 cm'1.
8h (400 MHz; CDCI3): 6.03 (1H, dtd, J 10.3, 3.3, 1.6, alkene CH), 5.96 (1H, dtd, 
J 10.2, 3.3, 1.6, alkene CH), 5.74 (1H, app. dq, J 10.3, 2.1, alkene CH), 5.40 
(1H, app. dq, J 10.2, 2.1, alkene CH), 4.85 (1H, t, J 4.5, OCHO), 3.98 -  3.92 
(2H, m, OCHHCHHO), 3.89 -  3.83 (2H, m, OCHWCHWO), 3.67 (1H, d, J 10.6, 
one of CH2OH), 3.62 -  3.55 (2H, m, one of CH2OH and CHOH), 2.71 -  2.68 
(2H, broad m, CH2 ring), 2.20 -  2.12 (1H, broad s, OH), 2.07 -  1.96 (1H, broad
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s, OH), 1.79 -  1.70 (1H, m, one of CH2), 1.69 -  1.66 (2H, m, CH2), 1.65 -  1.63 
(1H, m, one of CH2) and 1.55 -  1.41 (2H, broad m, CH2).
6C (100 MHz; CDCI3): 128.0 (CH), 127.3 (CH), 125.9 (2 x CH), 104.5 (CH),
76.6 (CH), 69.6 (CH2), 64.9 (2 x CH2), 46.9 (C), 33.4 (CH2), 32.7 (CH2), 27.2 
(CH2) and 20.8 (CH2).
Compound 109
OH 0 ^ \
115
Trifluoromethanesulfonic acid (8 pi, 0.091 mmol) was added dropwise to a 
solution of diol 115 (23 mg, 0.091 mmol) in CH2CI2 (1 ml) at 0 °C. The resulting 
brown solution was warmed to room temperature and stirred for 20 min before 
being quenched with saturated aqueous sodium hydrogen carbonate solution. 
The crude product was extracted with CH2CI2. The combined extracts were 
dried over Na2S 04 before the solvent was removed in vacuo. Chromatography 
on silica gel (1:6 EtOAc/ petroleum ether) afforded compound 109 (15 mg, 88 
%) as a colourless oil.
Spectroscopic data as previously reported (see page 130).
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5.4 Experimental Data for Chapter 3
((2-Bromocyclopent-1 -enyl)methoxy)(ferf-butyl)dimethylsilane (142)
Br
OTBS
142
Br
OH
141
fert-Butyldimethylsilyl chloride (2.17 g, 14.4 mmol), imidazole (1.96 g, 28.8 
mmol) and 4-DMAP (cat.) were added to a solution of alcohol 141 (2.32 g, 13.1 
mmol) in CH2 CI2 (30 ml). The resulting suspension was allowed to stir at room 
temperature for 18 h before being quenched with water. The mixture was 
extracted with CH2 CI2 , the combined extracts being dried (Na2S04), before the 
solvent was removed in vacuo. Chromatography on silica gel (petroleum ether) 
afforded the title compound (3.41 g, 90 %) as a colourless oil.
Vmax (Neat): 2955, 2929, 2896, 2856, 1657, 1471, 1463, 1370, 1255, 1104, 
1071, 1007, 899 and 776 cm'1.
§ h  (400 MHz; CDCI3 ): 4.27 -  4.26 (2 H, m, CH2OTBS), 2.67 -  2.61 (2 H, m, 
CH2), 2.45 -  2.40 (2 H, m, CH2), 1.97 -  1.90 (2 H, m, CH2), 0.90 (9 H, s, f-Bu) 
and 0.08 (6 H, s, 2 x CH3).
5c (100 MHz; CDCI3 ): 140.3 (C), 115.9 (C), 61.1 (CH2), 40.2 (CH2), 32.3 (CH2),
25.9 (3 x CH3), 21.5 (CH2), 18.3 (C) and -5.3 ( 2  x CH3).
MS-EI: m/z (%) = 289 (M -  H+, 32), 233 (100), 169 (100) and 97 (100). 
HRMS-EI: m/z[M -  H]+ calcd for C i2H22OSi79Br: 289.0623; found: 289.0622.
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1 -(2-((ferf-Butyldimethylsilyloxy)methyl)cyclopent-1 -enyl)hexan-2-ol (143)
Br
OTBS
142
OH
OTBS
143
f-Butyllithium (1.30 ml of 1.7 M solution in pentane, 2.21 mmol) was added to a 
solution of bromide 142 (322 mg, 1.11 mmol) in THF (10 ml) at -78 °C. After 
stirring for 10 minutes n-butyloxirane (92 mg, 0.922 mmol) was added. The 
resulting solution was stirred for 30 minutes at -78 °C before BF3.OEt2 (0.11 ml, 
0.922 mmol) was added. After stirring for an additional 30 minutes, the reaction 
was quenched at -78 °C with saturated aqueous NH4CI solution. The mixture 
was extracted with Et20, the combined extracts being dried (Na2S04) before 
the solvent was removed in vacuo. Chromatography on silica gel (Et20: 
petroleum ether 1:9) afforded the title compound (168 mg, 58 %) as a 
colourless oil.
Vmax (Neat): 2954, 2929, 2857, 1464, 1255, 1074, 1006, 838 and 776 cm'1.
Sh (400 MHz; CDCI3): 4.21 (1 H, d, J 12.1, one of CH2OTBS), 4.15 (1 H, d, J
12.1, one of CH2OTBS), 3.66 -  3.60 (1 H, m, CHOH), 2.49 -  2.37 (3 H, broad 
m, CH2 and one of CH2), 2.35 -  2.24 (2 H, m, CH2), 2.19 -  2.16 (1 H, m, one of 
CH2), 1.81 (2 H, app. quintet, J  7.5, CH2), 1.49 -  1.40 (3 H, broad m, alkyl),
1.38 -  1.29 (3 H, m, alkyl), 0.92 -  0.86 (12 H, m, f-Bu and CH3 alkyl) and 0.07 
(6 H, s, 2 x CH3).
6 c (125 MHz; CDCI3): 138.2 (C), 135.6 (C), 69.4 (CH), 59.6 (CH2), 37.2 (CH2),
37.0 (CH2), 36.8 (CH2), 34.9 (CH2), 28.0 (CH2), 25.9 (3 x CH3), 22.8 (CH2), 21.7 
(CH2), 18.4 (C), 14.1 (CH3) and -5.3 (2 x CH3).
MS-AP: m/z (%) = 311 (M -  H+, 46), 237 (58), 195 (56), 179 (100), 161 (100), 
135 (30), 121 (100) and 75 (100).
HRMS-AP: m/z [M -  H]+ calcd for C18H350 2Si: 311.2406; found: 311.2409.
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Ethyl cyclohexa-2,5-dienecarboxylate (144)66
C O . h C O j E t
22 144
Sodium metal (6.22 g, 270 mmol) was added in portions to a solution of 
benzoic acid 22 (10.0g, 81.9 mmol) in liquid NH3-EtOH (4:1, 500ml) at -78 °C. 
After the blue colour had subsided, solid NH4CI (17.5 g) was added and the 
ammonia allowed to evaporate. The mixture was acidified by addition of 2 M 
HCI and the aqueous layer extracted with Et20. The combined extracts were 
dried (Na2 S0 4 ) before the solvent was removed in vacuo. The residue was 
re-dissolved in EtOH (250 ml) and treated with conc. H2 S0 4  (-0.5 ml). The 
resulting solution was allowed to stir at room temperature for 16 h. The solvent 
was removed in vacuo and the reaction mixture neutralized by addition of 
saturated aqueous NaHC03 solution. The aqueous layer was extracted with 
Et20  and the combined extracts dried over Na2S04. The solvent was removed 
in vacuo affording the title compound (9.23 g, 74 %) as a pure colourless oil.
V m a x  (Nujol): 2981, 2873, 2821, 1735, 1366, 1179, 1034, 942, 898, 715 and 
668 cm'1.
5h (400 MHz; CDCI3): 5.90 -  5.86 (2 H, m, alkene CH), 5.84 -  5.79 (2 H, m, 
alkene CH), 4.16 (2 H, q, J 7.1, CH20), 3 .75 -3 .68  (1 H, broad m, CH), 2.71 -  
2.66 (2 H, broad m, CH2) and 1.27 (3 H, t, J7.1, CH3).
6c (100 MHz; CDCI3): 172.6 (C=0), 126.3 (2 x CH), 122.2 (2 x CH), 60.9 (CH2),
41.7 (CH), 25.8 (CH2) and 14.2 (CH3).
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1-Ethyl 1-methyl cyclohexa-2,5-diene-1,1-dicarboxylate (145)
C02Et
EtOsC^COsMe
'0
144 145
n-Butyllithium (13.2 ml of a 2.5 M solution in hexanes, 32.9 mmol) was added 
drop-wise to a solution of diisopropylamine (4.61 ml, 32.9 mmol) in THF (50 ml) 
at 0 °C. The mixture was allowed to stir for 30 minutes at the same temperature 
before being cooled to -78 °C. The ester 144 (5.01 g, 33.0 mmol) was added 
drop-wise and the reaction mixture allowed to stir for 30 minutes at -78 °C 
before methyl chloroformate (2.80 ml, 36.2 mmol) was added. The resulting 
solution was stirred for a further 15 minutes at -78 °C before the reaction was 
quenched with saturated aqueous NH4CI solution. The mixture was extracted 
with Et20, the combined extracts being dried (Na2 S0 4 ) before the solvent was 
removed in vacuo. Chromatography on silica gel (Et20: petroleum ether 1:19) 
afforded the title compound (5.84 g, 84 %) as a colourless oil.
Vmax (Neat): 2984, 2956, 1735, 1436, 1251, 1205, 1064, 1038, 860, 801, 778 
and 704 cm'1.
§ h (400 MHz; CDCI3): 6.07 -  6.02 (2 H, m, alkene CH), 5.98 (2 H, app. dt, J
10.4, 1.8, alkene CH), 4.20 (2 H, q, J 7.1, CH20), 3.75 (3 H, s, OCH3), 2.72 -  
2.70 (2 H, m, ring CH2) and 1.26 (3 H, t, J7.1, CH3).
8C (100 MHz; CDCI3): 170.3 (C), 169.6 (C), 127.8 (2 x CH), 122.2 (2 x CH),
61.9 (CH2), 55.4 (C), 52.9 (CH3), 25.9 (CH2) and 14.0 (CH3).
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Cyclohexa-2,5-diene-1,1 -diyldimethanol (146)
t r
145 146
A solution of diester 145 (5.84 g, 27.8 mmol) in THF (20 ml) was added slowly 
to a suspension of LiAIH4 (2.11 g, 55.6 mmol) in THF (60 ml). The mixture was 
allowed to stir at room temperature for 2 h before being quenched by slow 
addition of aqueous 2 M NaOH solution. The solution was dried (Na2SC>4 ), 
filtered and the solvent removed in vacuo. Chromatography on silica gel 
(EtOAc: petroleum ether 2: 1) afforded the title compound (2.59 g, 67 %) as a 
colourless solid, m.p. 82 -  84 °C.
V m a x  (Nujol): 3399, 2923, 2855, 1633, 1252, 1100, 1023, 984, 940, 898 and 
707 cm'1.
§ h (400 MHz; CDCI3): 6.09 -  6.04 (2 H, m, alkene CH), 5.60 -  5.56 (2 H, m, 
alkene CH), 3.52 (4 H, s, 2 x CH20), 2.72 (2 H, app. tt, J3A , 2.1, ring CH2) and 
1.69 (2 H, broad s, 2 x OH).
6c (100 MHz; CDCI3): 128.5 (2 x CH), 126.9 (2 x CH), 68.0 (2 x CH2), 44.6 (C) 
and 26.9 (CH2).
Eto C 0 2Me HO
(1 -((ferf-Butyldimethylsilyloxy)methyl)cyclohexa-2,5-dienyl)methanol (147)
OHTBSO
147
HO OH
146
n-Butyllithium (2.40 ml of 2.5 M solution in hexanes, 6.01 mmol) was added to 
a solution of diol 146 (886 mg, 6.33 mmol) in THF (15 ml) at -78 °C. The 
resulting solution was allowed to warm to room temperature over 1 h before a
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solution of te/7-butyldimethylsilyl chloride (859 mg, 5.70 mmol) in THF (5 ml) 
was added. The reaction mixture was stirred for 30 minutes before imidazole 
(cat.) was added. The resulting mixture was stirred for 16 h at room 
temperature before the reaction was quenched with saturated aqueous 
NaHC0 3  solution. The mixture was extracted with Et20, the combined extracts 
being dried (Na2 S0 4 ) before the solvent was removed in vacuo. 
Chromatography on silica gel (EtOAc: petroleum ether 1:1) afforded the title 
compound (1.38 g, 86 %) as a colourless oil.
Vmax (Neat): 3419, 3028, 2954, 2929, 2885, 2857, 1635, 1471, 1464, 1255, 
1084, 1046, 940, 838, 776 and 708 cm'1.
5h (500 MHz; CDCI3 ): 5.94 -  5.91 (2 H, m, alkene CH), 5.62 (2 H, app. dt, J
10.5, 2.0, alkene CH), 3.59 (2 H, s, CH2OH), 3.54 (2 H, s, CH2OTBS), 2.70 -  
2.68 (2 H, m, ring CH2), 2.17 -  1.87 (1 H, broad s, OH), 0.89 (9 H, s, f-Bu) and 
0.04 (6 H, s, 2 x CH3).
5c (125 MHz; CDCI3): 127.3 (2 x CH), 127.0 (2 x CH), 69.7 (CH2), 69.1 (CH2),
43.6 (C), 27.1 (CH2), 25.8 (3 x CH3), 18.2 (C) and -5.6 (2 x CH3).
MS-AP: m/z(%) =255 (MH+, 100), 237 (21), 177 (17), 156 (7), 130 (6) and 105 
(3).
HRMS-AP: m /z [M + H]+ calcd for C i4H270 2Si: 255.1780; found: 255.1776.
1-((fe/?-Butyldimethylsilyloxy)methyl)cyclohexa-2,5-dienecarbaldehyde
(148)67
CHO
TBSO
148
TBSO OH
147
Oxalyl chloride (0.59 ml, 6.89 mmol) was added drop-wise to a solution of 
DMSO (1.12 ml, 15.7 mmol) in CH2CI2 (20 ml) at -78 °C. The solution was 
stirred for 10 minutes before the alcohol 147 (499 mg, 1.96 mmol) was added 
drop-wise. After stirring for a further 10 minutes at -78 °C, triethylamine (3.57
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ml, 25.6 mmol) was added and the reaction mixture allowed to warm to room 
temperature over 2 h. The reaction was quenched by pouring into saturated 
aqueous NaHC0 3  solution. The crude product was extracted with CH2CI2 , the 
combined extracts being dried (Na2SC>4 ) before the solvent was removed in 
vacuo. Chromatography on silica gel (Et20: petroleum ether 1: 49) afforded the 
title compound (429 mg, 87 %) as a colourless oil.
Vmax (Neat): 3032, 2955, 2929, 2886, 2857, 1729, 1651, 1634, 1471, 1420, 
1256, 1111,1083, 839, 778 and 704 cm'1.
8 h (400 MHz; CDCI3): 9.51 (1 H, s, aldehyde CH), 6.04 -  6.00 (2 H, m, alkene 
CH), 5.71 (2 H, app. dt, J 10.5, 2.0, alkene CH), 3.76 (2 H, s, CH2OTBS), 2.74 
-  2.72 (2 H, m, ring CH2), 0.86 (9 H, s, t-Bu) and 0.03 (6 H, s, 2 x CH3).
8c (100 MHz; CDCI3): 200.9 (aldehyde CH), 128.3 (2 x CH), 122.7 (2 x CH),
67.3 (CH2), 55.3 (C), 27.0 (CH2), 25.7 (3 x CH3), 18.2 (C) and -5.6 (2 x CH3).
ferf-Butyldimethyl((1-(oxiran-2-yl)cyclohexa-2,5-dienyl)methoxy)silane
(149)
n-Butyllithium (1.75 ml of a 2.5 M solution in hexanes, 4.37 mmol) was added 
to a solution of aldehyde 148 (1.00 g, 3.97 mmol) and dibromomethane (0.42 
ml, 5.95 mmol) in THF (30 ml) at -78 °C. The reaction mixture was warmed to 
room temperature and stirred for 24 h, before being quenched with saturated 
aqueous NH4CI. The mixture was extracted with ether, the combined extracts 
being dried (Na2 S0 4 ) before the solvent was removed in vacuo affording a 
crude mixture of aldehyde and epoxide (aldehyde: epoxide ~ 2:7, 1.09 g). The 
aldehyde and epoxide were inseparable by column chromatography, so the 
crude mixture was re-dissolved in MeOH (15 ml) and NaBH4 (75 mg, 1.98 
mmol) added to reduce the excess aldehyde. After stirring for 1 h at room
TBSO CHO
148 149
142
temperature, the reaction was quenched with water and the mixture extracted 
with ether, the combined extracts being dried (Na2 S0 4 ) before the solvent was 
removed in vacuo. Chromatography on silica gel (Et20: petroleum ether 1:49) 
afforded the title compound (400 mg, 38 %) as a colourless oil.
V m a x  (Neat): 2955, 2929, 2886, 2857, 1471, 1464, 1254, 1106, 1080, 840, 777 
and 719 cm'1.
5h (400 MHz; CDCI3): 5.91 -  5.83 (2 H, m, alkene CH), 5.67 (1 H, app. dq, J
10.1, 2.0, alkene CH), 5.37 (1 H, app. dq, J10.3, 2.0, alkene CH), 3.63 (1 H, d, 
J9.3, one of CH2OTBS), 3.48 (1 H, d, J9.3, one of CH2OTBS), 3.13 (1 H, dd, J
4.0, 2.9, epoxide CH), 2.66 -  2.64 (3 H, m, one of epoxide CH2 and ring CH2),
2.60 (1 H, dd, J 5.1, 2.9, one of epoxide CH2), 0.90 (9 H, s, f-Bu), 0.05 (3 H, s, 
CH3) and 0.04 (3 H, s, CH3).
5C (100 MHz; CDCI3): 127.6 (CH), 126.2 (CH), 126.1 (CH), 124.9 (CH), 68.6 
(CH2), 55.2 (CH), 44.3 (CH2), 41.8 (C), 27.0 (CH2), 25.8 (3 x CH3), 18.3 (C) and 
-5.5 (2 x CH3).
MS-AP: m/z (%) = 267 (MH+, 100), 249 (28), 176 (8), 156 (13), 132 (22) and 
115 (3).
HRMS-AP: m /z [M + H]+ calcd for C i5H270 2Si: 267.1780; found: 267.1771.
(1-((fe/t-Butyldimethylsilyloxy)methyl)cyclohexa-2,5-dienyl)(2-((tert- 
butyldimethylsilyloxy)methyl)cyclopent-1  -enyl)methanol (150)
OTBSOHM xture of 
compounds 
148 anc 149 TBSO
150
Br
OTBS
142
f-Butyllithium (1.68 ml of 1.7 M solution in pentane, 2.86 mmol) was added to a 
solution of bromide 142 (416 mg, 1.43 mmol) in THF (10 ml) at -78 °C. After 
stirring for 10 minutes, a mixture of aldehyde 148 and epoxide 149 (1:2, 317 
mg) in THF (5 ml) was added. The resulting solution was stirred at -78 °C for
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20 minutes before BF3.OEt2 (0.15 ml, 1.19 mmol) was added. After stirring for 1 
h at -78 °C the reaction was quenched by addition of saturated aqueous NH4CI 
solution. The reaction mixture was extracted with Et20, the combined extracts 
being dried (Na2S 04) before the solvent was removed in vacuo. 
Chromatography on silica gel (Et20 : petroleum ether 3:97) afforded the title 
com pound  (127 mg, 65 %*) as a colourless oil.
* Yield based on the ca lcu la ted  am oun t o f a ldehyde 148 p resen t in the 1:2 
m ixture o f com pounds 148 a n d  149.
V m a x  (Neat): 3480, 3029, 2954, 2929, 2886, 2857, 1471, 1463, 1362, 1255, 
1086, 1006, 838 and 776 cm'1.
8h (400 MHz; CDCU): 5.88 -  5.82 (2 H, m, alkene CH), 5.78 -  5.73 (1 H, m, 
alkene CH), 5.44 (1 H, app. dt, J  10.3, 1.8, alkene CH), 4.68 (1 H, s, CHOH), 
4.29 (1 H, d, J  12.5, one of allylic CH2OTBS), 4.11 (1 H, d, J 12.5, one of allylic 
CH2OTBS), 3.62 (1 H, d, J  9.4, one of CH2OTBS), 3.51 (1 H, d, J9.4, one of 
CH2OTBS), 2.65 -  2.62 (2 H, broad m, 6-membered ring CH2), 2.53 -  2.26 (4
H, broad m, 2 x CH2-allyl), 1.70 (2 H, quintet, J  7.3, 5-membered ring CH2),
I .6 4 -  1.55 (1 H, broad s, OH), 0.91 (9 H, app. s, f-Bu), 0.89 (9 H, app. s, f-Bu), 
0.06 (9 H, s, 3 x CH3) and 0.05 (3 H, s, CH3).
8c (100 MHz; CDCI3): 139.0 (C), 137.6 (C), 127.4 (2 x CH), 125.9 (CH), 125.5 
(CH), 73.5 (CH), 71.2 (CH2), 59.9 (CH2), 45.6 (C), 34.4 (CH2), 33.7 (CH2), 27.1 
(CH2), 25.9 (3 x CH3), 22.3 (CH2), 18.3 (C), 18.2 (C), -5.2 (CH3), -5.3 (CH3) and 
-5.6 (2 x CH3).
MS-AP: m /z  (%) = 465 (MH+, 6), 447 (7), 333 (7), 317 (10), 315 (100), 241 (12), 
183 (56) and 156 (2).
HRMS-AP: m /z [M + H]+ calcd for C26H490 3Si2: 465.3220; found: 465.3241.
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1-(1-((ferf-Butyldimethylsilyloxy)methyl)cyclohexa-2,5-dienyl)-2-(2-((tert-
butyldimethylsilyloxy)methyl)cyclopent-1 -enyl)ethanol (151)
OH
TBSO
OTBS
151
TBSO
149
f-Butyllithium (2.06 ml of 1.7 M solution in pentane, 3.51 mmol) was added to a 
solution of bromide 142 (511 mg, 1.75 mmol) in THF (10 ml) at -78 °C. After 
stirring for 10 minutes, epoxide 149 (389 mg, 1.46 mmol) was added. The 
resulting solution was stirred for 20 minutes at -78 °C before BF3.OEt2 (0.18 ml, 
1.46 mmol) was added. After stirring for an additional 2 h, the reaction was 
quenched at -78 °C with saturated aqueous NH4CI solution. The mixture was 
extracted with Et20, the combined extracts being dried (Na2S04) before the 
solvent was removed in vacuo. Chromatography on silica gel (Et20: petroleum 
ether 1:99) afforded the title compound (103 mg, 15 %) as a colourless oil.
V m a x  (Neat): 3 4 6 6 ,  2 9 5 3 ,  2 9 2 8 ,  2 8 8 6 ,  2 8 5 7 ,  1 4 7 1 ,  1 4 6 3 ,  1 2 5 5 ,  1 1 0 4 ,  1 0 5 6 ,  8 3 7 ,  
7 7 6  and 7 3 4  cm'1.
§ h  (400 MHz; CDCI3 ): 5.92 (1 H, app. dtd, J 10.3, 3.3, 1.6, alkene CH), 5.84 (1 
H, app. dtd, J 10.3, 3.4, 1.5, alkene CH), 5.79 (1 H, app. dq, J 10.3, 1.9, alkene 
CH), 5.44 (1 H, app. dq, J 10.3, 2.0, alkene CH), 4.16 (2 H, s, allylic CH2OTBS), 
3.76 (1 H, dd, J  10.5, 2.5, CHOH), 3.67 (1 H, d, J 9.5, one of CH2OTBS), 3.57 
(1 H, d, J 9.5, one of CH2OTBS), 2.68 -  2.65 (2 H, broad m, 6-membered ring 
CH2), 2.50 -  2.37 (3 H, broad m, CH2 and one of CH2), 2.32 -  2.21 (2 H, m, 
one of CH2 and one of CH2), 2.13 -  2.09 (1 H, m, one of CH2), 1.79 (2 H, 
quintet, J 6.9, 5-membered ring CH2), 0.89 (9 H, s, f-Bu), 0.89 (9 H, s, f-Bu), 
0.06 (3 H, s, CH3), 0.06 (3 H, s, CH3), 0.04 (3 H, s, CH3) and 0.04 (3 H, s, CH3). 
8c ( 1 0 0  MHz; CDCI3): 137.1 (C), 136.5 (C), 128.1 (CH), 126.4 (CH), 126.2 (2 x 
CH), 73.7 (CH), 70.2 (CH2), 59.7 (CH2), 45.7 (C), 36.7 (CH2), 34.7 (CH2), 32.5 
(CH2), 27.3 (CH2), 26.0 (3 x CH3), 25.9 (3 x CH3), 21.6 (CH2), 18.5 (C), 18.3 (C), 
-5.2 (CH3), -5.3 (CH3) and -5.5 (2 x CH3).
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MS-ES: m/z (%) = 479 (MH+, 34), 347 (100), 329 (4), 215 (5) and 185 (6). 
HRMS-ES: m /z [M + H]+ calcd for C27H5i03Si2: 479.3377; found: 479.3387.
1 -(1 -(Hydroxymethyl)cyclohexa-2,5-dienyl)-2-(2- 
(hydroxymethyl)cyclopent-l -enyl)ethanol (152)
O h
TBSO
OTBS
151
O h
h O
O h
152
Tetrabutylammonium fluoride (0.55 ml of a 1 M solution in THF, 0.55 mmol) 
was added to a solution of compound 151 (88 mg, 0.18 mmol) in THF (5 ml) 
and the resulting solution was allowed to stir for 18 h at room temperature. The 
reaction was quenched with saturated aqueous NH4CI solution and the crude 
product extracted with Et20. The combined extracts were dried (Na2S04) 
before the solvent was removed in vacuo. Chromatography on silica gel 
(EtOAc: petroleum ether 3:1) afforded the title compound (36 mg, 78 %) as a 
colourless oil.
5h (400 MHz; MeOD): 5.92 (1 H, dtd, J 10.3, 3.3, 1.6, alkene CH), 5.84 (1 H, 
dtd, J  10.2, 3.3, 1.6, alkene CH), 5.63 (1 H, app. dq, J 10.3, 1.9, alkene CH),
5.45 (1 H, app. dq, J 10.2, 1.9, alkene CH), 4.07 -  3.95 (2 H, m, allyl CH2OH),
3.61 (1 H, dd, J 10.5, 2.3, CHOH), 3.53 (1 H, d, J 10.6, one of CH2OH), 3.46 (1 
H, d, J 10.6, one of CH2OH), 2.63 -  2.60 (2 H, broad m, 6-membered ring CH2),
2.45 -  2.31 (3 H, broad m, CH2 and one of CH2), 2.28 -  2.19 (2 H, m, one of 
CH2 and one of CH2), 2.10(1 H, app. d, J 14.4, one of CH2) and 1.79 -  1.72 (2 
H, m, CH2).
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3-Butyl-1 -methoxyisochroman (158)
OMe
158
MeO OMe
155
f-Butyllithium (2.35 ml of 1.7 M solution in pentane, 3.99 mmol) was added to a 
solution of bromide 155 (461 mg, 2.00 mmol) in THF (10 ml) at -78 °C. After 
stirring for 10 minutes n-butyloxirane (100 mg, 0.998 mmol) was added. The 
resulting solution was stirred for 15 minutes at -78 °C before BF3.THF (0.11 ml, 
0.998 mmol) was added. After stirring for an additional 30 minutes, the reaction 
was quenched at -78 °C with saturated aqueous NH4CI solution. The mixture 
was extracted with Et20 , the combined extracts being dried (Na2 S0 4 ) before 
the solvent was removed in vacuo. Chromatography on silica gel (Et20: hexane 
1:49) afforded the title compound (85 mg, 39 %) as a colourless oil.
Vmax (Neat): 2931, 2825, 1456, 1365, 1207, 1186, 1092, 1052, 1030, 747 and 
668 cm'1.
5h (400 MHz; CDCI3): 7.18 -  7.12 (3 H, m, aromatic CH), 7.04 -  7.02 (1 H, m, 
aromatic CH), 5.43 (1 H, s, OCHO), 4.03 -  3.97 (1 H, m, CHO), 3.48 (3 H, s, 
OCH3), 2.61 -  2.59 (2 H, m, benzylic CH2), 1.67 -  1.46 (3 H, broad m, alkyl), 
1.40 -  1.28 (3 H, broad m, alkyl) and 0.88 (3 H, t, J 7.2, CH3).
8C (100 MHz; CDCI3): 134.4 (C), 134.0 (C), 128.4 (CH), 128.1 (CH), 127.3 
(CH), 126.3 (CH), 98.5 (CH), 66.9 (CH), 55.2 (CH3), 35.3 (CH2), 34.1 (CH2), 
27.8 (CH2), 22.7 (CH2) and 14.1 (CH3).
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(1-(2-Bromo-1-(tert-butyldimethylsilyloxy)ethyl)cyclohexa-2,5-
dienyl)methanol (163)
o OTBS
TBSO HO
Br
149 163
f-Butyllithium (1.00 ml of 1.7 M solution in pentane, 1.70 mmol) was added to a 
solution of bromide 155 (196 mg, 0.850 mmol) in THF (10 ml) at -78 °C. After 
stirring for 10 minutes epoxide 149 (113 mg, 0.425 mmol) was added. The 
resulting solution was stirred for 15 minutes at -78 °C before BF3.THF (0.05 ml, 
0.425 mmol) was added. After stirring for an additional 1 h, the reaction was 
quenched at -78 °C with saturated aqueous NH4CI solution. The mixture was 
extracted with Et20 , the combined extracts being dried (Na2SC>4 ) before the 
solvent was removed in vacuo. Chromatography on silica gel (Et20: hexane 
1:99) afforded the title compound (94 mg, 64 %) as a colourless oil.
Vmax (Neat): 3478, 3029, 2928, 2857, 1472, 1253, 1106, 837, 777 and 655 cm'1. 
8h (400 MHz; CDCI3 ): 5.95 -  5.86 (2 H, m, alkene CH), 5.81 (1 H, ddd, J 10.4,
4.0, 2.0, alkene CH), 5.43 (1 H, ddd, J 10.1, 4.1, 2.0, alkene CH), 4.01 (1 H, 
app. broad d, J 10.5, CHOTBS), 3.72 (1 H, s, OH), 3.67 (1 H, d, J 9.5, one of 
CH2OH), 3.58 (1 H, d, J 9.5, one of CH2OH), 3.51 (1 H, dd, J10.5, 1.8, one of 
CH2Br), 3.26 (1 H, app. t, J 10.5, one of CH2Br), 2.68 -  2.64 (2 H, m, ring CH2), 
0.89 (9 H, s, f-Bu) and 0.05 (6 H, s, 2 x CH3).
6c (100 MHz; CDCI3): 127.4 (CH), 127.1 (CH), 126.6 (CH), 124.4 (CH), 76.5 
(CH), 70.8 (CH2), 45.2 (C), 37.9 (CH2), 27.2 (CH2), 25.8 (3 x CH3), 18.2 (C) and 
-5.6 (2 x CH3).
MS-AP: m/z (%) = 349 (MH+, 100), 347 (MH+, 94), 331 (27), 329 (24), 217 (53), 
215 (50), 199 (34), 197 (35), 158 (6), 156(13), 132(18) and 117 (12). 
HRMS-AP: m /z[M + H]+ calcd for C,5H280 2Si79Br: 347.1042; found: 347.1030.
148
2-Bromo-1 - ( ( 1  RS,3aSR,7aSR)-1 -(2-bromophenyl)-1,3,3a,6 ,7,7a- 
hexahydroisobenzofuran-4-yl)ethanone (159)
Br
HO
163
OTBS
Br
+ Br
M eu OMe
155
Br
159
Trifluoromethanesulfonic acid (0.01 ml, 0.12 mmol) was added to a mixture of 
compounds 163 and 155 (approx. 1:1, 51 mg) in CH2CI2 (2 ml) at 0 °C. The 
resulting solution was warmed to room temperature and stirred for 15 minutes 
before a further portion of trifluoromethanesulfonic acid (0.01 ml, 0.12 mmol) 
was added. After stirring for an additional 10 minutes, the reaction was 
quenched by addition of saturated aqueous NaHC03 solution. The crude 
mixture was extracted with CH2CI2, the combined extracts being dried 
(Na2 S0 4 ) before the solvent was removed in vacuo. Chromatography on silica 
gel (Et20: hexane 1:9) afforded the title compound (22 mg, 29 %*) as a 
colourless oil.
* Yield calculated over 2 steps.
5h (400 MHz; CDCI3): 7.56 -  7.51 (2 H, m, aromatic CH), 7.30 (1 H, app. td, J 
7.5, 1.0, aromatic CH), 7.13 (1 H, app. td, 7 7.6, 1.6, aromatic CH), 7.07 (1 H, 
app. dd, J 5.3, 1.7, alkene CH), 5.31 (1 H, d, 74.8, CHO), 4.50 (1 H, app. dd, J
9.1, 8.2, one of CH20), 4.19 (2 H, s, CH2Br), 3.63 (1 H, app. dd, *7 9.1, 8.3, one 
of CH20), 3.49 -  3.41 (1 H, m, ring junction CH), 2.80 (1 H, ddt, J 13.2, 6.6, 4.8, 
ring junction CH), 2.32 (1 H, dtd, J 19.7, 5.3, 2.0, one of CH2C=C), 2.24 -  2.14 
(1 H, broad m, one of CH2C=C), 1.08 (1 H, app, qd, J 13.2, 5.3, one of CH2) 
and 0.90 -  0.82 (1 H, m, one of CH2).
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8C (100 MHz; CDCI3 ): 192.1 (C=0), 143.6 (alkene CH), 138.7 (C), 137.3 (C),
132.3 (CH), 128.6 (CH), 128.2 (CH), 127.0 (CH), 121.3 (C), 82.8 (CH), 72.0 
(CH2), 38.4 (CH), 38.3 (CH), 29.7 (CH2), 25.8 (CH2) and 19.2 (CH2).
MS-AP: m/z (%) = 403 (48), 401 (100), 399 (M+H\ 52), 385 (33), 383 (65), 381 
(34) and 219 (34).
HRMS-AP: m /z [M + 1]+ calcd for C i6H170 279Br2: 398.9595; found: 398.9585.
5.5 Experimental Data for Chapter 4
(R)-1 -(1 -Phenylethyl)pyrrolidine-2,5-dione (215)
J  V 0 ^ 0
o ^ o  0 -------------- ►
M e^Ph
196
215
(R)-(+)-a-Methyl benzylamine 214 (13.8 ml, 107 mmol) was added to a 
suspension of succinic anhydride 196 (10.7 g, 107 mmol) in toluene (250 ml) 
and the mixture was heated under ruflux for 18 h. The solvent was removed in 
vacuo and the residue re-dissolved in acetic anhydride (100 ml). The resulting 
solution was heated under reflux for 2 h, before being poured onto crushed ice 
with stirring. The mixture was extracted with CH2 CI2 , the combined extracts 
being washed thoroughly with saturated aqueous NaHC03 solution and dried 
over Na2S 04. The solvent was removed in vacuo affording the title compound 
(21.7 g, 100 %) as a pure colourless oil.
Vmax (Neat): 2979, 2941, 1679, 1393, 1219, 1188, 1101, 1066, 1023, 953, 821 
and 786 cm'1.
5h (400 MHz; CDCI3): 7.39 (2 H, d, J 8.0, aromatic CH), 7.28 -  7.19 (3 H, m, 
aromatic CH), 5.36 (1 H, q, J 7.3, CH-Me), 2.57 (4 H, s, 2 x CH2) and 1.76 (3 H, 
d, J 7.3, Me).
5C (100 MHz; CDCI3): 177.1 (2 x C=0), 139.7 (C), 128.5 (2 x CH), 127.9 (CH),
127.7 (2 x CH), 50.4 (CH), 28.2 (2 x CH2) and 16.6 (CH3).
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[a]D: +63 (c = 1, MeOH).
[a]D: +91 (c = 1, CH2CI2), Lit.ref [a]D: +91.9 (c = 4, CH2CI2)
MS-AP: m/z{%) = 204 (MH+, 100), 141 (33) and 105 (6).
HRMS-AP: m /z [M + H f  calcd for C12H14N 02: 204.1025; found: 204.1018.
5-Hydroxy-1 -((R)-1 -phenylethyl)pyrrolidin-2 -one (216)
M e ^ P h  M e ^ P h
215 216
LiEt3BH (82.8 ml of 1.0 M solution in THF, 82.8 mmol) was added drop-wise to 
a solution of lactam 215 (12.0 g, 59.1 mmol) in THF (150 ml) at -78 °C. The 
mixture was allowed to stir for 40 mins before the THF was removed in vacuo. 
The residue was cooled to 0 °C and the reaction quenched by drop-wise 
addition of saturated aqueous NaHC03 solution. The mixture was extracted 
with CH2CI2, the combined extracts being treated with 30 % H20 2 solution (10 
ml), washed with brine and dried over Na2S04. The solvent was removed in 
vacuo affording the title compound (9.7 g, 80 %) as a pure colourless solid 
(approx. 2:1 mixture of diastereoisomers), m.p. 82 -  84 °C.
Vmax (Nujol): 3226, 2922, 2853, 1644, 1426, 1329, 1284, 1248, 1211, 1178, 
1059, 1025, 989, 914, 790, 700 and 671 cm'1.
5h (400 MHz; CDCI3): 7.37 -  7.26 (5 H, m, aromatic CH), 5.41 -  5.34 (1 H, m, 
CH-Me), 4.93 (1 H, t, J 6.0, CHOH), 2.69 -  2.58 (1 H, m, one of CH2C=0), 2.34 
-  2.27 (1 H, m, one of CH2C=0), 2.24 -  2.07 (1 H, m, one of pyrrolidine CH2), 
1.90 -  1.79 (1 H, m, one of pyrrolidine CH2) and 1.67 (3 H, d, J 7.2, Me).
6C (100 MHz; CDCI3): 174.8 (C), 140.0 (C), 128.9 (2 x CH), 127.9 (CH), 127.8 
(2 x CH), 82.4 (CH), 50.4 (CH), 29.2 (CH2), 29.1 (CH2) and 19.0 (CH3).
[a]D: +60 (c = 0.5, CH2CI2).
MS-ES: m/z (%) = 247 (MH+ + MeCN, 100), 206 (MH+, 85), 205 (31), 188 (14), 
164 (13) and 155 (2).
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HRMS-ES: m/z[U + H]+ calcd for C i2Hi6N02: 206.1181; found: 206.1177.
(R)-5-Allyl-1 -((R)-1 -phenylethyl)pyrrolidin-2 -one (217)
O ^ ^ O h  -------------- ►
M e^^Ph M e^^Ph
216 217
Boron trifluoride diethyl etherate (5.79 ml, 47.0 mmol) was added drop-wise to 
a solution of hydroxyl lactam 216 (6.43 g, 31.4 mmol) in CH2CI2 at -78 °C. Allyl 
trimethylsilane (15.0 ml, 94.1 mmol) was then added drop-wise and the 
reaction mixture allowed to warm to room temperature over 16 h. The reaction 
was quenched with saturated aqueous NaHC03 solution and the aqueous layer 
extracted with CH2CI2. The combined organic fractions were dried over Na2SC>4 
before the solvent was removed in vacuo affording the title compound (6.88 g, 
96 %) as a pure orange oil (4.4:1 mixture of diastereoisomers).
Vmax (Neat): 3063, 2976, 2936, 1681, 1368, 1286, 1215, 1183, 1055, 1028, 998, 
917 and 788 cm'1.
8h (400 MHz; CDCI3): 7.39 (2 H, d, J 7.5, aromatic CH), 7.33 -  7.29 (2 H, m, 
aromatic CH), 7.26 -  7.24 (1 H, m, aromatic CH), 5.51 -  5.39 (2 H, m, alkene 
CH and CH-Ph), 4.98 -  4.95 (1 H, m, one of alkene CH2), 4.88 (1 H, app. dq, J
17.1, 1.4, one of alkene CH2), 3.76 (1 H, app. ddd, J 11.9, 8.4, 3.5, CH-allyl),
2.53 -  2.44 (1 H, m, one of CH2C=0), 2.32 (1 H, app. ddd, J 17.0, 9.9, 4.7, one 
of CH2C=0), 2.06 (1 H, ddt, J 12.9, 9.8, 8.2, one of pyrrolidine CH2), 1.92 -  
1.86 (1 H, m, one of CH2C=C), 1.78 -  1.67 (2 H, m, one of pyrrolidine CH2 and 
one of CH2C=C) and 1.65 (3 H, d, J 7.3, Me).
5C ( 1 0 0  MHz; CDCI3): 175.6 (C=0), 142.0 (C), 133.5 (CH), 128.6 (2 x CH),
127.6 (CH), 127.4 (2 x CH), 118.4 (CH2), 56.5 (CH), 49.7 (CH), 39.0 (CH2),
30.5 (CH2), 24.2 (CH2) and 16.5 (CH3).
[a ]o : +147 (c = 1, MeOH).
MS-ES: m/z (%) = 230 (MH+, 100).
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HRMS-ES: m/z[M + H]+ calcd for C i5H20NO: 230.1545; found: 230.1547.
2-((R)-5-Oxo-1 -((R)-1 -phenylethyl)pyrrolidin-2-yl)acetaldehyde (218)
J \  J \  .CHO
M e ^ P h  M e ^ P h
217 218
Potassium osmate dihydrate (cat.), sodium periodate (24.1 g, 113 mmol) and 
2,6-lutidine (6.56 ml, 56.3 mmol) were added to a solution of allyl lactam 217 
(6.45 g, 28.2 mmol) in dioxane-H20  (3:1, 520 ml) and the resulting suspension 
was allowed to stir at room temperature for 18 h. The reaction was quenched 
with water and the mixture extracted with CH2CI2. The combined extracts were 
dried over Na2 S0 4  before the solvent was removed in vacuo. Flash 
chromatography on silica gel (EtOAc: Me2CO 1:2) afforded the title compound 
(4.87 g, 75 %) as a colourless oil (6.4:1 mixture of diastereoisomers).
Vmax (Neat): 3061, 2975, 1720, 1670, 1417, 1373, 1286, 1215, 1182, 1026, 788 
and 758 cm'1.
5h (400 MHz; CDCI3): 9.33 (1 H, s, aldehyde), 7.34 -  7.24 (5 H, m, aromatic 
CH), 5.52 (1 H, q, J7.2, CH-Me), 4.20 (1 H, app. ddd, J11.8, 7.9, 3.5, CHN),
2.54 -  2.45 (1 H, m, one of pyrrolidine CH2C=0), 2.36 (1 H, ddd, J 16.7, 9.7,
4.2, one of pyrrollidine CH2C=0), 2.26 (1 H, ddd, J 17.9, 12.7, 8.5, one of 
pyrrolidine CH2), 2.15 (1 H, app. dd, J 18.0, 8.9, one of CH2CHO), 2.06 (1 H, 
dd, J 18.1, 3.5, one of CH2CHO), 1.65 -  1.61 (1 H, m, one of pyrrolidine CH2) 
and 1.58 (3 H, d, J7 .3, Me).
8C (100 MHz; CDCI3 ): 199.8 (aldehyde CH), 175.2 (lactam C=0), 141.3 (C),
128.8 (2 x CH), 127.9 (CH), 127.4 (2 x CH), 50.8 (CH), 48.9 (CH), 48.6 (CH2),
30.0 (CH2), 25.9 (CH2) and 16.0 (CH3).
[a]D: +124 (c = 1, MeOH).
MS-ES: m/z (%) = 232 (MH+, 100).
HRMS-ES: m/z[U  + H]+ calcd for C i4Hi8N02: 232.1338; found: 232.1330.
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(R)-5-((Z)-Non-2-enyl)-1 -((R)-1 -phenylethyl)pyrrolidin-2-one (219)
J T } "
M e^Ph
O /
CHO
218
OJ T ) ;,N
M e^Ph
n-CgH-|3
219
n-Butyllithium (15.3 ml of a 2.5 M solution in hexanes, 38.3 mmol) was added 
drop-wise to a solution of heptyl phosphonium iodide (18.7 g, 38.3 mmol) in 
THF (150 ml) at 0 °C. The solution was allowed to stir at 0 °C for 2 h before a 
solution of aldehyde 218 (4.42 g, 19.1 mmol) in THF (15 ml) was added at -78 
°C. The resulting solution was allowed to warm to room temperature and stirred 
for 16 h. The reaction was quenched with saturated aqueous NaHC03 solution 
and the aqueous layer extracted with CH2CI2. The combined organic fractions 
were dried over Na2 S0 4  before the solvent was removed in vacuo. 
Chromatography on silica gel (EtOAc: hexane 1:2) afforded the title compound 
(3.45 g, 58 %) as a yellow oil (6.6:1 mixture of diastereoisomers).
Vmax (Neat): 2928, 2855, 1686, 1416, 1365, 1265, 1216, 1182, 1118 and 787 
cm'1.
5h (400 MHz; CDCI3): 7.39 (2 H, d, J7.4, aromatic CH), 7.31 (2 H, app. t, J7A, 
aromatic CH), 7.25 (1 H, d, J 7.0, aromatic CH), 5.49 -  5.36 (2 H, m, CHMe 
and alkene CH), 5.09 -  5.02 (1 H, m, alkene CH), 3.76 -  3.65 (1 H, m, CHN), 
2.51 (1 H, app. dt, J 17.1, 8.8, one of CH2C=0), 2.35 (1 H, ddd, J 17.1, 9.8, 4.9, 
one of CH2C=0), 2.10 -  2.00 (2 H, m, CH2C=C), 1.94 -  1.88 (1 H, m, one of 
pyrrolidine CH2), 1.81 (2 H, app. q, J 6.5, CH2C=C), 1.73 -  1.67 (1 H, m, one of 
pyrrolidine CH2), 1.65 (3 H, d, J7 .2, Me), 1.30 -  1.22 (8 H, broad m, alkyl) and 
0.88 (3 H, t, J7.0, CH3 alkyl).
6C (100 MHz; CDCI3): 175.6 (C=0), 142.1 (C), 133.4 (CH), 128.5 (2 x CH),
127.5 (CH), 127.3 (2 x CH), 124.0 (CH), 57.1 (CH), 49.7 (CH), 32.2 (CH2), 31.9 
(CH2), 30.5 (CH2), 29.6 (CH2), 29.1 (CH2), 27.6 (CH2), 24.4 (CH2), 22.8 (CH2),
16.5 (CH3) and 14.3 (CH3).
[a ]D: +110 (c = 1, MeOH).
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MS-ES: m /z  (%) = 314 (MH+, 100).
HRMS-ES: m /z [M + H]+ calcd for C 2 1 H 3 2 N O :  314.2484; found: 314.2499.
(R,Z)-5-(Non-2-enyl)pyrrolidin-2-one (220)
o o
H /i-Cgh-|3
220
219
Sodium metal (1.19 g, 51.6 mmol) was added portion-wise to a solution of 
alkenyl lactam 219 (3.23 g, 10.3 mmol) in liquid NH3-THF-EtOH (8:1:1, 240 ml) 
at -78 °C until the blue colour persisted for longer than 3 mins. After the 
solution had turned colourless, solid NH4CI was added and the ammonia 
allowed to evaporate. The reaction mixture was then washed with water and 
extracted with EtOAc. The combined extracts were dried over Na2S04 before 
the solvent was removed in vacuo affording the title compound (1.93 g, 89 %) 
as a pure yellow oil.
Vmax (Neat): 3225, 2920, 2860, 1694, 1462, 1379, 1346, 1292, 1262, 1204, 
1083 and 734 cm'1.
8h (400 MHz; CDCI3 ): 6.00 -  5.73 (1 H, broad s, NH), 5.59 -  5.52 (1 H, m, 
alkene CH), 5.34 -  5.27 (1 H, m, alkene CH), 3.71 -  3.64 (1 H, m, CHNH), 2.38 
-  2.32 (2 H, m, CH2C=0), 2.30 -  2.17 (3 H, m, CH2C=C and one of pyrrolidine 
CH2), 2.03 (2 H, app. q, J7.1, CH2C=C), 1.80 -  1.71 (1 H, m, one of pyrrolidine 
CH2), 1.35 -  1.22 (8 H, broad m, alkyl) and 0.88 (3 H, t, J6.8, CH3 alkyl).
6c (100 MHz; CDCI3): 178.2 (C=0), 134.1 (CH), 124.1 (CH), 54.6 (CH), 34.5 
(CH2), 31.9 (CH2), 30.4 (CH2), 29.7 (CH2), 29.2 (CH2), 27.7 (CH2), 27.0 (CH2),
22.8 (CH2) and 14.3 (CH3).
[a ]o : +15 (c = 1, MeOH).
MS-AP: m/z (%) = 251 (MH+ + MeCN, 100), 210 (MH+, 43), 124 (4) and 83 (3). 
HRMS-AP: m /z[M + H]+ calcd for C i3H24NO: 210.1858; found: 210.1848.
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(R,Z)-5-(Non-2-enyl)pyrrolidine-2-thione (221)
H '^CeH-i3 |_| n-CgH-13
220 221
Lawesson’s reagent (1.91 g, 4.71 mmol) was added to a solution of lactam 220 
(1.79 g, 8.56 mmol) in THF (80 ml). The resulting solution was allowed to stir at 
room temperature for 2 h before the solvent was removed in vacuo. 
Chromatography on silica gel (EtOAc: petroleum ether 1:9) afforded the title 
compound (1.62 g, 84 %) as a yellow oil.
Vmax (Neat): 3162, 2925, 2854, 1530, 1456, 1377, 1294, 1119, 1068 and 726 
cm'1.
5h (400 MHz; CDCI3): 7.87 -  7.63 (1 H, broad s, NH), 5.60 (1 H, dt, J 11.4, 7.5, 
alkene CH), 5.35 -  5.27 (1 H, m, alkene CH), 3.94 (1 H, app. quintet, J 7.0, 
CHNH), 2.98 (1 H, ddd, J 18.2, 9.4, 5.2, one of CH2C=S), 2.93 -  2.84 (1 H, m, 
one of CH2C=S), 2.39 -  2.24 (3 H, m, CH2C=C and one of pyrrolidine CH2),
2.06 -  2.00 (2 H, m, CH2C=C), 1.90 -  1.81 (1 H, m, one of pyrrolidine CH2),
1.39 -  1.27 (8 H, broad m, alkyl) and 0.88 (3 H, t, J 6.8, CH3 alkyl).
6C (100 MHz; CDCI3): 205.6 (C=S), 134.7 (CH), 123.4 (CH), 62.5 (CH), 43.2 
(CH2), 33.3 (CH2), 31.9 (CH2), 29.7 (CH2), 29.2 (2 x CH2), 27.7 (CH2), 22.8 
(CH2) and 14.3 (CH3).
[a]D: +37 (c = 1, MeOH).
MS-ES: m/z (%) = 226 (MH+, 100).
HRMS-ES: m/z[U  + H]+ calcd for C i3H24NS: 226.1629; found: 226.1621.
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(E)-Methyl 2-((R)-5-((Z)-non-2-enyl)pyrrolidin-2-ylidene)-3-oxobutanoate
(222)
s
13
M e02C
■ ' /
H MeOC H
221 222
To a solution of thiolactam 221 (1.51 g, 6.71 mmol) in CH2 CI2 (50 ml) were 
added solid NaHC03  (2.26 g, 26.8 mmol) and methyl 2 -bromoacetoacetate 
(2.62 g, 13.4 mmol), and the mixture was heated under reflux for 16 h. The 
reaction mixture was then cooled before being filtered through silica and 
concentrated in vacuo. Chromatography on silica gel (Et2 0: petroleum ether 
1:9) afforded the title compound (1.74 g, 84 %) as an orange oil.
Vmax (Neat): 3203, 2928, 2855, 1694, 1600, 1538, 1434, 1359, 1315, 1242, 
1189, 1069, 1013, 914 and 784 cm'1.
8 h (400 MHz; CDCU): 5.61 -  5.54 (1 H, m, alkene CH), 5.36 -  5.29 (1 H, m, 
alkene CH), 3.93 (1 H, app. quintet, J 6 .6 , CHNH), 3.73 (3 H, s, OCH3), 3.22 (1 
H, ddd, J 18.6, 9.5, 5.4, one of pyrrolidine CH2 C=C), 3.07 ( 1  H, app. ddd, J
18.6, 9.4, 7.3, one of pyrrolidine CH2 C=C), 2.40 (3 H, s, CH3), 2.38 -  2.22 (2 H, 
m, CH2 C=C), 2.18 -  2.09 (1 H, m, one of pyrrolidine CH2), 2.01 (2 H, app. q, J 
6 .8 , CH2 C=C), 1.70 -  1.61 (1 H, m, one of pyrrolidine CH2), 1.37 -  1.21 ( 8  H, 
broad m, alkyl) and 0.87 (3 H, t, J6.9, CH3  alkyl).
6 C ( 1 0 0  MHz; CDCI3): 197.9 (C=0), 173.8 (C), 169.4 (C), 134.3 (CH), 123.7 
(CH), 98.6 (C), 60.9 (CH), 50.7 (CH3), 35.1 (CH2), 33.7 (CH2), 31.9 (CH2), 31.0 
(CH3), 29.7 (CH2), 29.1 (CH2), 27.6 (CH2), 26.9 (CH2), 22.8 (CH2) and 14.3 
(CH3).
[a ]o : +73 (c = 1, MeOH).
MS-AP: m/z (%) = 308 (MH+, 100) and 276 (22).
HRMS-AP: m/z[U  + H]+ calcd for C i8 H3 0 NO3: 308.2226; found: 308.2221.
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(Z)-Methyl 2-((R)-5-((Z)-non-2-enyl)pyrrolidin-2-ylidene)acetate (223)
M e02C
•'/
n-CeH -j 3 n'CeH-|3MeOC H M e02C H
222 223
Sodium metal (128 mg, 5.57 mmol) was dissolved in dry MeOH (15 ml) under 
nitrogen and allowed to stir for 30 mins. A solution of p- keto-ester 222 (1.71 g, 
5.57 mmol) in dry MeOH (5 ml) was then added and the mixture heated at 
reflux for 2 h. The solvent was removed in vacuo and the resulting residue 
dissolved in chloroform, washed with saturated aqueous sodium carbonate 
solution and dried over sodium sulphate. The solvent was removed in vacuo. 
Chromatography on silica gel (Et2 0: petroleum ether 1:9) afforded the title 
compound (1.24 g, 84 %) as a yellow oil.
Vmax (Neat): 3362, 2925, 2855, 1667, 1606, 1469, 1430, 1376, 1294, 1237, 
1147 and 1041, cm'1.
5h (400 MHz; CDCI3): 8.08 -  7.87 ( 1  H, broad s, NH), 5.57 -  5.50 ( 1  H, m, 
alkene CH), 5.38 -  5.30 (1 H, m, alkene CH), 4.48 (1 H, s, CHC=0), 3.79 (1 H, 
app. quintet, J 6.5, CHNH), 3.63 (3 H, s, OCH3), 2.68 -  2.53 (2 H, m, 
pyrrolidine CH2 C=C), 2.30 ( 1  H, app. dt, J 14.3, 7.2, one of CH2C=C), 2.24 -  
2.17 (1 H, m, one of CH2 C=C), 2.13 -  2.06 ( 1  H, m, one of pyrrolidine CH2), 
2 . 0 2  ( 2  H, app. q, J 6 .8 , CH2 C=C), 1.65 -  1.56 (1 H, m, one of pyrrolidine CH2), 
1.35 -  1.20 ( 8  H, broad m, alkyl) and 0.87 (3 H, t, J6.9, CH3 alkyl).
5C (100 MHz; CDCI3): 171.1 (C), 166.0 (C), 133.7 (CH), 124.5 (CH), 76.3 (CH),
59.8 (CH), 50.3 (CH3), 34.1 (CH2), 32.1 (CH2), 32.0 (CH2), 29.7 (CH2), 29.2 
(CH2), 28.0 (CH2), 27.7 (CH2), 22.8 (CH2) and 14.3 (CH3).
[a]□: +149 (c = 1, MeOH).
MS-ES: m/z (%) = 266 (MH+, 100).
HRMS-ES: m/z[U  + H]+ calcd for C i6 H2 8 N02: 266.2120; found: 266.2108.
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(3S,7R)-Methyl 7-((Z)-non-2-enyl)-3-pentyl-1 -thioxo-1,2,3,5,6,7-
hexahydropyrrolo[1,2-c]pyrimidine-4-carboxylate (224) and (3R,7R)- 
methyl 7-((Z)-non-2-enyl)-3-pentyl-1 -thioxo-1,2,3,5,6,7-
hexahydropyrrolo[1,2-c]pyrimidine-4-carboxylate (225)
MeOoC CcHe n i3
223
224
■</
225
n-CgH-13
■ </
rj-Cg h -| 3
To a solution of trimethylsilyl isothiocyanate (1.27 ml, 8.98 mmol) in CH2 CI2 (40 
ml) was added hexanal (1.10 ml, 8.98 mmol) and the solution was stirred at 
room temperature for 30 mins. A solution of alkylidine pyrrolidine 223 (1.19 g, 
4.49 mmol) in CH2 CI2 ( 1 0  ml) was then added and the resulting solution 
allowed to stir for 45 mins. The reaction was quenched with -0.1 M NaOH 
solution and the aqueous layer extracted with CH2 CI2. The combined extracts 
were dried over sodium sulphate before the solvent was removed in vacuo. 
Chromatography on silica gel (Et2 0: petroleum ether 1 :9) afforded, in order of 
elution, compound 224 (833 mg, 46 %) and compound 225 (425 mg, 23 %), 
both as yellow oils.
Data for compound 224:
vmax (Neat): 3198, 2914, 2860, 1699, 1660, 1432, 1386, 1222, 1162, 1098, 971, 
933, 893, 827 and 776 cm'1.
5h (400 MHz; CDCI3): 6.72 ( 1  H, broad s, NH), 5.53 (1 H, dt, J 10.8, 7.4, alkene 
CH), 5.34 -  5.27 (1 H, m, alkene CH), 4.56 (1 H, app. ddt, J 8.5, 6.4, 3.2,
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CHNC=S), 4.28 -  4.26 (1 H, m, CH-pentyl), 3.72 (3 H, s, OCH3), 3.39 -  3.32 (1
H, m, one of pyrrolidine CH2 C=C), 3.06 (1 H, app. dd, J 13.4, 6 .2 , one of 
pyrrolidine CH2C=C), 2.97 -  2.87 ( 1  H, m, one of CH2 C=C), 2.21 ( 1  H, dt, J
13.7, 9.3, one of CH2 C=C), 2.08 ( 2  H, app. broad q, J 7.3, CH2C=C), 1.95 -
I.90 (2 H, m, pyrrolidine CH2), 1.63 -  1.50 ( 2  H, broad m, alkyl), 1.43 -  1.21 
(14 H, broad m, alkyl) and 0.89 -  0.86 ( 6  H, m, 2 x CH3 alkyl).
6 c (100 MHz; CDCI3): 175.5 (C=S), 166.3 (C=0), 150.0 (C), 134.0 (CH), 124.4 
(CH), 99.9 (C), 63.4 (CH), 52.3 (CH), 51.5 (CH3), 38.0 (CH2), 32.0 (CH2), 31.6 
(CH2), 30.7 (CH2), 29.9 (CH2), 29.2 (CH2), 28.8 (CH2), 27.9 (CH2), 26.0 (CH2), 
23.7 (CH2), 22.9 (CH2), 22.8 (CH2) and 14.3 (2 x CH3).
[a]D: - 36 (c = 1, MeOH).
MS-ES: m/z(%) = 407 (MH+, 100).
HRMS-ES: m/z[M + H]+ calcd for C2 3 H3 9 N2 0 2 S: 407.2732; found: 407.2728.
Data for compound 225:
vmax (Neat): 3198, 2980, 1693, 1644, 1427, 1381, 1333, 1223, 1155, 1105, 976, 
933, 889 and 778 cm'1.
5h (400 MHz; CDCI3): 6.98 ( 1  H, app. broad d, J3.4, NH), 5.54 ( 1  H, dt, J 1 0 .8 ,
7.3, alkene CH), 5.35 -  5.28 (1 H, m, alkene CH), 4.91 (1 H, tt, J 8 .6 , 2.9, 
CHNC=S), 4.28 (1 H, app. dt, J 7 .5, 3.8, CH-pentyl), 3.73 (3 H, s, OCH3), 3.29 
( 1  H, ddd, J 18.9, 9.9, 2.9, one of pyrrolidine CH2 C=C), 3.01 (1 H, app. dt, J 
18.9, 9.4, one of pyrrolidine CH2 C=C), 2.69 -  2.63 (1 H, m, one of CH2 C=C), 
2.43 -  2.35 (1 H, m, one of CH2 C=C), 2 .13 -1 .95  (3 H, broad m, CH2 C=C and 
one of pyrrolidine CH2), 1.86 -  1.79 (1 H, m, one of pyrrolidine CH2), 1.57 -  
1.42 (2 H, broad m, alkyl), 1.39 -  1.20 (14 H, broad m, alkyl) and 0.89 -  0.85 ( 6  
H, m, 2 x CH3  alkyl).
6 c (100 MHz; CDCI3): 176.0 (C=S), 166.2 (C=0), 150.7 (C), 134.2 (CH), 123.8 
(CH), 100.5 (C), 63.1 (CH), 52.0 (CH), 51.6 (CH3), 37.0 (CH2), 32.0 (CH2), 31.6 
(CH2), 31.2 (CH2), 30.6 (CH2), 29.8 (CH2), 29.2 (CH2), 27.8 (CH2), 24.9 (CH2),
23.9 (CH2), 22.8 ( 2  x CH2), 14.3 (CH3) and 14.2 (CH3).
[a]D: + 99 (c = 1, MeOH).
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MS-ES: m/z (%) = 407 (MH+, 100).
HRMS-ES: m/z[U  + H]+ calcd for C2 3 H3 9 N2 0 2 S: 407.2732; found: 407.2734.
Ethyl 3-pentyl-1 -thioxo-1,2,3,5,6,7-hexahydropyrrolo[1,2-c]pyrimidine-4-
carboxylate (229)
A solution of trimethylsilyl isothiocyanate (1.84 ml, 13.0 mmol) and hexanal 
(1.60 ml, 13.0 mmol) in CH2 CI2 ( 2 0  ml) was stirred at room temperature for 30 
minutes before a solution of (Z)-ethyl 2-(pyrrolidin-2-ylidene)acetate 228 (1.01 
g, 6.52 mmol) in CH2 CI2 (5 ml) was added. The reaction mixture was allowed to 
stir for a further 45 minutes at room temperature before being quenched with 
-0.1 M NaOH. The aqueous layer was extracted with CH2 CI2 and the combined 
organic extracts dried over Na2 S0 4  before the solvent was removed in vacuo. 
Chromatography on silica gel (EtOAc: hexane, 1 :9) afforded the title compound 
(585 mg, 30 %) as a yellow oil.
Vmax (Neat): 3197, 2928, 2857, 1694, 1650, 1537, 1379, 1305, 1250, 1219, 
1162, 1102, 1073, 1037, 935, 905, 877, 776, 729 and 638 cm'1.
8 h (400 MHz; CDCI3): 6.94 ( 1  H, s, NH), 4.29 (1 H, app. dt, J 7.7, 3.7, CHN), 
4 .2 3 -4 .1 5  (2 H, m, CH2 0), 4 .06 -3 .96  (2 H, m, CH2 N), 3.31 (1 H, ddd, J 18.2,
8.4, 3.7, one of CH2C=C), 2.99 ( 1  H, app. dt, J 18.2, 9.0, one of CH2 C=C), 2 . 1 2  
-  2.01 (1 H, broad m, one of pyrrolidine CH2), 1.99 -  1.89 (1 H, m, one of 
pyrrolidine CH2), 1.61 -  1.46 (2 H, broad m, alkyl), 1.45 -  1.35 (1 H, broad m, 
alkyl), 1.34 -  1.23 ( 8  H, m, CH3 CH20  and alkyl) and 0.87 (3 H, t, J 6.9, CH3 
alkyl).
228
229
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5c (100 MHz; CDCI3): 176.3 (C), 165.5 (C), 150.2 (C), 100.7 (C), 60.3 (CH2),
52.0 (CH), 36.9 (CH2), 32.0 (CH2), 31.4 (CH2), 23.8 (CH2), 22.6 (CH2), 21.2 
(CH2), 14.4 (CH3) and 14.1 (CH3).
MS-EI: m/z (%) = 296 (M+, 9), 251 (10), 225 (100), 197 (93), 179 (24), 165 (9), 
151 (33), 120 (3), 92 (5) and 65 (4).
HRMS-EI: m /z[M]+ calcd for C i5 H2 4 N2 0 2 S: 296.1559; found: 296.1558.
4-(Ethoxycarbonyl)-1-(methylthio)-3-pentyl-3,5,6,7-tetrahydropyrrolo[1,2- 
c]pyrimidin-2 -ium iodide (230)
229
SMe
230
lodomethane (0.35 ml, 5.64 mmol) was added to a solution of thiourea 229 
(556 mg, 1. 8 8  mmol) in acetone (5 ml) and the resulting solution was stirred at 
room temperature for 18 h. The volatiles were removed in vacuo, affording the 
title compound (705 mg, 8 6  %) as a pure orange oil.
Vmax (Neat): 3411, 2957, 2870, 1698, 1668, 1563, 1466, 1428, 1381, 1335, 
1260, 1232, 1200, 1074, 734 and 700 cm'1.
§H (400 MHz; C D C I 3 ) :  5.09 -  5.02 (1 H, m, CHN), 4.30 -  4.14 (2 H, m, CH2 0), 
3.92 -  3.87 (1 H, m, one of CH2 N), 3.73 -  3.67 (1 H, m, one of CH2 N), 3.40 (1 
H, ddd, J 18.5, 8.3, 2.7, one of CH2 C=C), 3.16 (3 H, s, SCH3), 3.04 -  2.94 (1 H, 
m, one of CH2 C=C), 2.36 -  2.25 (1 H, m, one of pyrrolidine CH2), 2.20 -  2.08 (1 
H, m, one of pyrrolidine CH2)1.78 -  1.61 (2 H, broad m, CH2 alkyl), 1.40 -  1.23 
(9 H, broad m, CH3 CH20  and alkyl) and 0.89 -  0.84 (3 H, m, CH3 alkyl).
5C ( 1 0 0  MHz; CDCI3): 164.6 (C), 164.0 (C), 148.9 (C), 104.3 (C), 61.2 (CH2),
51.9 (CH), 50.1 (CH2), 36.5 (CH2), 31.4 (CH2), 30.3 (CH2), 23.4 (CH2), 22.4 (2 x 
CH2), 17.7 (CH3), 14.3 (CH3) and 14.0 (CH3).
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MS-CI: m /z  (%) = 311 (M H\ 61), 297 (44), 239 (100), 225 (42), 2 1 1  (25), 143 
(77) and 117(19).
HRMS-CI: m /z [M + H]+ calcd for C1 6 H2 7 N2 O2 S: 311.1793; found: 311.1799.
4-(Ethoxycarbonyl)-3-pentyl-2,3,6,7-tetrahydropyrrolo[1,2 -c]pyrimidin- 
1(5H)-iminium formate (231)
A solution of isothiourea 230 (100 mg, 0.228 mmol) in a mixture of 30 % 
aqueous ammonium hydroxide solution and acetonitrile (1:1, 3 ml) was heated 
in a microwave at 130 °C for 15 minutes and then at 165 °C for 30 minutes. 
The reaction mixture was extracted with CH2 CI2 , the combined extracts being 
dried over Na2 S 0 4  before the solvent was removed in vacuo. Chromatography 
on silica gel (CH2 CI2 : MeOH: HC02 H: H20  85:14:0.5:0.5) afforded the title 
compound ( 6 6  mg, 89 %) as an orange oil.
vmax (Neat): 3346, 2959, 2953, 1682, 1651, 1456, 1397, 1332, 1310, 1250, 
1220, 1187, 1104 and 732 cm'1.
5h (400 MHz; C D C I 3 ) :  5.80 (1 H, broad s, NH), 4.31 -4 .2 6  (1 H, m, CHN), 4.21 
-  4.12 (2 H, m, CH2 0), 3.70 -  3.66 (2 H, m, CH2 N), 3.21 (1 H, ddd, J 18.2, 8.5,
4.5, one of CH2 C=C), 3.05 -  2.95 (1 H, m, one of CH2 C=C), 2.07 -  1.88 ( 2  H, 
m, pyrrolidine CH2), 1.54 -  1.49 ( 2  H, m, alkyl), 1.44 -  1.31 ( 2  H, broad m, 
alkyl), 1.31 -  1.23 (7 H, broad m, CH3 CH20  and alkyl) and 0.86 (3 H, t, J 6.9, 
CH3 alkyl).
5C ( 1 0 0  MHz; CDCI3): 165.8 (C), 165.4 (CH formate), 153.6 ( 2  x C), 98.8 (C),
59.9 (CH2), 51.8 (CH), 46.6 (CH2), 37.1 (CH2), 31.9 (CH2), 31.4 (CH2), 24.1 
(CH2), 22.6 (CH2), 21.5 (CH2), 14.4 (CH3) and 14.0 (CH3).
MS-ES: m/z (%) = 280 (MH+, 1 0 0 ), 226 (2 ) and 197 (1 ).
230 231
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HRMS-ES: m/z[M + H]+ calcd for C i5H26N30 2: 280.2025; found: 280.2038.
(3S,7R)-4-(Methoxycarbonyl)-7-((Z)-non-2-enyl)-3-pentyl-2,3,6,7- 
tetrahydropyrrolo[1,2-c]pyrimidin-1(5H)-iminium formate (232)
To a solution of bicyclic thiourea 224 (118 mg, 0.291 mmol) in dry MeOH (3 ml) 
was added iodomethane (0.02 ml, 0.291 mmol) and the mixture was heated at 
reflux for 1 h. The volatiles were removed in vacuo and the resulting residue 
re-dissolved in dry MeOH (3 ml). The solution was transferred to a mixture of 
NH4 OAc (112 mg, 1.45 mmol) in dry MeOH (2 ml) and liquid ammonia bubbled 
through the reaction for 10 mins. The resulting suspension was heated in a 
sealed tube at 80°C for 48 h. The solvent was removed in vacuo before 
chromatography on silica gel (CH2 CI2 : MeOH: HCO2 H: H20  84:14:0.5:0.5) 
afforded the title compound (121 mg, 96%) as an orange oil.
Vmax (Solution in CH2CI2): 3229, 3155, 2927, 2856, 1699, 1649, 1599, 1548, 
1438, 1379, 1346, 1212, 1177, 1104, 912 and 646 cm'1.
8 h (400 MHz; CDCI3): 8.18 (1 H, s, NH), 8.08 -  7.77 ( 2  H, broad s, NH2), 5.57 
(1 H, dt, J 11.0, 7.2, alkene CH), 5.52 -  5.43 (1 H, m, alkene CH), 4.73 -  4.69 
( 1  H, m, CHNC=N), 4.46 -  4.42 ( 1  H, m, CH-pentyl), 3.74 (3 H, s, OCH3), 3.32 
( 1  H, dd, J 18.7, 7.9, one of pyrrolidine CH2 C=C), 2.93 -  2.83 (1 H, m, one of 
pyrrolidine CH2 C=C), 2.49 -  2.45 (1 H, m, one of CH2 C=C), 2.34 ( 1  H, dt, J
14.3, 9.1, one of CH2 C=C), 2.11 -  1.95 (4 H, broad m, CH2 C=C and pyrrolidine 
CH2), 1.71 -  1.50 (3 H, broad m, alkyl), 1.43 -  1.24 ( 1 2  H, broad m, alkyl) and 
0.89 -  0.85 ( 6  H, m, 2  x CH3 alkyl).
5C (100 MHz; CDCI3): 165.1 (C=0), 150.9 (C=N), 149.7 (C), 134.7 (CH), 123.0 
(CH), 1 0 2 . 0  (C), 60.3 (CH), 51.9 (CH3), 50.9 (CH), 37.5 (CH2), 31.9 (CH2), 31.4
224 232
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(CH2), 29.6 (CH2), 29.5 (CH2), 29.2 (CH2), 28.9 (CH2), 27.7 (CH2), 26.6 (CH2), 
24.1 (CH2), 22.8 (CH2), 22.6 (CH2) and 14.3 ( 2  x CH3).
[a]D: + 7 (c = 1, MeOH).
MS-AP: m/z (%) = 390 (MH+, 100).
HRMS-AP: m/z[U  + H]+ calcd for C2 3 H4 oN3 0 2: 390.3121; found: 390.3134.
(3R,7R)-4-(Methoxycarbonyl)-7-((Z)-non-2-enyl)-3-pentyl-2,3,6,7- 
tetrahydropyrrolo[1,2-c]pyrimidin-1(5H)-iminium formate (233)
M e02C
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To a solution of bicyclic thiourea 225 (252 mg, 0.621 mmol) in dry MeOH (5 ml) 
was added iodomethane (0.04 ml, 0.621 mmol) and the mixture was heated at 
reflux for 1 h. The volatiles were removed in vacuo and the resulting residue 
re-dissolved in dry MeOH (5 ml). The solution was transferred to a mixture of 
NH4 OAc (239 mg, 3.10 mmol) in dry MeOH (3 ml) and liquid ammonia bubbled 
through the reaction for 10 mins. The resulting suspension was heated in a 
sealed tube at 80°C for 48 h. The solvent was removed in vacuo before 
chromatography on silica gel (CH2 CI2: MeOH: HC02 H: H20  84:14:0.5:0.5) 
afforded the titie compound (233 mg, 8 6 %) as an orange oil.
Vmax (Solution in CH2CI2): 3241, 3148, 2957, 2927, 2856, 1696, 1681, 1655, 
1548, 1436, 1385, 1349, 1184 and 1106 cm'1.
5h (400 MHz; CDCfe): 8.99 -  8.65 (1 H, broad s, NH), 8.16 -  7.60 ( 2  H, broad s, 
NH2), 5.58 (1 H, dt, J 10.6, 7.4, alkene CH), 5.39 -  5.32 (1 H, m, alkene), 4.96 
-  4.88 (1 H, m, CHNC=N), 4.43 (1 H, app. dd, J 7.0, 3.8, CH-pentyl), 3.74 (3 H, 
s, OCH3), 3.20 (1 H, ddd, J 19.0, 10.0, 3.8, one of pyrroldine CH2 C=C), 3.07 -  
2.98 ( 1  H, m, one of pyrrolidine CH2 C=C), 2.52 -  2.36 ( 2  H, m, CH2 C=C), 2 . 2 1  
(1 H, app. dq, J 12.7, 9.1, one of pyrrolidine CH2), 2.00 ( 2  H, app. q, J 6 .6 ,
165
CH2C=C), 1.93 -  1.86 (1 H, m, one of pyrrolidine CH2), 1.58 -  1.40 (3 H, m, 
alkyl), 1.36 -  1.24 (13 H, broad m, alkyl) and 0.87 ( 6  H, app. t, J6.4, 2 x CH3 
alkyl).
8 C (100 MHz; CDCI3): 165.2 (C=0), 151.4 (C=S), 150.6 (C), 135.1 (CH), 1 2 2 . 2  
(CH), 102.8 (C), 60.1 (CH), 51.9 (CH3), 50.3 (CH), 36.7 (CH2), 31.9 (CH2), 31.5 
(CH2), 30.9 (CH3), 29.7 (CH2), 29.2 ( 2  x CH2), 27.8 (CH2), 26.4 (CH2), 24.1 
(CH2), 22.8 (CH2), 22.7 (CH2) 14.3 (CH3) and 14.2 (CH3).
[a]D: + 19(c = 1, MeOH).
MS-AP: m/z (%) = 390 (MH+, 100) and 376 (1).
HRMS-AP: m /z [M + H]+ calcd for C2 3 H4 0 N3 O2: 390.3121; found: 390.3113.
(4S,7S,8af?)-Methyl 7-heptyl-4-pentyl-1,2,4,5,7,8-hexahydro-11 aH-2a1,5,6- 
triaza-acenaphthylene-3-carboxylate (234)
To a solution of bicyclic guanidine 232 (100 mg, 0.230 mmol) in MeCN (3 ml) 
were added iodine (350 mg, 1.38 mmol) and potassium carbonate (95 mg,
0.690 mmol) and the resulting mixture was allowed to stir at room temperature 
for 3 h. The reaction mixture was filtered through silica and concentrated in 
vacuo. The crude tricyclic guanidine was immediately re-dissolved in EtOAc ( 6  
ml), and triethylamine (0.16 ml, 1.15 mmol) and 10 % Pd/C (cat.) added. The 
black suspension was de-gassed and stirred under an atmosphere of H2 for 16 
h. The reaction mixture was filtered through celite and the solvent removed in 
vacuo. Chromatography on silica gel (EtOAc:CH2CI2 1 :2 ) afforded the title 
compound (49 mg, 55 %) as a yellow oil.
Vmax (Solution in CH2CI2): 3180, 2931, 2856, 1704, 1679, 1644, 1573, 1493, 
1437, 1373, 1335, 1227, 1195, 1115, 1080, 917 and 702 cm'1.
232 234
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8 h (400 MHz; CD3OD): 4.40 (1 H, app. dd, J7.4, 4.2, H-4), 4.11 (1 H, app. tdd, 
J 10.3, 6.5, 3.8, H-8 a), 3.74 (3 H, s, OCH3), 3.67 -  3.60 (1 H, m, H-7), 3.41 (1
H, app. dd, J  18.7, 9.0, H-2(3), 2.89 (1 H, ddd, J 18.7, 11.4, 8.9, H-2a), 2 .4 6 - 
2.39 (2 H, m, H-1 (3 and H-8 P), 1.77 -  1.62 (2 H, m, H-1a and H-8 0 ), 1.60 -
I.48 (3 H, m, three of H-10/H-15), 1.41 -  1.27 (17 H, m, one of H-10/H-15 and 
alkyl) and 0.90 -  0.87 ( 6  H, m, 2 x CH3).
5c ( 1 0 0  MHz; CDCI3 ): 165.0 (C), 149.1 (C), 148.5 (C), 103.3 (C), 57.4 (CH),
52.0 (CH3), 51.3 (CH), 50.9 (CH), 37.1 (CH2), 34.7 (CH2), 33.9 (CH2), 31.9 
(CH2), 31.4 (CH2), 30.0 (CH2), 29.6 (CH2), 29.4 (CH2), 29.2 (CH2), 25.5 (CH2), 
24.3 (CH2), 22.8 (CH2), 22.6 (CH2) and 14.3 (2 x CH3).
[a]D: -  13(c = 0.5, MeOH).
MS-ES: m/z(%) = 390 (MH+, 100), 146(2) and 130 (4).
HRMS-ES: m/z [M + H]+ calcd for C2 3 H4 0 N3 O2: 390.3121; found: 390.3111.
(4f?,7S,8aR)-Methyl 7-heptyl-4-pentyl-1,2,4,5,7,8-hexahydro-11 aH-2a1,5,6- 
triaza-acenaphthylene-3 -carboxylate (batzelladine C methyl ester) (235)
MeO
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To a solution of bicyclic guanidine 233 (53 mg, 0.12 mmol) in dry CH2 CI2 (2 ml) 
at 0 °C was added potassium carbonate (51 mg, 0.37 mmol), followed by 
iodine monochloride (0.18 ml of a 1 M solution in CH2 CI2 , 0.18 mmol) dropwise. 
The resulting suspension was allowed to warm to room temperature and stirred 
for ~3 h (TLC). The solvent was removed in vacuo before chromatography on 
silica gel (EtOAc: CH2 CI2 1 :2 ) afforded the tricyclic guanidine (51 mg, 81 %) as 
a brown oil. The tricyclic guanidine (41 mg, 0.080 mmol) was immediately re­
dissolved in EtOAc (3 ml), and triethylamine (0.05 ml, 0.40 mmol) and 10 % 
Pd/C (cat.) added. The black suspension was de-gassed and stirred under an 
atmosphere of H2 for 16 h. The reaction mixture was filtered before
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chromatography on silica gel (MeOH:EtOAc 1:19) afforded the title compound 
(17 mg, 55 %) as a yellow oil).
vmax (Solution in CH2CI2): 3177, 2926, 2856, 1682, 1644, 1574, 1435, 1372,
1336, 1199, 1097 and 736 cm'1.
§h (400 MHz; CD3OD): 4.46 -  4.44 (1 H, m, H-4), 3.93 (1 H, tdd, J 11.4, 5.4,
2.7, H-8a), 3.70 (3 H, s, Me ester), 3.60 (1 H, app. td, J 11.1, 6.4, H-7), 3.32 (1 
H, dd, J 18.2, 7.8, H-2p), 2.79 (1 H, dddd, J 18.2, 12.0, 7.5, 1.4, H-2a), 2.38 (1 
H, ddd, J 13.1, 3.9, 2.9, H-8(3), 2.33 -  2.27 (1 H, m, H-1p), 1.72 -  1.52 (5 H, 
broad m, H-1 a, H-10 and H-15), 1.35 -  1.24 (17 H, m, H-8a and alkyl) and 0.88 
-0 .8 5  (6 H, m, 2 x CH3 alkyl).
5C (125 MHz; CD3OD): 58.9 (CH), 53.8 (CH), 52.5 (CH), 52.2 (CH3), 38.2 (CH2),
36.0 (CH2), 33.3 (CH2), 33.1 (CH2), 32.7 (CH2), 31.1 (CH2), 30.6 (CH2), 30.5 
(CH2), 30.4 (CH2), 26.1 (CH2), 24.5 (CH2), 23.8 (CH2), 23.7 (CH2), 14.5 (CH3) 
and 14.4 (CH3).
[a ]D: -2.4 (c = 0.5, MeOH), lit. [a ]D: -4.2 (c = 0.93, MeOH)
MS-ES: m/z (%) = 390 (MH+, 100), 361 (8) and 342 (1).
HRMS-ES: m/z [M + H]+ calcd for C23H40N3O2: 390.3121; found: 390.3113.
4-((4-Azidobutoxy)carbonyl)-3-pentyl-2,3,6,7-tetrahydropyrrolo[1,2- 
c]pyrimidin-1(5H)-iminium formate (237)
237
A-©,
236
4-Azidobutanol (214 mg, 1.86 mmol) and Otera’s catalyst65 (103 mg, 0.19 
mmol) were added to a solution of guanidine 236 (58 mg, 0.19 mmol) in 
toluene (1 ml). The resulting mixture was heated under reflux for 24 h before 
the solvent was removed in vacuo. Chromatography on silica gel (MeOH: 
CH2CI2 1:19) afforded the title compound (27 mg, 37 %) as a yellow oil.
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Vmax (Neat): 3228, 3140, 2941, 2857, 2099, 1685, 1674, 1437, 1355, 1252, 
1176, 1104 and 734 cm'1.
8H (400 MHz; CDCI3): 8.81 (1 H, s, NH), 8 .19-7 .92  (2 H, broad s, NH2), 4 .47 - 
4.41 (1 H, broad m, CHNH), 4.19 (2 H, t, J5.8, CH20), 3.98 (2 H, app. dd, J8.5,
5.3, CH2N), 3.35 -  3.27 (3 H, m, CH2N3 and one of CH2C=C), 2.96 (1 H, app. dt, 
J 18.6, 9.5, one of CH2C=C), 2.31 -  2.19 (1 H, broad m, one of pyrrolidine CH2), 
2.15 -  2.04 (1 H, broad m, one pyrrolidine CH2), 1.82 -  1.73 (2 H, broad m, 
CH2 alkyl), 1.70 -  1.46 (6 H, broad m, alkyl), 1.44 -  1.25 (4 H, broad m, alkyl) 
and 0.88 (3 H, t, J 6.7, CH3 alkyl).
8c (100 MHz; CDCI3): 164.4 (C), 151.9 (C), 150.3 (C), 102.6 (C), 64.0 (CH2),
50.9 (CH2), 50.4 (CH), 48.7 (CH2), 36.8 (CH2), 31.3 (CH2), 30.8 (CH2), 26.1 
(CH2), 25.6 (CH2), 23.9 (CH2), 22.5 (CH2), 22.0 (CH2) and 14.1 (CH3).
MS-ES: m/z (%) = 349 (MH+, 100%) and 266 (3).
HRMS-ES: m /z [M + H]+ calcd for C i7H29N60 2: 349.2352; found: 349.2363.
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